Original Article

Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients with Reduced Left Ventricular Ejection Fractions

The SOLVD Investigators*

N Engl J Med 1992; 327:685-691September 3, 1992

Abstract

Abstract

Background.

It is not known whether the treatment of patients with asymptomatic left ventricular dysfunction reduces mortality and morbidity. We studied the effect of an angiotensin-converting—enzyme inhibitor, enalapril, on total mortality and mortality from cardiovascular causes, the development of heart failure, and hospitalization for heart failure among patients with ejection fractions of 0.35 or less who were not receiving drug treatment for heart failure.

Full Text of Background....

Methods.

Patients were randomly assigned to receive either placebo (n = 2117) or enalapril (n = 2111) at doses of 2.5 to 20 mg per day in a double-blind trial. Follow-up averaged 37.4 months.

Full Text of Methods....

Results.

There were 334 deaths in the placebo group, as compared with 313 in the enalapril group (reduction in risk, 8 percent by the log-rank test; 95 percent confidence interval, -8 percent [an increase of 8 percent] to 21 percent; P = 0.30). The reduction in mortality from cardiovascular causes was larger but was not statistically significant (298 deaths in the placebo group vs. 265 in the enalapril group; risk reduction, 12 percent; 95 percent confidence interval, -3 to 26 percent; P = 0.12). When we combined patients in whom heart failure developed and those who died, the total number of deaths and cases of heart failure was lower in the enalapril group than in the placebo group (630 vs. 818; risk reduction, 29 percent; 95 percent confidence interval, 21 to 36 percent; P<0.001). In addition, fewer patients given enalapril died or were hospitalized for heart failure (434 in the enalapril group vs. 518 in the placebo group; risk reduction, 20 percent; 95 percent confidence interval, 9 to 30 percent; P<0.001).

Full Text of Results....

Conclusions.

The angiotensin-converting—enzyme inhibitor enalapril significantly reduced the incidence of heart failure and the rate of related hospitalizations, as compared with the rates in the group given placebo, among patients with asymptomatic left ventricular dysfunction. There was also a trend toward fewer deaths due to cardiovascular causes among the patients who received enalapril. (N Engl J Med 1992;327:685–91.)

Full Text of Conclusions....

Read the Full Article...

Media in This Article

Figure 1Total Mortality (Upper Panel) and Mortality from Cardiovascular Causes (Lower Panel) in the Prevention Trial.

Figure 2Death or Hospitalization for Congestive Heart Failure (CHF) and Death or Development of Heart Failure in the Prevention Trial.

Article Activity

810 articles have cited this article

Article

ANGIOTENSIN-converting—enzyme inhibitors reduce mortality and the need for hospitalization and improve functional status in patients with symptomatic congestive heart failure.1 2 3 Despite such treatment, however, the mortality and morbidity rates associated with this condition are still high. Efforts to prevent the development of heart failure in patients with asymptomatic left ventricular dysfunction are therefore warranted.

Angiotensin-converting—enzyme inhibitors improve the ejection fraction and exercise tolerance in asymptomatic patients with myocardial infarction and low ejection fractions.4 , 5 The effects of such drugs on survival, the incidence of heart failure, and the frequency of hospitalization for heart failure are not known, however. This Prevention Trial, a part of the Studies of Left Ventricular Dysfunction (SOLVD), was designed to determine whether an angiotensin-converting—enzyme inhibitor, enalapril, could reduce mortality, the incidence of heart failure, and the rate of related hospitalizations in patients with ejection fractions of 0.35 or less who were not receiving therapy for heart failure (henceforth referred to as patients with asymptomatic left ventricular dysfunction).

Methods

Organization of the Study

The SOLVD Prevention Trial was a randomized, double-blind, placebo-controlled trial. A total of 4228 patients with asymptomatic left ventricular dysfunction were randomly assigned to receive either enalapril or placebo at one of 83 hospitals linked to 23 centers in the United States, Canada, and Belgium. All data were collected and analyzed at the coordinating center at the University of North Carolina at Chapel Hill. The study was organized and conducted by the project office located at the Clinical Trials Branch of the National Heart, Lung, and Blood Institute and by a steering committee consisting of principal investigators from the centers.6 An independent Data and Safety Monitoring Board oversaw the progress of the study. The study was approved by the institutional review board of each hospital, and all the patients provided informed consent.

Eligibility of Patients, Run-in Period, and Randomization

Patients known to have heart disease who had ejection fractions of 0.35 or less and who were not receiving diuretics, digoxin, or vasodilators for the treatment of heart failure were eligible for the Prevention Trial. Patients were allowed to receive diuretics for hypertension, digoxin for current or past atrial fibrillation, or nitrates for angina. Details of the measurement of the ejection fraction, exclusion criteria, screening procedure, and the run-in period have been reported previously.1 , 6 Patients who had no evidence of overt heart failure at the end of the three-week run-in period, during which they were given enalapril for the first week and placebo for the remainder, were entered into the Prevention Trial. Patients were randomly assigned to receive enalapril at an initial dose of 2.5 mg twice daily, which was gradually increased to 10 mg twice daily unless side effects developed, or a matching placebo. After randomization, the patients were seen after two weeks, six weeks, and four months, and every four months thereafter.

Follow-up and Outcome Measures

At the time of this report, the vital status of four patients in the enalapril group and three in the placebo group was unknown. For all patients not lost to follow-up, information on clinical status, the development of heart failure, use of medications other than those prescribed as part of the study, hospitalizations, adherence to the study regimen, and side effects was systematically recorded at each follow-up visit. For patients who died, were hospitalized, or had heart failure, the cause of death, the primary reason for hospitalization, and the development of heart failure were ascertained and classified by the principal investigator at each center, who was unaware of the patients' treatment, using standardized forms. Four overlapping definitions of heart failure, of increasing severity, were used: (1) heart failure, identified by the study physician on the basis of symptoms, signs, or the need for changes in therapy; (2) heart failure requiring the addition of a diuretic, digoxin, or a vasodilator to the patient's regimen (in the case of patients already receiving any one of these drugs at base line, the additional drug had to be prescribed for this indication); (3) heart failure requiring hospitalization; and (4) progressive heart failure causing death. When heart failure developed, the patients' physicians could use treatments at their discretion, but it was recommended that angiotensin-converting—enzyme inhibitors be used only after other drugs had been tried.

Statistical Analysis

The primary hypothesis of the Prevention Trial was that enalapril would reduce total mortality. A subsidiary hypothesis was that enalapril would reduce the incidence of heart failure and the rate of hospitalization for heart failure. The last two end points were combined with mortality to avoid the problem of competing risks.7 Such analyses are more conservative and methodologically more correct than analyses of secondary outcomes alone. However, data on the incidence of heart failure and hospitalization are also provided in the tables. A one-sided test with a significance level of 0.025 (equivalent to a nominal two-sided P value of 0.05) was specified in the protocol; however, at the request of the Journal, two-sided significance levels are reported. We estimated that a sample of 4100 patients followed for an average of three years would provide a 90 percent power to detect a 25 percent reduction in mortality.1 , 6 The sample size was increased to 4600 in order to protect against unexpectedly low event rates or poor compliance. We recruited 4228 patients from July 1986 through May 1990. A termination date of August 31, 1991, was set for the study in advance. Deaths occurring between the patients' final follow-up visits and this date are also reported. Details of monitoring, adjustment of the critical z value, and tests for heterogeneity have been reported earlier.1 A stratified log-rank statistic was used to compare the life-table survival curves and the development of heart failure for all patients randomly assigned to the two groups.8 , 9

Results

The clinical characteristics of the two study groups were similar at base line (Table 1Table 1Base-Line Clinical Characteristics and Drug Therapy, According to Treatment Group.). The mean left ventricular ejection fraction was 0.28; 67 percent of the patients were in New York Heart Association (NYHA) functional class I, and 33 percent were in class II; one third of the patients had angina, and 74 percent were not receiving diuretics or digoxin for any reason. The average follow-up was 37.4 months (range, 14.6 to 62.0).

Mortality

There were 334 deaths in the placebo group, as compared with 313 in the enalapril group, for a reduction in risk of 8 percent as calculated from the log-rank test (95 percent confidence interval, -8 percent [an increase of 8 percent] to 21 percent; P = 0.30) (Fig. 1Figure 1Total Mortality (Upper Panel) and Mortality from Cardiovascular Causes (Lower Panel) in the Prevention Trial. and Table 2Table 2Deaths, Causes of Death, Development of Heart Failure, and Hospitalizations for Heart Failure, According to Treatment Group.). The difference was entirely due to a reduction in deaths due to cardiovascular causes (298 in the placebo group, as compared with 265 in the enalapril group; risk reduction, 12 percent; 95 percent confidence interval, -3 to 26 percent; P = 0.12). Among the deaths from cardiovascular causes, the difference in mortality between the groups was observed mainly in terms of those classified as due to progressive heart failure (106 in the placebo group vs. 85 in the enalapril group); there was little difference between the groups in the number of deaths presumed to be due primarily to arrhythmia (105 vs. 98).

Hospitalization for Heart Failure

Altogether, 518 patients in the placebo group (24.5 percent) and 434 in the enalapril group (20.6 percent) died or were hospitalized for new or worsening heart failure (risk reduction, 20 percent; 95 percent confidence interval, 9 to 30 percent; P<0.001) (Table 2 and Fig. 2Figure 2Death or Hospitalization for Congestive Heart Failure (CHF) and Death or Development of Heart Failure in the Prevention Trial.). By one year, there had been 218 such events in the placebo group (10.3 percent), as compared with 167 in the enalapril group (7.9 percent) (risk reduction, 25 percent; 95 percent confidence interval, 8 to 38 percent). After one year there were a further 300 such events among the 1899 remaining patients in the placebo group (15.8 percent), as compared with 267 among the 1944 in the enalapril group (13.7 percent).

There were 454 hospitalizations for heart failure in the placebo group, as compared with 306 in the enalapril group; 102 patients in the placebo group (4.8 percent) and 58 patients in the enalapril group (2.7 percent) were hospitalized more than once for worsening heart failure (risk reduction, 44 percent; 95 percent confidence interval, 23 to 59 percent). The median length of time to the first hospitalization for heart failure was 13.2 months in the placebo group. The length of time before there were a similar number of hospitalizations in the enalapril group was 27.8 months.

Development of Heart Failure

In the placebo group, 818 patients had heart failure or died (38.6 percent), as compared with 630 in the enalapril group (29.8 percent) (Fig. 2) (risk reduction, 29 percent; 95 percent confidence interval, 21 to 36 percent; P<0.001). The median length of time to the development of heart failure was 8.3 months in the placebo group. The length of time to the development of a similar number of events in the enalapril group was 22.3 months. Significant reductions in the incidence of heart failure were observed regardless of the definition of heart failure used. The difference in the rates of heart failure was seen as early as three months after randomization (143 patients in the placebo group vs. 82 in the enalapril group), and the groups continued to diverge until the end of the study.

The Development of Heart Failure and Hospitalization for Heart Failure in Relation to Subsequent Mortality

The difference in mortality between the groups was attributable only to the lower incidence of heart failure among patients assigned to enalapril (Table 3Table 3Mortality and Use of Angiotensin-Converting—Enzyme (ACE) Inhibitors at the End of the Study Period among Patients Who Had Congestive Heart Failure (CHF) or Patients Hospitalized for CHF, As Compared with Patients without CHF or Hospitalization.); 156 patients in the placebo group and 121 in the enalapril group died after heart failure developed (mortality among patients with heart failure, 24.4 percent and 27.6 percent, respectively). Among patients who did not have heart failure, the mortality rates were 12.1 percent in the placebo group and 11.5 percent in the enalapril group. Similar analyses of deaths among patients who died after hospitalization for heart failure (89 deaths in the placebo group and 63 in the enalapril group) also demonstrated a difference, whereas there was little difference in mortality among patients not hospitalized for heart failure (245 deaths in the placebo group and 250 in the enalapril group). Therefore, the difference in the incidence of heart failure accounted for the lower mortality with enalapril. However, 40.9 percent of the patients in the placebo group who had heart failure subsequently received an angiotensin-converting—enzyme inhibitor.

The rate of mortality among patients who were hospitalized for heart failure (regardless of their treatment assignment) was about 33 percent, as compared with 13 percent among those who had not been hospitalized by the end of the study. After adjustment for differences in length of follow-up, the relative risk of death at one year among those who were hospitalized, as compared with those who were not hospitalized, was 4.6 (95 percent confidence interval, 3.4 to 6.3), indicating that hospitalization for heart failure was associated with a substantially higher risk of death.

All Hospitalizations

Altogether, 967 patients in the placebo group (45.7 percent) and 876 in the enalapril group (41.5 percent) were hospitalized primarily for a cardiovascular reason (P = 0.006), whereas 534 patients in the placebo group (25.2 percent) and 595 patients in the enalapril group (28.1 percent) were hospitalized for a noncardiovascular reason. The total number of patients hospitalized for any reason was 1202 in the placebo group, as compared with 1167 in the enalapril group (P = 0.34). The total number of hospitalizations was 2839 in the placebo group and 2645 in the enalapril group (P = 0.12).

Outcomes in Subgroups

The effect of treatment on various outcome measures was examined in several subgroups specified by the protocol; these were defined by base-line serum sodium levels, use of vasodilators, ejection fraction, and cause of ventricular dysfunction. We also examined the effects of treatment among patients with no functional disability (NYHA functional class I) and among those who were not receiving digoxin or diuretics at entry. Because the overall results regarding mortality in the Prevention Trial did not reach conventional levels of statistical significance, analysis of mortality in subgroups is less reliable than similar analyses of data on the rates of heart failure or hospitalizations for heart failure. There was a significant trend toward less benefit from enalapril among patients with a higher ejection fraction (Fig. 3Figure 3Effect of Enalapril on Mortality, Incidence of Congestive Heart Failure (CHF), and Hospitalization for Heart Failure in Various Subgroups Defined According to the Ejection Fraction.). The benefits of treatment in terms of the frequency of hospitalization or the development of heart failure were consistent in most of the other specified subgroups. The benefits among those who were not receiving digoxin or diuretics (reduction in the frequency of death or hospitalization, 25 percent [95 percent confidence interval, 12 to 36 percent]; reduction in the incidence of heart failure, 39 percent [95 percent confidence interval, 29 to 47 percent]) and among those in functional class I (reduction in mortality or hospitalization, 21 percent [95 percent confidence interval, 7 to 33 percent]; reduction in mortality or development of heart failure, 28 percent [95 percent confidence interval, 18 to 37 percent]) were similar to the overall results.

Adherence to the Study Regimen, Side Effects, and Changes in Blood Pressure, Serum Electrolyte Levels, and Renal Function

The final mean daily dose of enalapril among all randomized patients was 12.7 mg. Among the patients in the enalapril group who were taking enalapril, the mean daily dose was 16.7 mg. At the last visit, 1.9 percent of the enalapril group was receiving 2.5 mg daily, 6.9 percent was receiving 5 mg daily, 11.1 percent was receiving 10 mg daily, and 56.1 percent was receiving 20 mg daily. Twenty-four percent of the patients in the enalapril group and 27 percent in the placebo group had stopped taking blinded medication by the end of the study. The study medication was discontinued in 218 patients in the placebo group and 102 in the enalapril group because of worsening heart failure. More patients were receiving diuretics and digoxin in the placebo group than in the enalapril group at one year (diuretics: 30 percent vs. 22 percent; digoxin: 19 percent vs. 15 percent), at two years (diuretics: 33 percent vs. 24 percent; digoxin: 23 percent vs. 17 percent), and at three years (diuretics: 35 percent vs. 27 percent; digoxin: 24 percent vs. 18 percent).

A high proportion of patients in both groups reported side effects during the trial (76 percent in the enalapril group vs. 72 percent in the placebo group). There were significantly more reports of dizziness or fainting (45.8 percent vs. 39.2 percent) and cough (33.8 percent vs. 27.3 percent) in the enalapril group. There was no difference in the frequency of angioedema (1.4 percent in each group); most cases of angioedema were mild and did not require the discontinuation of medication. Overall, 8 percent of the patients in the enalapril group and 45 percent in the placebo group permanently discontinued the study medication because of side effects. Forty-three patients in the enalapril group and 41 in the placebo group were given a diagnosis of cancer. Of these, 19 patients in the enalapril group and 13 in the placebo group were identified as having a cancer of the gastrointestinal tract, liver, gallbladder, or pancreas.

When averaged over all follow-up visits, systolic and diastolic blood pressures were significantly lower in the enalapril group than in the placebo group (by 5.2 and 3.2 mm Hg, respectively). Serum potassium and creatinine levels were slightly but significantly higher in the enalapril group (by 0.1 mmol per liter and 0.04 mg per deciliter [3.5 μmol per liter], respectively).

Discussion

Although a significant reduction in total mortality with enalapril treatment was not observed in the Prevention Trial, enalapril, an angiotensin-converting—enzyme inhibitor, significantly reduced the incidence of heart failure and the need for hospitalizations for heart failure among patients with asymptomatic left ventricular dysfunction. There was also a trend (albeit not a significant one) toward fewer deaths due to cardiovascular causes. Although the relative reductions in total mortality and mortality from cardiovascular causes were smaller in the Prevention Trial (8 percent and 12 percent, respectively) than in the previously reported Treatment Trial (16 percent and 18 percent, respectively),1 the direction of the effects was similar in both trials. However, the effects on the frequency of hospitalization for heart failure (a 36 percent reduction in both trials) and deaths from progressive heart failure (a 19 percent reduction in the Treatment Trial and a 21 percent reduction in the Prevention Trial) were similar.

The effect of enalapril in preventing the development of heart failure was evident as early as six weeks after randomization, and the difference between the two groups continued to increase until the end of the study. Similar results were observed for the rates of hospitalization for heart failure and death. After the development of heart failure or after hospitalization for heart failure, the mortality rates increased substantially as compared with those in patients in whom heart failure had not developed. This difference indicates that the development of heart failure has a serious adverse effect on prognosis.10

There were consistent reductions in the proportion of patients hospitalized for cardiovascular reasons in both the Treatment Trial and the Prevention Trial. There was a significant reduction in the proportion of patients in the enalapril group hospitalized for noncardiovascular reasons in the Treatment Trial,1 whereas the opposite was observed in the Prevention Trial. The contradictory differences in the frequency of hospitalization for noncardiovascular reasons are probably due to chance. In the two trials combined, the number of hospitalizations for noncardiovascular reasons was virtually identical in the two groups (996 in the placebo groups vs. 997 in the enalapril groups). No significant difference in hospitalizations in any specific noncardiovascular category was observed in either trial.

During the study, more patients randomly assigned to the placebo group than to the enalapril group received digoxin, diuretics, or angiotensin-converting—enzyme inhibitors that were not part of the study regimen. In all, 40.9 percent of patients in whom heart failure developed and 50.9 percent of those who were hospitalized in the placebo group were prescribed an angiotensin-converting—enzyme inhibitor, generally after the development of heart failure. Because the reduction in mortality with enalapril was chiefly attributable to a lower incidence of heart failure, the frequent use of angiotensin-converting—enzyme inhibitors and perhaps other drugs in this group is likely to have led to the underestimation of the reduction in mortality with enalapril. Our data can also be interpreted as indicating that there may be only a small difference in mortality between asymptomatic patients treated preventively and those treated with careful follow-up and initiation of therapy if heart failure develops.

The reductions in the frequency of hospitalization and the incidence of heart failure were of approximately the same magnitude among patients who were receiving diuretics or digoxin at entry and those who were not receiving such agents; the reductions were also similar among patients in NYHA functional classes I and II. The benefits of enalapril in preventing heart failure and hospitalization were greatest among the patients with the lowest ejection fractions. Similar trends toward lesser benefit among patients with higher ejection fractions were observed in the SOLVD Treatment Trial,1 suggesting that caution be exercised in extrapolating the results of the SOLVD trials to patients with ejection fractions above 0.35.

The major side effects observed in this study — hypotension, cough, and elevated serum potassium levels — are similar to those observed in the SOLVD Treatment Trial and other trials of angiotensin-converting—enzyme inhibitors in similar patients.1 2 3 The frequency of side effects in the SOLVD trials may be higher than in other studies because of our substantially longer follow-up and the fact that patients were asked about these side effects at each visit. The proportion of patients who reported skin rashes, taste disturbances, or any other side effect was no higher in the enalapril group than in the placebo group in either SOLVD trial. The excess rate of gastrointestinal cancer is similar to that observed in the Treatment Trial.1 When the data from both trials were combined, there were 38 cases of gastrointestinal cancer in the enalapril group as compared with 22 in the placebo group. Although this difference would be nominally significant when taken in isolation, this was one of numerous comparisons and the tests of significance are therefore less reliable. The frequency of these cancers did not increase with longer drug exposure (there were 20 cases in the first two years and 18 thereafter in the enalapril group, as compared with 12 and 10 in the placebo group), and the cancers were widely dispersed throughout the gastrointestinal tract (rectum, cecum, and colon: 26 in the enalapril group vs. 17 in the placebo group; esophagus and stomach: 5 vs. 1; gallbladder, pancreas, and liver: 7 vs. 4). For these reasons, the excess gastrointestinal cancers in the enalapril group were probably not causally related to the study treatment but rather a chance finding. It would be prudent, however, to examine this relation in other studies.

In the SOLVD Prevention Trial, enalapril was well tolerated by patients with asymptomatic left ventricular dysfunction; it reduced the incidence of heart failure and related hospitalizations, with a trend toward fewer cardiovascular deaths. However, the lack of a statistically significant effect on overall mortality or on the rate of deaths presumed to be due to arrhythmia emphasizes the need to explore more effective means, or additional means, of treating patients with left ventricular dysfunction.

Appendix

The following investigators and institutions participated in the SOLVD Prevention Trial. Principal investigators are indicated with asterisks.

University of Michigan Medical Center, Ann Arbor — J.M. Nicklas,* B. Pitt (study chairman),* G. Timmis, G. Breneman, S.M. Jafri, W.F.C. Duvernoy, S.W. Davis, M.J. Goldberg, J. Blair, G.B.J. Mancini, T. Johnson, C. Luckoff, G. Henry, M.B. Wlodkowski, M. Czajka, D. Reinstein, J. Richards, R. Lewis, D.E. Davey, K. Mallotte, A. Moll, L. Quain, P. Thomasma, S. Schreiber, and E. Ursiny; University of Alabama at Birmingham Medical Center — W.J. Rogers,* J.G. Arciniegas, V. Bittner, T.M. Bulle, J.B. Cavender, E.D. Charles, L.J. Dell'Italia, M.J. Henzlova, W.A. MacLean, S.E. Papapietro, T.D. Paine, M.F. Salvia, L.T. Sheffield, A.W.H. Stanley, E. Van Tassel, H.A. Taylor, K. Carlisle, A. Baker, G. Blackburn, B. Bonville, K. Bynum, S. Deriso, D. Kerns, N. Lambert, L. Merritt, V. Nance, E. Reddy, F. Atkins, and M. Cox; University of Louvain, Brussels, Belgium — H. Pouleur,* M.F. Rousseau,* J. Melin, B. Marchandise, E. Schroeder, and S. Ahn; Brigham and Women's Hospital, Harvard Medical School, and BrocktonWest Roxbury Veterans Affairs Medical Center, Boston — K.M. McIntyre,* D. Tow, D. Pietro, E. Gillie, G.V.R.K. Sharma, P. Woods, M.E.C. Dondero, R. Brown, W. Strauss, and J. Loscalzo; Tufts—New England Medical Center, Boston — D. Salem,* M.A. Konstam, J.E. Udelson, A. Weinshel, W. Gaasch, N. Dolan, R. Hoshino, C. Lane, S. Kelly, L. Kilcoyne, D. Kinan, J. Metherall, L. Paradise, and H. Toltsis; Weiler Hospital, Albert Einstein College of Medicine, Bronx, N.Y. — T.H. LeJemtel,* W.H. Frishman, J. Wexler, M. Galvao, L.A. Mills, and M. Jones; Buffalo General Hospital and Veterans Affairs Medical Center, Buffalo, N.Y. — R.M. Kohn,* P.D. Morey, K.E. Forte, M.J. Hong, J.L. Maddi, J.A. Zizzi, Jr., E.J. Bernaski, N.A. Roberts, M.M. Bonora, J.A. Celano, L.D. Banks, and E.M. Muffoletto; University of Illinois School of Medicine, Chicago — S. Rich,* B.H. Brundage,* J.G. Shanes,* M.A. Papp, J. Mathew, L. Berarducci, J.K. Ghali, R. Cooper, B.J. Dierenfeldt, S. Stanford, P. Mumby, S. Davidson, and T. Adams; University of Florida and Veterans Affairs Medical Center, Gainesville — C.J. Pepine,* C.R. Conti, J.L. Mehta, M.C. Limacher, R.L. Feldman, E.A. Geiser, J.A. Hill, C.R. Lambert, X. Prida, K. McCoy, A. Miranda, N.K. Norvell, J.R. Green, Jr., A.B. Miller, D.L. Perchalski, E. Handberg, and B. Hall; Victoria General Hospital, Halifax, N.S. — D.E. Johnstone,* M.J. Gardner, T.J. Montague, L.D. Lalonde, G.A. Klassen, K.K. Teo, B.M. Chandler, B. Carew, S. Black, M. Francis, and S. Martin; Baylor College of Medicine, Houston — J.B. Young,* C.M. Pratt, M.A. Quinones, R. Roberts, C. Kingry, D. Gibson, C. Foreman, H. Kopelen, A. Galan, L. Miller, K. Yang, G. Marks, and M. Francis; Michigan State University, Lansing — P.C. Kirlin,* P.W. Willis, III,* J.W.Jones, W.M. Baird, T. Fritz, B. Perry, R. McNamara, R.H. Murray, L.E. Scaffidi, H. Boichot, N. Solis, C. Bachman, C. Fooy, K. McKay, M. Van der Puy, K. Hiner, E. Worden, and P. Hearns; University of Minnesota Medical School, Minneapolis — J.N. Cohn,* S.H. Kubo, G.S. Francis, C. Peterson, I.F. Goldenberg, J.W. McBride, D. Berman, W. Hession, S.R. Goldsmith, W.R. Pederson, S. Holmer, G.K. Bjerken, K. Monson, J. Pearson, B. O'Toole-Brehm, and L. Mensing; Montreal Heart Institute, Montreal — M.G. Bourassa,* C. Goulet, M. Joyal, G. Gosselin, M. Labbe, M. Methe, H. Benjamin, S. Mortin, and D. Leclerc; Vanderbilt University School of Medicine, Nashville — M.W. Kronenberg,* G.C. Friesinger,* B.F. Byrd III, W.B. Campbell, J.H. Nadeau, S. Schilling, D.M. Howe, T.R. Edens, Y.D. Bernard, L.A. Brown, and R.F. Smith; University of Medicine and Dentistry of New Jersey and the Robert Wood Johnson Medical School, New Brunswick — J.B. Kostis,* D.M. Shindler, C.R. Lacy, Sumathisena, S. Karstensen, J. Williams, B. Hill, L. Wood, and J. Steinhagen; Temple University Hospital, Philadelphia — M. Jessup,* S. Brozena,* M. Victor, J. Hagaman, M. Cannon, J. McDonough, S. Luhmann, A.L. Smith, J. Kelly, and D. Stinson; Oregon Health Sciences University, Portland — B. Greenberg,* H. DeMots, J. Grover, S. Reinhart, D. Nauman, D. Dutton, M. Guillotte, and M. Schmit; Brown University, Providence, R.I. — R.J. Capone,* C. McNulty, S. Sharma, A. Sadaniantz, L. Gorkin, K. Handshaw, L. Erikson, C. Lamore, L. Redfern, P. Rubbert, and D. Tremblay; University of Rochester Medical Center, Rochester, N.Y. — W.B. Hood, Jr.,* C.S. Liang, P.G. Fitzpatrick, J.F. Richeson, K.J. Acciari, L.D. Divers, T.M. Stone, M.J. Farrell, K.D. Miller, A.W. Moore, K.L. Wellington, R.M. Easley, Jr., G.F. Ryan, S. Barold, J.A. Gillespie, L. Cove, M.P. Roache, and J.M. Malcolm; University of Washington Medical Center, Seattle — D.K. Stewart,* J.W. Kennedy, J.H. Caldwell, J.A. Murray, T.D. Hegg, R. Wallach, R. Chamusco, P. Kudenchuck, S. Olmstead, H. Dash, J. Gorham, A. Resnick, L. Cahill, R. Letterer, T. Kempf, P. Gardner, J. Dalquist, and M. Olsufka; Overlook Hospital, Summit, N.J. — J.J. Gregory,* D.C. Brock, R. Lauer, A. Greene, S.J. Fischl, R. Slama, E. Stein, A. Kalischer, L. Diehl, S. Facchinei, J. Romano, E. O'Leary, G. Kimball, and L. Brock; Westchester County Medical Center, New York Medical College, Valhalla — M.V. Herman,* M.B. Weiss, R.H. Kay, M. Evans, K. Lerrick, C. Unger, S. Ripa, J. Blake, M. Reid, D. Braga, N. Treulieb, and T. Cutrone. Neurohumoral Laboratory, University of Texas Health Science Center, Houston — C. Benedict,* O.B. Holland, F. Bodola, D. Cappolino, W.L. Sheng, S. Chakravarthy, A.A. Entezami, C. Sullivan, and C.W. Wu; Coordinating Center, University of North Carolina at Chapel Hill — C.E. Davis,* J.D. Hosking, S.I. Bangdiwala, J. Barrett, C. Garces, K.M. Kral, E.R. Toretsky, M.E. Youngblood, D. Stewart, C.J. Hazard, D.H. Weiner, K.F. Adams, Jr., L.-G. Ekelund, W.J. Ko, I. Jarrad, G. Williams, B.J. Shelton, D.Jones, J.J. Nelson, V. Smith, and M. Thorn; Project Office, Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Bethesda, Md. — S. Yusuf (project officer),* J. Probstfield, J. Verter, E. Schron, S. Schumacker, P. Davis, and E. Webster; Data and Safety Monitoring Board — E. Rapaport (chairman), B.W. Brown, L.S. Cohen, M. Halperin (deceased), M. Packer, L. Walters, R. Gunnar, and W. Friedewald; Writing Committee — S. Yusuf, B. Pitt, C.E. Davis, W.B. Hood, and J.N. Cohn.

Address reprint requests to Dr. Yusuf at the Clinical Trials Branch, Division of Epidemiology and Clinical Applications, National Heart, Lung, and Blood Institute, Federal Bldg., Rm. 5C08, 7550 Wisconsin Ave., Bethesda, MD 20892.

Supported under contracts from the National Heart, Lung, and Blood Institute and by a gift from Merck Sharp and Dohme, which had no part in the design, conduct, or monitoring of the study or in the analysis, interpretation, or reporting of the results.

*The investigators and institutions participating in the SOLVD study are listed in the Appendix.

References

References

1. 1

   The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure . N Engl J Med 1991;325:293–302.
   Full Text | Web of Science | Medline

2. 2

   The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) . N Engl J Med 1987;316: 1429–35.
   Full Text | Web of Science | Medline

3. 3

   Captopril Multicenter Research Group. A placebo-controlled trial of captopril in refractory chronic congestive heart failure . J Am Coll Cardiol 1983; 2:755–63.
   CrossRef | Web of Science | Medline

4. 4

   Pfeffer MA, Lamas GA, Vaughan DE, Parisi AF, Braunwald E. Effect of captopril on progressive ventricular dilation after anterior myocardial infarction . N Engl J Med 1988;319:80–6.
   Full Text | Web of Science | Medline

5. 5

   Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction . Lancet 1988;1:255–9.
   CrossRef | Web of Science | Medline

6. 6

   The SOLVD Investigators. Studies of Left Ventricular Dysfunction (SOLVD) — rationale, design and methods: two trials that evaluate the effect of enalapril in patients with reduced ejection fraction . Am J Cardiol 1990;66:315–22.
   CrossRef | Web of Science | Medline

7. Erratum, Am J Cardiol 1990;66:1026.
   

8. 7

   Fleiss JL, Bigger JT Jr, McDermott M, et al. Nonfatal myocardial infarction is, by itself, an inappropriate end point in clinical trials in cardiology . Circulation 1990;81:684–5.
   CrossRef | Web of Science | Medline

9. 8

   Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples . Br J Cancer 1977;35:1–39.
   CrossRef | Web of Science | Medline

10. 9

    Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
    

11. 10

    McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham Study . N Engl J Med 1971; 285:1441–6.
    Full Text | Web of Science | Medline

Citing Articles (810)

Citing Articles

1. 1

   Rajaa F Faris, Marcus Flather, Henry Purcell, Philip A Poole-Wilson, Andrew JS Coats, Rajaa F Faris. 2012. Diuretics for heart failure. .
   CrossRef

2. 2

   E. Sieswerda, A. Postma, E. C. van Dalen, H. J. H. van der Pal, W. J. E. Tissing, L. A. J. Rammeloo, W. E. M. Kok, F. E. van Leeuwen, H. N. Caron, L. C. M. Kremer, . (2012) The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Annals of Oncology
   CrossRef

3. 3

   Elizabeth J. Brant, Albert Q. Lam, Julian L. Seifter. 2011. Pharmacology of Vasopressin and the Renin-Angiotensin-Aldosterone System. .
   CrossRef

4. 4

   Bertram Pitt. (2011) The Role of Mineralocorticoid Receptor Antagonists in Patients with American College of Cardiology/American Heart Association StageB Heart Failure. Heart Failure Clinics
   CrossRef

5. 5

   Patrick Collier, Kenneth M. McDonald. (2011) The Role of Renin Angiotensin System Intervention in Stage B Heart Failure. Heart Failure Clinics
   CrossRef

6. 6

   Enrico Vizzardi, Ivano Bonadei, Francesca Del Magro, Silvia Bugatti, Antonio D’Aloia, Antonio Curnis, Livio Dei Cas. (2011) When Oral Anticoagulation Therapy is Needed in Patients With Cardiomyopathies: A Review of Literature. Heart, Lung and Circulation
   CrossRef

7. 7

   Kai M. Eggers, Per Venge. (2011) Utility of B-type natriuretic peptides and cardiac troponins for population screening regarding cardiac abnormalities. Pathology1
   CrossRef

8. 8

   Andreas P. Kalogeropoulos, Vasiliki V. Georgiopoulou, Mihai Gheorghiade, Javed Butler. (2011) Echocardiographic Evaluation of Left Ventricular Structure and Function: New Modalities and Potential Applications in Clinical Trials. Journal of Cardiac Failure
   CrossRef

9. 9

   Cornelia A.J. Brouwer, Aleida Postma, Judith M. Vonk, Nynke Zwart, Maarten P. van den Berg, Margreet Th.E. Bink-Boelkens, Wil V. Dolsma, Andries J. Smit, Elisabeth G.E. de Vries, W.J.E. Tissing, Jourik A. Gietema. (2011) Systolic and diastolic dysfunction in long-term adult survivors of childhood cancer. European Journal of Cancer 47:16, 2453-2462
   CrossRef

10. 10

    A. Tomaschitz, S. Pilz, E. Ritz, A. Morganti, T. Grammer, K. Amrein, B. O. Boehm, W. Marz. (2011) Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. European Heart Journal 32:21, 2642-2649
    CrossRef

11. 11

    Daniel Jacoby, Oltjan Albajrami, Lavanya Bellumkonda. (2011) Natural History of End-stage LV Dysfunction: Has It Improved from the Classic Franciosa and Cohn Graph?. Cardiology Clinics 29:4, 485-495
    CrossRef

12. 12

    J. M. Testani, S. G. Coca, R. P. Shannon, S. E. Kimmel, T. P. Cappola. (2011) Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials. European Journal of Heart Failure 13:11, 1224-1230
    CrossRef

13. 13

    Paul M. McKie, John A. Schirger, Lisa C. Costello-Boerrigter, Sherry L. Benike, Lynn K. Harstad, Kent R. Bailey, David O. Hodge, Margaret M. Redfield, Robert D. Simari, John C. Burnett, Horng H. Chen. (2011) Impaired Natriuretic and Renal Endocrine Response to Acute Volume Expansion in Pre-Clinical Systolic and Diastolic Dysfunction. Journal of the American College of Cardiology 58:20, 2095-2103
    CrossRef

14. 14

    Paul A. Scott, Laurence D. Sterns, Anthony S. Tang. (2011) Do patients at high risk of nonsudden cardiac death benefit from prophylactic ICD therapy?. Current Opinion in Cardiology1
    CrossRef

15. 15

    F. A. McAlister, . (2011) Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers are beneficial in normotensive atherosclerotic patients: a collaborative meta-analysis of randomized trials. European Heart Journal
    CrossRef

16. 16

    M. Volpe. (2011) Should all patients at high cardiovascular risk receive renin-angiotensin system blockers?. QJM
    CrossRef

17. 17

    Daniel P. Judge, David A. Kass, W. Reid Thompson, Kathryn R. Wagner. (2011) Pathophysiology and Therapy of Cardiac Dysfunction in Duchenne Muscular Dystrophy. American Journal Cardiovascular Drugs 11:5, 287-294
    CrossRef

18. 18

    José Luis Górriz Teruel, Sandra Beltrán Catalán. (2011) Assessment of Renal Function, Iatrogenic Hyperkalemia and Acute Renal Dysfunction in Cardiology. Contrast-Induced Nephropathy. Revista Española de Cardiología (English Edition)
    CrossRef

19. 19

    José Luis Górriz Teruel, Sandra Beltrán Catalán. (2011) Valoración de afección renal, disfunción renal aguda e hiperpotasemia por fármacos usados en cardiología y nefrotoxicidad por contrastes. Revista Española de Cardiología
    CrossRef

20. 20

    Elske Sieswerda, Elvira C van Dalen, Aleida Postma, Daniel KL Cheuk, Huib N Caron, Leontien CM Kremer, Elske Sieswerda. 2011. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. .
    CrossRef

21. 21

    Christopher R. deFilippi, Robert H. Christenson, Willem J. Kop, John S. Gottdiener, Min Zhan, Stephen L. Seliger. (2011) Left Ventricular Ejection Fraction Assessment in Older Adults. Journal of the American College of Cardiology 58:14, 1497-1506
    CrossRef

22. 22

    Joseph L. Izzo Jr, Matthew R. Weir. (2011) Angiotensin-Converting Enzyme Inhibitors. The Journal of Clinical Hypertension 13:9, 667-675
    CrossRef

23. 23

    A. Mark Richards. (2011) Left Ventricular Ejection Fraction in Addition to N-Terminal Pro–B-Type Natriuretic Peptide for Risk Stratification in the Ambulant Elderly. Journal of the American College of Cardiology 58:14, 1507-1508
    CrossRef

24. 24

    D. Jacoby, W. J. McKenna. (2011) Genetics of inherited cardiomyopathy. European Heart Journal
    CrossRef

25. 25

    Christopher C. Afendulis, Yulei He, Alan M. Zaslavsky, Michael E. Chernew. (2011) The Impact of Medicare Part D on Hospitalization Rates. Health Services Research 46:4, 1022-1038
    CrossRef

26. 26

    M. Zhuo, J. Dong, Y. Zheng, L. Zuo. (2011) Are ACEI/ARBs associated with the decreased peritoneal protein clearance in long-term PD patients?. Nephrology Dialysis Transplantation 26:8, 2684-2690
    CrossRef

27. 27

    Selcuk Adabag, Henri Roukoz, Inder S. Anand, Arthur J. Moss. (2011) Cardiac Resynchronization Therapy in Patients With Minimal Heart Failure. Journal of the American College of Cardiology 58:9, 935-941
    CrossRef

28. 28

    Bruce J. Kimura, Norihiro Yogo, Charles W. O'Connell, James N. Phan, Brian K. Showalter, Tanya Wolfson. (2011) Cardiopulmonary Limited Ultrasound Examination for “Quick-Look” Bedside Application. The American Journal of Cardiology 108:4, 586-590
    CrossRef

29. 29

    Xavier Bosch, Jordi Esteve, Marta Sitges, Teresa M. de Caralt, Ariadna Domènech, José T. Ortiz, Mariano Monzó, Manuel Morales-Ruiz, Rosario J. Perea, Montserrat Rovira. (2011) Prevention of Chemotherapy-Induced Left Ventricular Dysfunction With Enalapril and Carvedilol: Rationale and Design of the OVERCOME Trial. Journal of Cardiac Failure 17:8, 643-648
    CrossRef

30. 30

    Jean-Claude Daubert, Erwan Donal, Cecilia Linde. (2011) A plea for the wider use of CRT-P in candidates for cardiac resynchronisation therapy. Heart Failure Reviews
    CrossRef

31. 31

    Judy Ying Chen, Ning Kang, Deborah Taira Juarez, Irina Yermilov, Ronald S. Braithwaite, Krista A. Hodges, Antonio Legorreta, Richard S. Chung. (2011) Heart Failure Patients Receiving ACEIs/ARBs were Less Likely to be Hospitalized or to Use Emergency Care in the Following Year. Journal for Healthcare Quality 33:4, 29-36
    CrossRef

32. 32

    Ilke Sipahi, Josephine Chou, Prasun Mishra, Sara M. Debanne, Daniel I. Simon, James C. Fang. (2011) Meta-Analysis of Randomized Controlled Trials on Effect of Angiotensin-Converting Enzyme Inhibitors on Cancer Risk. The American Journal of Cardiology 108:2, 294-301
    CrossRef

33. 33

    Thomas Yeoh, Christopher Hayward, Victoria Benson, Angela Sheu, Zara Richmond, Michael P. Feneley, Anne M. Keogh, Peter Macdonald, Diane Fatkin. (2011) A Randomised, Placebo-controlled Trial of Carvedilol in Early Familial Dilated Cardiomyopathy. Heart, Lung and Circulation
    CrossRef

34. 34

    Ryan P. Morrissey, Lawrence Czer, Prediman K. Shah. (2011) Chronic Heart Failure. American Journal Cardiovascular Drugs 11:3, 153-171
    CrossRef

35. 35

    Amy McCurley, Iris Z. Jaffe. (2011) Mineralocorticoid receptors in vascular function and disease. Molecular and Cellular Endocrinology
    CrossRef

36. 36

    Roman Pfister, Richard Cairns, Erland Erdmann, Christian A. Schneider. (2011) A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: An analysis of the PROactive study. International Journal of Cardiology
    CrossRef

37. 37

    Jay Pandhi, John S. Gottdiener, Traci M. Bartz, Willem J. Kop, Mandeep R. Mehra. (2011) Comparison of Characteristics and Outcomes of Asymptomatic Versus Symptomatic Left Ventricular Dysfunction in Subjects 65 Years Old or Older (from the Cardiovascular Health Study). The American Journal of Cardiology 107:11, 1667-1674
    CrossRef

38. 38

    Kurt C. Roberts-Thomson, Dennis H. Lau, Prashanthan Sanders. (2011) The diagnosis and management of ventricular arrhythmias. Nature Reviews Cardiology 8:6, 311-321
    CrossRef

39. 39

    M. Azizi, M. Frank, O. Steichen, A. Blanchard. (2011) Intérêts et limites de l’inhibition de la rénine par l’aliskiren. Annales Pharmaceutiques Françaises 69:3, 142-150
    CrossRef

40. 40

    Ragab A. Mahfouz, Mohammad A. El Tahlawi, Amr A. Ateya, Ashraf Elsaied. (2011) Early Detection of Silent Ischemia and Diastolic Dysfunction in Asymptomatic Young Hypertensive Patients. Echocardiography 28:5, 564-569
    CrossRef

41. 41

    Pierre Vladimir Ennezat, Claire Vannesson, Nadia Bouabdallaoui, Sylvestre Maréchaux, Philippe Asseman, Thierry H LeJemtel. (2011) Imagine how many lives you save: angiotensin-converting enzyme inhibition for atherosclerotic vascular disease in the present era of risk reduction. Expert Opinion on Pharmacotherapy 12:6, 883-897
    CrossRef

42. 42

    Fabio Angeli, Gianpaolo Reboldi, Paolo Verdecchia. (2011) Modern treatment of patients at risk: still a HOPE for ACE inhibitors?. Expert Opinion on Pharmacotherapy 12:6, 839-843
    CrossRef

43. 43

    Raymond T. Yan, David Bluemke, Antoinette Gomes, Gregory Burke, Steve Shea, Kiang Liu, Hossein Bahrami, Shantanu Sinha, Colin Wu, Veronica Fernandes, Robyn McClelland, João A.C. Lima. (2011) Regional Left Ventricular Myocardial Dysfunction as a Predictor of Incident Cardiovascular Events. Journal of the American College of Cardiology 57:17, 1735-1744
    CrossRef

44. 44

    Qi Qian, Dennis M. Manning, Narith Ou, Mark J. Klarich, Dorinda J. Leutink, Ann R. Loth, Francisco Lopez-Jimenez. (2011) ACEi/ARB for systolic heart failure: Closing the quality gap with a sustainable intervention at an academic medical center. Journal of Hospital Medicine 6:3, 156-160
    CrossRef

45. 45

    Finn Akerström, Luis Rodríguez-Padial. (2011) Hypertension, the J-Curve and the INVEST Trial. The American Journal of Cardiology 107:3, 490-491
    CrossRef

46. 46

    William T Abraham, Philip B Adamson, Robert C Bourge, Mark F Aaron, Maria Rosa Costanzo, Lynne W Stevenson, Warren Strickland, Suresh Neelagaru, Nirav Raval, Steven Krueger, Stanislav Weiner, David Shavelle, Bradley Jeffries, Jay S Yadav. (2011) Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. The Lancet 377:9766, 658-666
    CrossRef

47. 47

    H. Krum, B. Massie, W. T. Abraham, K. Dickstein, L. Kober, J. J. V. McMurray, A. Desai, C. Gimpelewicz, A. Kandra, B. Reimund, H. Rattunde, J. Armbrecht, , H. Krum, B. Massie, W. Abraham, K. Dickstein, L. Kober, J. McMurray, K. Swedberg, S. Pocock, B. Pitt, S. Borer Jeffrey, J. Rouleau, M. Wibberg, S. Solomon, S. Desai Akshay, P. Finn, L. Weinrauch, H. Hartley, A.-C. Pouleur, E. Barkoudah, C. Duong, A. Rogers. (2011) Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. European Journal of Heart Failure 13:1, 107-114
    CrossRef

48. 48

    Sripal Bangalore, Sunil Kumar, Sverre E Kjeldsen, Harikrishna Makani, Ehud Grossman, Jørn Wetterslev, Ajay K Gupta, Peter S Sever, Christian Gluud, Franz H Messerli. (2011) Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials. The Lancet Oncology 12:1, 65-82
    CrossRef

49. 49

    Andrew L. Avins, Alice Pressman, Lynn Ackerson, Peter Rudd, John Neuhaus, Eric Vittinghoff. (2010) Placebo Adherence and Its Association with Morbidity and Mortality in the Studies of Left Ventricular Dysfunction. Journal of General Internal Medicine 25:12, 1275-1281
    CrossRef

50. 50

    Navtej S. Chahal, Tiong K. Lim, Piyush Jain, John C. Chambers, Jaspal S. Kooner, Roxy Senior. (2010) The Distinct Relationships of Carotid Plaque Disease and Carotid Intima-Media Thickness with Left Ventricular Function. Journal of the American Society of Echocardiography 23:12, 1303-1309
    CrossRef

51. 51

    Helen Smith, Matthew Hankins, Andrew Hodson, Charles George. (2010) Measuring the adherence to medication of elderly patients with heart failure: Is there a gold standard?. International Journal of Cardiology 145:1, 122-123
    CrossRef

52. 52

    Javier Padillo, Pilar Rioja, María C. Muñoz-Villanueva, Juan A. Vallejo, Rubén Ciria, Jordi Muntane, Antonio Sitges-Serra, Guillermo Solórzano, Manuel De la Mata. (2010) BNP as marker of heart dysfunction in patients with liver cirrhosis. European Journal of Gastroenterology & Hepatology 22:11, 1331-1336
    CrossRef

53. 53

    Douglas L. Kosmicki, Sean P. Collins, Michael C. Kontos, Michel Zuber, Peter Kipfer, Christine Attenhofer Jost, Andrew D. Michaels. (2010) Noninvasive Prediction of Left Ventricular Systolic Dysfunction in Patients With Clinically Suspected Heart Failure Using Acoustic Cardiography. Congestive Heart Failure 16:6, 249-253
    CrossRef

54. 54

    Geoffrey J. Yoon, Melinda L. Telli, David P. Kao, Kelly Y. Matsuda, Robert W. Carlson, Ronald M. Witteles. (2010) Left Ventricular Dysfunction in Patients Receiving Cardiotoxic Cancer Therapies. Journal of the American College of Cardiology 56:20, 1644-1650
    CrossRef

55. 55

    Bruce J. Kimura, Glynn W. Gilcrease III, Brian K. Showalter, James N. Phan, Tanya Wolfson. (2010) Diagnostic performance of a pocket-sized ultrasound device for quick-look cardiac imaging. The American Journal of Emergency Medicine
    CrossRef

56. 56

    Barry H. Greenberg, John G. F. Cleland. 2010. Emerging Therapies for Heart Failure. , 157-175.
    CrossRef

57. 57

    Vijay U. Rao, John R. Teerlink. 2010. Treating Systolic Heart Failure. , 287-326.
    CrossRef

58. 58

    Ruchika Dutta, Barry H. Greenberg. 2010. Neurohormonal Blocking Agents in the Treatment of Patients with Left Ventricular Dysfunction and Heart Failure. , 83-116.
    CrossRef

59. 59

    L.J. Murray, S. Ramakrishnan, L. O'Toole, I.H. Manifold, O.P. Purohit, R.E. Coleman. (2010) Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery. The Breast 19:5, 339-344
    CrossRef

60. 60

    Giuseppe Boriani, Igor Diemberger, Cinzia Valzania, Mauro Biffi, Cristian Martignani, Emanuel Raschi, Valentina Mantovani, Matteo Ziacchi, Matteo Bertini, Fabrizio De Ponti, Angelo Branzi. (2010) Role of drugs and devices in patients at risk of sudden cardiac death. Fundamental & Clinical Pharmacology 24:5, 575-594
    CrossRef

61. 61

    Diane M. Richardson, Kevin T. Bain, James J. Diamond, Karen D. Novielli, Seina P. Lee, Neil I. Goldfarb. (2010) Effectiveness of Guideline-Recommended Cardiac Drugs for Reducing Mortality in the Elderly Medicare Heart Failure Population. Drugs & Aging 27:10, 845-854
    CrossRef

62. 62

    Domenic A. Sica. (2010) Angiotensin Receptor Blockers and the Risk of Malignancy. Drug Safety 33:9, 709-712
    CrossRef

63. 63

    Henry Krum, Aldo Maggioni. (2010) Renin Inhibitors in Chronic Heart Failure: The Aliskiren Observation of Heart Failure Treatment Study in Context. Clinical Cardiology 33:9, 536-541
    CrossRef

64. 64

    Sophie Günther, Hideo A. Baba, Steffen Hauptmann, Hans-Jürgen Holzhausen, Claudia Großmann, Karla Punkt, Tina Kusche, Larry R. Jones, Ulrich Gergs, Joachim Neumann. (2010) Losartan reduces mortality in a genetic model of heart failure. Naunyn-Schmiedeberg's Archives of Pharmacology 382:3, 265-278
    CrossRef

65. 65

    F. d. D. Cruz, V. S. Issa, S. M. Ayub-Ferreira, P. R. Chizzola, G. E. C. Souza, L. F. P. Moreira, J. R. Lanz-Luces, E. A. Bocchi. (2010) Effect of a sequential education and monitoring programme on quality-of-life components in heart failure. European Journal of Heart Failure 12:9, 1009-1015
    CrossRef

66. 66

    Saul Blecker, Kunihiro Matsushita, Ervin Fox, Stuart D. Russell, Edgar R. Miller, Herman Taylor, Frederick Brancati, Josef Coresh. (2010) Left ventricular dysfunction as a risk factor for cardiovascular and noncardiovascular hospitalizations in African Americans. American Heart Journal 160:3, 488-495
    CrossRef

67. 67

    Michael Böhm, Ulrich Laufs, Michael Pfreundschuh. (2010) Angiotensin-receptor blockade, cancer, and concerns. The Lancet Oncology 11:9, 818-819
    CrossRef

68. 68

    Ray E. Hershberger, Ana Morales, Jill D. Siegfried. (2010) Clinical and genetic issues in dilated cardiomyopathy: A review for genetics professionals. Genetics in Medicine1
    CrossRef

69. 69

    D. L. Mann, R. Bogaev, G. D. Buckberg. (2010) Cardiac remodelling and myocardial recovery: lost in translation?. European Journal of Heart Failure 12:8, 789-796
    CrossRef

70. 70

    Thomas J Povsic, Christopher M O’Connor. (2010) Cell therapy for heart failure: the need for a new therapeutic strategy. Expert Review of Cardiovascular Therapy 8:8, 1107-1126
    CrossRef

71. 71

    Robert M. Weiss, Richard E. Kerber, Jane K. Jones, Carrie M. Stephan, Christina J. Trout, Paul D. Lindower, Kimberly S. Staffey, Kevin P. Campbell, Katherine D. Mathews. (2010) Exercise-Induced Left Ventricular Systolic Dysfunction in Women Heterozygous for Dystrophinopathy. Journal of the American Society of Echocardiography 23:8, 848-853
    CrossRef

72. 72

    Kathy Hebert, Ron Horswell, Paul Heidenreich, Jennifer Miranda, Lee Arcement. (2010) Handheld Ultrasound, B-Natriuretic Peptide for Screening Stage B Heart Failure. Southern Medical Journal 103:7, 616-622
    CrossRef

73. 73

    Daniel G. Kramer, Thomas A. Trikalinos, David M. Kent, George V. Antonopoulos, Marvin A. Konstam, James E. Udelson. (2010) Quantitative Evaluation of Drug or Device Effects on Ventricular Remodeling as Predictors of Therapeutic Effects on Mortality in Patients With Heart Failure and Reduced Ejection Fraction. Journal of the American College of Cardiology 56:5, 392-406
    CrossRef

74. 74

    Shizu Oyamada, Cesario Bianchi, Shinji Takai, Michael P. Robich, Richard T. Clements, Louis Chu, Frank W. Sellke. (2010) Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin–angiotensin system. Basic Research in Cardiology 105:4, 513-522
    CrossRef

75. 75

    Jay S. Kaufman, Thu T. Nguyen, Richard S. Cooper. (2010) Race, Medicine, and the Science Behind BiDil: How ACE-Inhibition Took the Fall for the First Ethnic Drug. The Review of Black Political Economy 37:2, 115-130
    CrossRef

76. 76

    F. Zannad, J. J. V. McMurray, H. Drexler, H. Krum, D. J. van Veldhuisen, K. Swedberg, H. Shi, J. Vincent, B. Pitt. (2010) Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF). European Journal of Heart Failure 12:6, 617-622
    CrossRef

77. 77

    D. Castagno, P. S. Jhund, J. J. V. McMurray, J. D. Lewsey, E. Erdmann, F. Zannad, W. J. Remme, J. L. Lopez-Sendon, P. Lechat, F. Follath, C. Hoglund, V. Mareev, Z. Sadowski, R. J. Seabra-Gomes, H. J. Dargie. (2010) Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial. European Journal of Heart Failure 12:6, 607-616
    CrossRef

78. 78

    (2010) Section 7: Heart Failure in Patients With Reduced Ejection Fraction. Journal of Cardiac Failure 16:6, e73-e97
    CrossRef

79. 79

    (2010) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 16:6, e157-e165
    CrossRef

80. 80

    J. R. de Berrazueta, A. Guerra-Ruiz, M. T. Garcia-Unzueta, G. Martin Toca, R. Sainz Laso, M. Saez de Adana, M. A. Casanova Martin, M. Cobo, J. LLorca. (2010) Endothelial dysfunction, measured by reactive hyperaemia using strain-gauge plethysmography, is an independent predictor of adverse outcome in heart failure. European Journal of Heart Failure 12:5, 477-483
    CrossRef

81. 81

    Jay N. Cohn. (2010) Detecting the Patient at Risk of Heart FailureEditorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of the JACC or the American College of Cardiology.. Journal of the American College of Cardiology 55:19, 2138-2139
    CrossRef

82. 82

    Bodh I Jugdutt. (2010) Heart failure in the elderly: advances and challenges. Expert Review of Cardiovascular Therapy 8:5, 695-715
    CrossRef

83. 83

    Rebecca Scully, Steven E. Lipshultz. 2010. Cardiovascular Toxicity of Antitumor Drugs: Dimensions of the Problem in Children. , 97-126.
    CrossRef

84. 84

    Chih-Chang Wei, Naoki Hase, Yukiko Inoue, Eddie W. Bradley, Eiji Yahiro, Ming Li, Nawazish Naqvi, Pamela C. Powell, Ke Shi, Yoshimasa Takahashi, Keijiro Saku, Hidenori Urata, Louis J. Dell’Italia, Ahsan Husain. (2010) Mast cell chymase limits the cardiac efficacy of Ang I–converting enzyme inhibitor therapy in rodents. Journal of Clinical Investigation 120:4, 1229-1239
    CrossRef

85. 85

    John J. Atherton. (2010) Screening for Left Ventricular Systolic Dysfunction: Is Imaging a Solution?. JACC: Cardiovascular Imaging 3:4, 421-428
    CrossRef

86. 86

    Salim Hayek, Mona Nemer. (2010) Cardiac Natriuretic Peptides: From Basic Discovery to Clinical Practice. Cardiovascular Therapeuticsno-no
    CrossRef

87. 87

    Alexander Doumas, Timothy S. Draper, Edgar C. Schick, William H. Gaasch. (2010) Prevalence and Clinical Characteristics of Nondilated Cardiomyopathy and the Effect of Atrial Fibrillation. The American Journal of Cardiology 105:6, 884-887
    CrossRef

88. 88

    Prakash C. Deedwania, Joel A. Lardizabal. (2010) Atrial Fibrillation in Heart Failure: A Comprehensive Review. The American Journal of Medicine 123:3, 198-204
    CrossRef

89. 89

    Ravi V. Shah, Akshay S. Desai, Michael M. Givertz. (2010) The Effect of Renin-Angiotensin System Inhibitors on Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. Journal of Cardiac Failure 16:3, 260-267
    CrossRef

90. 90

    Bernhard Maisch, Sabine Pankuweit. (2010) Therapie der fortgeschrittenen Herz - insuffizienz: medikamentös, Resynchronisation (CRT), Operation. Herz 35:2, 94-101
    CrossRef

91. 91

    Lori B. Daniels, Paul Clopton, Kevin Jiang, Barry Greenberg, Alan S. Maisel. (2010) Prognosis of Stage A or B Heart Failure Patients With Elevated B-type Natriuretic Peptide Levels. Journal of Cardiac Failure 16:2, 93-98
    CrossRef

92. 92

    Michael Bader. (2010) Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy. Annual Review of Pharmacology and Toxicology 50:1, 439-465
    CrossRef

93. 93

    McMurray, John J.V., . (2010) Systolic Heart Failure. New England Journal of Medicine 362:3, 228-238
    Full Text

94. 94

    (2010) Cardiac-Resynchronization Therapy. New England Journal of Medicine 362:2, 177-179
    Full Text

95. 95

    J.M. Neutel. (2010) Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Current Medical Research and Opinion 26:1, 213-222
    CrossRef

96. 96

    Barry Greenberg. (2010) Pre-Clinical Diastolic Dysfunction in Diabetic Patients. Journal of the American College of Cardiology 55:4, 306-308
    CrossRef

97. 97

    Srikanth Katragadda, Rohit R Arora. (2010) Role of Angiotensin-Converting Enzyme Inhibitors in Vascular Modulation: Beyond the Hypertensive Effects. American Journal of Therapeutics 17:1, e11-e23
    CrossRef

98. 98

    Juan Pablo Kaski, Perry Elliott. 2010. Cardiomyopathies. , 1003-1034.
    CrossRef

99. 99

    Matteo Cesari, Claudio Pedone, Raffaele Antonelli Incalzi, Marco Pahor. (2010) ACE-Inhibition and Physical Function: Results From the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) Study. Journal of the American Medical Directors Association 11:1, 26-32
    CrossRef

100. 100

     M. Bohm, F. Mahfoud, C. Werner, K. Teo, M. Baumhakel. (2009) Cardiovascular protection: a breakthrough for high-risk patients. European Heart Journal Supplements 11:Suppl F, F19-F26
     CrossRef

101. 101

     Veli K. Topkara, Srikanth Kondareddy, Douglas L. Mann. (2009) Modulation of left ventricular dilation remodeling with epicardial restraint devices in postmyocardial infarction heart failure. Current Heart Failure Reports 6:4, 229-235
     CrossRef

102. 102

     Ken Yajima, Akira Shimada, Hiroshi Hirose, Yoichi Oikawa, Satoru Yamada, Shu Meguro, Junichiro Irie, Seiko Irie. (2009) Effect on the Atherogenic Marker Plasminogen Activator Inhibitor Type-1 of Addition of the ACE Inhibitor Imidapril to Angiotensin II Type 1 Receptor Antagonist Therapy in Hypertensive Patients with Abnormal Glucose Metabolism. Clinical Drug Investigation 29:12, 811-819
     CrossRef

103. 103

     Prem Soman, James E. Udelson. (2009) Gated SPECT Myocardial Perfusion Imaging for the Prediction of Incident Heart Failure. JACC: Cardiovascular Imaging 2:12, 1401-1403
     CrossRef

104. 104

     Tuomas Kerola, Tuomo Nieminen, Sirpa Hartikainen, Raimo Sulkava, OLLI Vuolteenaho, Raimo Kettunen. (2009) High-density lipoprotein is superior to B-type natriuretic peptide as a marker of systolic dysfunction in an elderly general population. Scandinavian Journal of Clinical & Laboratory Investigation 69:8, 865-872
     CrossRef

105. 105

     Young-Sin Kim, Barry Greenberg. (2009) Update on renin-angiotensin-aldosterone blockade in heart failure. Current Treatment Options in Cardiovascular Medicine 11:6, 455-466
     CrossRef

106. 106

     K. K. Teo. (2009) Clinical evidence from ONTARGET: proven cardio- and vascular protection. European Heart Journal Supplements 11:Suppl F, F9-F15
     CrossRef

107. 107

     Kwame O. Akosah, Vicki L. Mchugh, Michelle A. Mathiason, Kara J. Kallies, Ross Pinter, Virginia B. Thayer. (2009) Closing the Heart Failure Management Gap in the Community: Managing Hypotension and Impact on Outcomes. Journal of Cardiac Failure 15:10, 906-911
     CrossRef

108. 108

     Izo Helber, Alexandra A. Dos Santos, Ednei L. Antonio, Ronald L.G. Flumignan, Danilo S. Bocalini, Camila Piccolo, Mihai Gheorghiade, Paulo J.F. Tucci. (2009) Digitoxin Prolongs Survival of Female Rats With Heart Failure Due to Large Myocardial Infarction. Journal of Cardiac Failure 15:9, 798-804
     CrossRef

109. 109

     Elske Sieswerda, Elvira C van Dalen, Aleida Postma, Huib N Caron, Leontien CM Kremer, Elske Sieswerda. 2009. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. .
     CrossRef

110. 110

     Giovanna Pelà, Paolo Pattoneri, Mariadele Passera, Giovanni Tirabassi, Claudio Reverberi, Alberto Montanari, Tiziano Gherli. (2009) Long-term effects of perindopril on left ventricular structure and function in patients with stable coronary artery disease: a conventional and Doppler tissue echocardiographic pilot study. Journal of Cardiovascular Medicine 10:10, 781-786
     CrossRef

111. 111

     Sachiko Sakurabayashi-Kitade, Yoshikazu Aoka, Hirotaka Nagashima, Hiroshi Kasanuki, Nobuhisa Hagiwara, Masatoshi Kawana. (2009) Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice. Atherosclerosis 206:1, 54-60
     CrossRef

112. 112

     Aneta Aleksova, Gastone Sabbadini, Marco Merlo, Bruno Pinamonti, Giulia Barbati, Massimo Zecchin, Rossana Bussani, Furio Silvestri, Anna M Iorio, Davide Stolfo, Matteo Dal Ferro, Andreea M Dragos, Gennaro Meringolo, Stelios Pyxaras, Francesco Lo Giudice, Andrea Perkan, Andrea di Lenarda, Gianfranco Sinagra. (2009) Natural history of dilated cardiomyopathy: from asymptomatic left ventricular dysfunction to heart failure – a subgroup analysis from the Trieste Cardiomyopathy Registry. Journal of Cardiovascular Medicine 10:9, 699-705
     CrossRef

113. 113

     Barry M. Massie. (2009) Prevention of Heart Failure With Chlorthalidone in ALLHAT: Placing the Results Into Perspective. The Journal of Clinical Hypertension 11:9, 462-465
     CrossRef

114. 114

     Elizabeth L. Strevel, Lillian L. Siu. (2009) Cardiovascular toxicity of molecularly targeted agents. European Journal of Cancer 45, 318-331
     CrossRef

115. 115

     (2009) CardioPulse Articles. European Heart Journal 30:15, 1809-1818
     CrossRef

116. 116

     Mitchell H. Rosner. (2009) Hyponatremia in Heart Failure: The Role of Arginine Vasopressin and Diuretics. Cardiovascular Drugs and Therapy 23:4, 307-315
     CrossRef

117. 117

     David J Grieve, Roslyn S Cassidy, Brian D Green. (2009) Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?. British Journal of Pharmacology 157:8, 1340-1351
     CrossRef

118. 118

     M. L. Simoons. (2009) Angiotensin-converting enzyme inhibition by perindopril in cardiovascular disease. European Heart Journal Supplements 11:Suppl E, E4-E8
     CrossRef

119. 119

     M. Klapholz. (2009)  -Blocker Use for the Stages of Heart Failure. Mayo Clinic Proceedings 84:8, 718-729
     CrossRef

120. 120

     SJOERD A. MOLLEMA, PATRICK KLEIN, JOGIEN HEERSCHE, MARTIN J. SCHALIJ, ERNST E. VAN DER WALL, MICHEL I.M. VERSTEEGH, ROBERT J.M. KLAUTZ, LIESELOT VAN ERVEN, JEROEN J. BAX. (2009) Left Ventricular Ejection Fraction as Criterion for Implantation of an Implantable Cardioverter-Defibrillator in Heart Failure Patients Undergoing Surgical Left Ventricular Reconstruction. Pacing and Clinical Electrophysiology 32:7, 913-917
     CrossRef

121. 121

     Irene Betti, Gabriele Castelli, Alessandro Barchielli, Cinzia Beligni, Vittorio Boscherini, Leonardo De Luca, Gianni Messeri, Mihai Gheorghiade, Alan Maisel, Alfredo Zuppiroli. (2009) The Role of N-terminal PRO-Brain Natriuretic Peptide and Echocardiography for Screening Asymptomatic Left Ventricular Dysfunction in a Population at High Risk for Heart Failure. The PROBE-HF Study. Journal of Cardiac Failure 15:5, 377-384
     CrossRef

122. 122

     Santiago Garcia, Mariana Canoniero, Larry Young. (2009) The Effect of July Admission in the Process of Care of Patients with Acute Cardiovascular Conditions. Southern Medical Journal 102:6, 602-607
     CrossRef

123. 123

     Amir Ravandi, Koon K Teo. (2009) Blocking the renin–angiotensin system: dual- versus mono-therapy. Expert Review of Cardiovascular Therapy 7:6, 667-674
     CrossRef

124. 124

     G. Tasevska-Dinevska, L. M. A. Kennedy, P. M. Nilsson, R. Willenheimer. (2009) Gender aspects on heart failure incidence and mortality in a middle-aged, urban, community-based population sample: the Malmö preventive project. European Journal of Epidemiology 24:5, 249-257
     CrossRef

125. 125

     Camila Manrique, Guido Lastra, Michael Gardner, James R. Sowers. (2009) The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress. Medical Clinics of North America 93:3, 569-582
     CrossRef

126. 126

     Deddo Moertl, Rudolf Berger, Alexandra Hammer, Martin Huelsmann, Raisa Hutuleac, Richard Pacher. (2009) B-Type Natriuretic Peptide Predicts Benefit From a Home-Based Nurse Care in Chronic Heart Failure. Journal of Cardiac Failure 15:3, 233-240
     CrossRef

127. 127

     GRZEGORZ PIETRASIK, ILAN GOLDENBERG, SCOTT McNITT, BRONISLAVA POLONSKY, ARTHUR J. MOSS, WOJCIECH ZAREBA. (2009) Efficacy of Medical Therapy for the Reduction of Heart Failure Events in Patients with Implanted Cardioverter Defibrillators. Journal of Cardiovascular Electrophysiology 20:4, 395-400
     CrossRef

128. 128

     Jun Iwanami, Masaki Mogi, Masaru Iwai, Masatsugu Horiuchi. (2009) Inhibition of the renin–angiotensin system and target organ protection. Hypertension Research 32:4, 229-237
     CrossRef

129. 129

     Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy. (2009) 2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology 53:15, e1-e90
     CrossRef

130. 130

     Saraswathy Manickavasagam, Ramanna Merla, Michael M Koerner, Ken Fujise, Sanjay Kunapuli, Salvatore Rosanio, Alejandro Barbagelata. (2009) Management of hypertension in chronic heart failure. Expert Review of Cardiovascular Therapy 7:4, 423-433
     CrossRef

131. 131

     Christos Chatzikyrkou, Hermann Haller, Jan Menne. (2009) Fixed-dose combination of lercanidipine/enalapril in the treatment of hypertension in the elderly. Aging Health 5:2, 141-149
     CrossRef

132. 132

     James A. de Lemos, Darren K. McGuire, Amit Khera, Sandeep R. Das, Sabina A. Murphy, Torbjorn Omland, Mark H. Drazner. (2009) Screening the population for left ventricular hypertrophy and left ventricular systolic dysfunction using natriuretic peptides: Results from the Dallas Heart Study. American Heart Journal 157:4, 746-753.e2
     CrossRef

133. 133

     A L Jones, M Barlow, P J Barrett-Lee, P A Canney, I M Gilmour, S D Robb, C J Plummer, A M Wardley, M W Verrill. (2009) Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. British Journal of Cancer 100:5, 684-692
     CrossRef

134. 134

     Michael Rudnicki, Gert Mayer. (2009) Significance of genetic polymorphisms of the renin–angiotensin–aldosterone system in cardiovascular and renal disease. Pharmacogenomics 10:3, 463-476
     CrossRef

135. 135

     Henry Krum, William T Abraham. (2009) Heart failure. The Lancet 373:9667, 941-955
     CrossRef

136. 136

     Karl E. Hammermeister, Diane Fairclough, Caroline Bublitz Emsermann, Richard Hamman, Michael Ho, Stephanie Phibbs, Mary Plomondon, Robert Valuck, David West, John F. Steiner. (2009) Effectiveness of hydralazine/isosorbide dinitrate in racial/ethnic subgroups with heart failure. Clinical Therapeutics 31:3, 632-643
     CrossRef

137. 137

     Michele McGrady, Henry Krum. (2009) Screening: The New Frontier in Heart Failure Management. Cardiovascular Therapeutics 27:1, 1-3
     CrossRef

138. 138

     B. A. Koplan, W. G. Stevenson. (2009) Ventricular Tachycardia and Sudden Cardiac Death. Mayo Clinic Proceedings 84:3, 289-297
     CrossRef

139. 139

     Matteo Cesari, Stephen B. Kritchevsky, Hal H. Atkinson, Brenda W. Penninx, Mauro Di Bari, Russell P. Tracy, Marco Pahor. (2009) Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers. American Heart Journal 157:2, 334.e1-334.e8
     CrossRef

140. 140

     Duncan J. Campbell. (2009) Angiotensin vaccination: What is the prospect of success?. Current Hypertension Reports 11:1, 63-68
     CrossRef

141. 141

     L. David Martin, Eric E. Howell, Roy C. Ziegelstein, Carol Martire, Quinn E. Whiting-O'Keefe, Edward P. Shapiro, David B. Hellmann. (2009) Hand-carried Ultrasound Performed by Hospitalists: Does It Improve the Cardiac Physical Examination?. The American Journal of Medicine 122:1, 35-41
     CrossRef

142. 142

     W. Frank Peacock, Gregg C. Fonarow, Douglas S. Ander, Sean P. Collins, Mihai Gheorghiade, J. Douglas Kirk, Gerasimos Filippatos, Deborah B. Diercks, Robin J. Trupp, Brian Hiestand, Ezra A. Amsterdam, William T. Abraham, Ezra A. Amsterdam, Gail Dodge, David F. Gaieski, Diane Gurney, Christy O. Hayes, Judd E. Hollander, Kay Holmes, James L. Januzzi, Phillip Levy, Alan Maisel, Chadwick D. Miller, Peter S. Pang, Elsie Selby, Alan B. Storrow, Neal L. Weintraub, Clyde W. Yancy, Raymond D. Bahr, Andra L. Blomkalns, James McCord, Richard M. Nowak, Robert J. Stomel. (2009) Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient—part 1. Acute Cardiac Care 11:1, 3-42
     CrossRef

143. 143

     T. Jared Bunch, John D. Day, Brian Olshansky, Kira Q. Stolen, Christopher M. Mullin. (2009) Newly detected atrial fibrillation in patients with an implantable cardioverter-defibrillator is a strong risk marker of increased mortality. Heart Rhythm 6:1, 2-8
     CrossRef

144. 144

     John C. Alexander, Daniel E. Salazar. 2009. Modern Drug Discovery and Development. , 361-380.
     CrossRef

145. 145

     Christopher D. Lang, Rohit R. Arora, Sandeep A. Saha, Janos Molnar. (2008) Bayesian Meta-Analysis of Tissue Angiotensin-Converting Enzyme Inhibitors for Reduction of Adverse Cardiovascular Events in Patients with Diabetes Mellitus and Preserved Left Ventricular Function. Journal of the CardioMetabolic Syndrome 3:1, 45-52
     CrossRef

146. 146

     Michele Emdin, Marianna Fontana, Roberta Poletti, Alessandra Gabutti, Chiara Mammini, Andrea Rossi, Luigi Emilio Pastormerlo, Lorenzo Masi, Claudio Passino, Aldo Clerico. (2008) Natriuretic peptide testing in primary care patients. Clinical Chemistry and Laboratory Medicine 46:11, 1533-1542
     CrossRef

147. 147

     Ji Chen, Ernest V. Garcia, Stamatios Lerakis, Maureen M. Henneman, Jeroen J. Bax, Mark A. Trimble, Salvador Borges-Neto, Eric J. Velazquez, Ami E. Iskandrian. (2008) Left Ventricular Mechanical Dyssynchrony as Assessed by Phase Analysis of ECG-Gated SPECT Myocardial Perfusion Imaging. Echocardiography 25:10, 1186-1194
     CrossRef

148. 148

     Stuart D. Russell, Leslie W. Miller, Francis D. Pagani. (2008) Advanced Heart Failure: A Call to Action. Congestive Heart Failure 14:6, 316-321
     CrossRef

149. 149

     M. Angelyn Bethel, Rury Holman, Steven M. Haffner, Robert M. Califf, Alice Huntsman-Labed, Tsushung A. Hua, John McMurray. (2008) Determining the most appropriate components for a composite clinical trial outcome. American Heart Journal 156:4, 633-640
     CrossRef

150. 150

     Ken McDonald. (2008) Prevalencia de la insuficiencia cardiaca: un reflejo de lo bueno y lo malo de la asistencia cardiovascular moderna. Revista Española de Cardiología 61:10, 1010-1012
     CrossRef

151. 151

     Julian Segura, Luis M. Ruilope. (2008) Hyperkalemia Risk and Treatment of Heart Failure. Heart Failure Clinics 4:4, 455-464
     CrossRef

152. 152

     Uptal D. Patel, Adrian F. Hernandez, Li Liang, Eric D. Peterson, Kenneth A. LaBresh, Clyde W. Yancy, Nancy M. Albert, Gray Ellrodt, Gregg C. Fonarow. (2008) Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines—Heart Failure Program study. American Heart Journal 156:4, 674-681
     CrossRef

153. 153

     Marc A. Simon, John Watson, J. Timothy Baldwin, William R. Wagner, Harvey S. Borovetz. (2008) Current and Future Considerations in the Use of Mechanical Circulatory Support Devices*. Annual Review of Biomedical Engineering 10:1, 59-84
     CrossRef

154. 154

     Theresa A. McDonagh, Kenneth McDonald, Alan S. Maisel. (2008) Screening for Asymptomatic Left Ventricular Dysfunction Using B-Type Natriuretic Peptide. Congestive Heart Failure 14, 5-8
     CrossRef

155. 155

     Christian Mueller. (2008) Cost-Effectiveness of B-Type Natriuretic Peptide Testing. Congestive Heart Failure 14, 35-37
     CrossRef

156. 156

     Marc Vanderheyden, Jozef Bartunek, Gerasimos Filippatos, Marc Goethals, Bruno Van Vlem, Alan Maisel. (2008) Cardiovascular Disease in Patients With Chronic Renal Impairment: Role of Natriuretic Peptides. Congestive Heart Failure 14, 38-42
     CrossRef

157. 157

     Marc Vanderheyden, Jozef Bartunek, Gerasimos Filippatos, Marc Goethals, Bruno Van Vlem, Alan Maisel. (2008) Cardiovascular Disease in Patients With Chronic Renal Impairment: Role of Natriuretic Peptides. Congestive Heart Failure 14:4, 38-42
     CrossRef

158. 158

     Theresa A. McDonagh, Kenneth McDonald, Alan S. Maisel. (2008) Screening for Asymptomatic Left Ventricular Dysfunction Using B-Type Natriuretic Peptide. Congestive Heart Failure 14:4, 5-8
     CrossRef

159. 159

     Christian Mueller. (2008) Cost-Effectiveness of B-Type Natriuretic Peptide Testing. Congestive Heart Failure 14:4, 35-37
     CrossRef

160. 160

     Shahriar Iravanian, Samuel C. Dudley. (2008) The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Heart Rhythm 5:6, S12-S17
     CrossRef

161. 161

     M. L. Telli, R. M. Witteles, G. A. Fisher, S. Srinivas. (2008) Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Annals of Oncology 19:9, 1613-1618
     CrossRef

162. 162

     Ahmed Zaiem, Faiez Zannad. (2008) Perindopril: beyond lowering blood pressure. Future Cardiology 4:3, 219-235
     CrossRef

163. 163

     John Kellett. (2008) Prognostication — The lost skill of medicine. European Journal of Internal Medicine 19:3, 155-164
     CrossRef

164. 164

     Aysha Arshad, Anisha Mandava, Ganesh Kamath, Dan Musat. (2008) Sudden Cardiac Death and the Role of Medical Therapy. Progress in Cardiovascular Diseases 50:6, 420-438
     CrossRef

165. 165

     Rachid Lakhdar, Mouaz H. Al-Mallah, David E. Lanfear. (2008) Safety and Tolerability of Angiotensin-Converting Enzyme Inhibitor Versus the Combination of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker in Patients With Left Ventricular Dysfunction: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Cardiac Failure 14:3, 181-188
     CrossRef

166. 166

     Derek V. Exner, Jay N. Cohn. (2008) Arguments prove nothing unless verified. A commentary on Kaufman's “Epidemiologic analysis of racial/ethnic disparities: Some fundamental issues and a cautionary example”. Social Science & Medicine 66:8, 1675-1677
     CrossRef

167. 167

     T. Thum, G. Ertl, J. Bauersachs. (2008) Prävention des linksventrikulären Remodelings. Der Kardiologe 2:2, 100-107
     CrossRef

168. 168

     Frédéric Jacques, Michel Carrier, Guy B. Pelletier, Michel White, Normand Racine, Michel Pellerin, Denis Bouchard, Philippe Demers, Louis P. Perrault. (2008) Two decades of cardiac transplantation at the Montreal Heart Institute. Canadian Journal of Cardiology 24:3, 217-221
     CrossRef

169. 169

     Anthony N. DeMaria. (2008) Clinical Trials and Clinical Judgment. Journal of the American College of Cardiology 51:11, 1120-1122
     CrossRef

170. 170

     Y. O. Xu-Cai, D. J. Brotman, C. O. Phillips, F. A. Michota, W. H. W. Tang, C. M. Whinney, A. Panneerselvam, E. D. Hixson, M. Garcia, G. S. Francis, A. K. Jaffer. (2008) Outcomes of Patients With Stable Heart Failure Undergoing Elective Noncardiac Surgery. Mayo Clinic Proceedings 83:3, 280-288
     CrossRef

171. 171

     Christine K Choy, Jo E Rodgers, Jean M Nappi, Stuart T Haines. (2008) Type 2 Diabetes Mellitus and Heart Failure. Pharmacotherapy 28:2, 170-192
     CrossRef

172. 172

     Joaquim Gascón, Pedro Albajar, Elías Cañas, María Flores, Jordi Gómez i Prat, Ramón N. Herrera, Carlos A. Lafuente, Héctor L. Luciardi, Álvaro Moncayo, Lluís Molina, José Muñoz, Sabino Puente, Ginés Sanz, Begoña Treviño, Xavier Sergio-Salles. (2008) Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica. Enfermedades Infecciosas y Microbiología Clínica 26:2, 99-106
     CrossRef

173. 173

     Alan H. Gradman, Rishi Kad. (2008) Renin Inhibition in Hypertension. Journal of the American College of Cardiology 51:5, 519-528
     CrossRef

174. 174

     Simon de Denus B, Jean-Claude Tardif, Michel White, Martial G Bourassa, Normand Racine, Sylvie Levesque, Anique Ducharme. (2008) Temporal variations in hematocrit values in patients with left ventricular dysfunction: Relationship with cause-specific mortality and morbidity and optimal monitoring – further insights from SOLVD. Canadian Journal of Cardiology 24:1, 45-48
     CrossRef

175. 175

     Enrique Galve. (2008) Fármacos antialdosterónicos: su papel en la insuficiencia cardíaca. Medicina Clínica 130:1, 30-34
     CrossRef

176. 176

     M.D. Cheitlin. (2008) Metoprolol Reverses Left Ventricular Remodeling in Patients With Asymptomatic Systolic Dysfunction: The REversal of VEntricular Remodeling with Toprol-XL (REVERT) Trial. Yearbook of Medicine 2008, 394-395
     CrossRef

177. 177

     Macaulay A. C. Onuigbo, Nnonyelum T. C. Onuigbo. (2008) Renal Failure and Concurrent RAAS Blockade in Older CKD Patients with Renal Artery Stenosis: An Extended Mayo Clinic Prospective 63-Month Experience. Renal Failure 30:4, 363-371
     CrossRef

178. 178

     Philip F. Binkley, Amanda Lesinski, Jeanette Pohorence Ferguson, Patricia S. Hatton, Laura Yamokoski, Sheetal Hardikar, Glen E. Cooke, Carl V. Leier. (2008) Recovery of normal ventricular function in patients with dilated cardiomyopathy: Predictors of an increasingly prevalent clinical event. American Heart Journal 155:1, 69-74
     CrossRef

179. 179

     Jithendra B Somaratne, Gillian A Whalley, Warwick Bagg, Robert N Doughty. (2008) Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus. Expert Review of Cardiovascular Therapy 6:1, 109-125
     CrossRef

180. 180

     Macaulay A.C. Onuigbo, Nnonyelum T.C. Onuigbo. (2008) Late Onset Azotemia from RAAS Blockade in CKD Patients with Normal Renal Arteries and No Precipitating Risk Factors. Renal Failure 30:1, 73-80
     CrossRef

181. 181

     RICHARD W. TROUGHTON, JAY RITZEMA-CARTER, M. GARY NICHOLLS. 2008. Role of Neurohormones. , 345-366.
     CrossRef

182. 182

     Masoor Kamalesh. (2007) Heart Failure in Diabetes and Related Conditions. Journal of Cardiac Failure 13:10, 861-873
     CrossRef

183. 183

     Fahim H. Jafary, Mahesh Kumar, Irfan E. Chandna. (2007) Prognosis of Hospitalized New-Onset Systolic Heart Failure in Indo-Asians—A Lethal Problem. Journal of Cardiac Failure 13:10, 855-860
     CrossRef

184. 184

     Ahmad Zankar, Jose A. Joglar, R Haris Naseem. (2007) Cardiac Resynchronization Therapy in Patients With Chronic Atrial Fibrillation. Cardiology in Review 15:6, 310-315
     CrossRef

185. 185

     Seema Thakral, A. K. Madan. (2007) Urea inclusion compounds of enalapril maleate for the improvement of pharmaceutical characteristics. Journal of Pharmacy and Pharmacology 59:11, 1501-1507
     CrossRef

186. 186

     Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Heart Failure Clinics 3:4, 423-436
     CrossRef

187. 187

     Daniel J. Salzberg. (2007) Is RAS blockade routinely indicated in hypertensive kidney transplant patients?. Current Hypertension Reports 9:5, 422-429
     CrossRef

188. 188

     Sjoerd A. Mollema, Su San Liem, Matthew S. Suffoletto, Gabe B. Bleeker, Bas L. van der Hoeven, Nico R. van de Veire, Eric Boersma, Eduard R. Holman, Ernst E. van der Wall, Martin J. Schalij, John Gorcsan, Jeroen J. Bax. (2007) Left Ventricular Dyssynchrony Acutely After Myocardial Infarction Predicts Left Ventricular Remodeling. Journal of the American College of Cardiology 50:16, 1532-1540
     CrossRef

189. 189

     Paul A. Heidenreich, Gregg C. Fonarow. (2007) Quality Indicators for the Care of Heart Failure in Vulnerable Elders. Journal of the American Geriatrics Society 55, S340-S346
     CrossRef

190. 190

     M. L. Bots, W. J. Remme, T. F. Lüscher, K. M. Fox, M. Bertrand, R. Ferrari, M. L. Simoons, D. E. Grobbee, . (2007) ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a Sub-Study of the EUROPA Trial. Cardiovascular Drugs and Therapy 21:4, 269-279
     CrossRef

191. 191

     C.M. Schannwell, M.G. Hennersdorf, B.E. Strauer. (2007) Hochdruck und Herzinsuffizienz. Der Internist 48:9, 909-920
     CrossRef

192. 192

     G. Mathur, B. Noronha, E. Rodrigues, G. Davis. (2007) The role of angiotensin II type 1 receptor blockers in the prevention and management of diabetes mellitus. Diabetes, Obesity and Metabolism 9:5, 617-629
     CrossRef

193. 193

     Kanu Chatterjee, Barry Massie. (2007) Systolic and Diastolic Heart Failure: Differences and Similarities. Journal of Cardiac Failure 13:7, 569-576
     CrossRef

194. 194

     Michel Azizi, Grégoire Wuerzner. (2007) Rationale for Combining Blockers of the Renin-Angiotensin System. Seminars in Nephrology 27:5, 544-554
     CrossRef

195. 195

     Roger J.F. Baskett, Derek V. Exner, Gregory M. Hirsch, William A. Ghali. (2007) Mitral insufficiency and morbidity and mortality in left ventricular dysfunction. Canadian Journal of Cardiology 23:10, 797-800
     CrossRef

196. 196

     Richard Weachter, Greg Flaker. (2007) Cardiac resynchronization therapy: predictors of failure and strategies to overcome. Expert Review of Cardiovascular Therapy 5:4, 625-628
     CrossRef

197. 197

     Bruce J. Kimura, David J. Shaw, Donna L. Agan, Stan A. Amundson, Andrew C. Ping, Anthony N. DeMaria. (2007) Value of a Cardiovascular Limited Ultrasound Examination Using a Hand-Carried Ultrasound Device on Clinical Management in an Outpatient Medical Clinic. The American Journal of Cardiology 100:2, 321-325
     CrossRef

198. 198

     Alan H. Gradman. (2007) Treating Patients for Cardiovascular Protection: Combination Therapy to Achieve Complete Renin-Angiotensin System Blockade. Preventive Cardiology 10:3, 147-155
     CrossRef

199. 199

     Lev Lubarsky, Neil L. Coplan. (2007) Angiotensin-Converting Enzyme Inhibitors in Acute Myocardial Infarction: A Clinical Approach. Preventive Cardiology 10:3, 156-159
     CrossRef

200. 200

     Alan K. Berger, Sue Duval, Connie Manske, Gabriela Vazquez, Cheryl Barber, Leslie Miller, Russell V. Luepker. (2007) Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. American Heart Journal 153:6, 1064-1073
     CrossRef

201. 201

     John G. F. Cleland, Periaswamy Velavan, Mansour Nasir. (2007) Fighting against sudden death: A single or multidisciplinary approach. Journal of Interventional Cardiac Electrophysiology 17:3, 205-210
     CrossRef

202. 202

     Michael E. Field, Michael O. Sweeney. (2007) Socio-economic analysis of cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology 17:3, 225-236
     CrossRef

203. 203

     Mark E Dunlap. (2007) New Studies Influencing Treatment of Heart Failure: 2006 Update. Pharmacotherapy 27:4 Part 2, 3S-11S
     CrossRef

204. 204

     M Mahmoudi, N Curzen, P J Gallagher. (2007) Atherogenesis: the role of inflammation and infection. Histopathology 50:5, 535-546
     CrossRef

205. 205

     Joaquim Gascón, Pedro Albajar, Elías Cañas, María Flores, Jordi Gómez i Prat, Ramón N. Herrera, Carlos A. Lafuente, Héctor L. Luciardi, Álvaro Moncayo, Lluís Molina, José Muñoz, Sabino Puente, Ginés Sanz, Begoña Treviño, Xavier Sergio-Salles. (2007) Diagnóstico, manejo y tratamiento de la cardiopatía chagásica crónica en áreas donde la infección por Trypanosoma cruzi no es endémica. Revista Española de Cardiología 60:3, 285-293
     CrossRef

206. 206

     Tiong Keng Lim, Girish Dwivedi, Sajad Hayat, Paul O Collinson, Roxy Senior. (2007) Cost Effectiveness of the B Type Natriuretic Peptide, Electrocardiography, and Portable Echocardiography for the Assessment of Patients from the Community with Suspected Heart Failure. Echocardiography 24:3, 228-236
     CrossRef

207. 207

     Purvi S. Gandhi, Ramesh K. Goyal, Anil R. Jain, B. Srinivas Mallya, Vishal M. Gupta, Dhiren S. Shah, Bharat R. Trivedi, Naman A. Shastri, Chirag B. Mehta, Kalpana A. Jain, Niren S. Bhavasar, Urmi J. Shah. (2007) Beneficial effects of carvedilol as a concomitant therapy to angiotensin-converting enzyme inhibitor in patients with ischemic left ventricular systolic dysfunction. Canadian Journal of Physiology and Pharmacology 85:2, 193-199
     CrossRef

208. 208

     Wilbert S. Aronow. (2007) Treatment of Heart Failure with Abnormal Left Ventricular Systolic Function in the Elderly. Clinics in Geriatric Medicine 23:1, 61-81
     CrossRef

209. 209

     Frederick A. Masoudi, Silvio E. Inzucchi. (2007) Diabetes Mellitus and Heart Failure: Epidemiology, Mechanisms, and Pharmacotherapy. The American Journal of Cardiology 99:4, 113-132
     CrossRef

210. 210

     R. Parker Ward, Sascha N. Goonewardena, Georgeanne Lammertin, Roberto M. Lang. (2007) Comparison of the Frequency of Abnormal Cardiac Findings by Echocardiography in Patients With and Without Peripheral Arterial Disease. The American Journal of Cardiology 99:4, 499-503
     CrossRef

211. 211

     Roman M. Sniecinski, Susan Wright, Jerrold H. Levy. 2007. Cardiovascular Pharmacology. , 33-52.
     CrossRef

212. 212

     Joaquim Gascón, Pedro Albajar, Elías Cañas, María Flores, Jordi Gómez i Prat, Ramón N. Herrera, Carlos A. Lafuente, Héctor L. Luciardi, Álvaro Moncayo, Lluís Molina, José Muñoz, Sabino Puente, Ginés Sanz, Begoña Treviño, Xavier Sergio-Salles. (2007) Diagnosis, Management, and Treatment of Chronic Chagas' Heart Disease in Areas Where Trypanosoma cruzi Infection Is Not Endemic. Revista Española de Cardiología (English Edition) 60:3, 285-293
     CrossRef

213. 213

     Eman Hamad, Paul J Mather, Siva Srinivasan, Sharon Rubin, David J Whellan, Arthur M Feldman. (2007) Pharmacologic Therapy of Chronic Heart Failure. American Journal of Cardiovascular Drugs 7:4, 235-248
     CrossRef

214. 214

     David Sidebotham, Robert Doughty. 2007. Heart Failure. , 278-292.
     CrossRef

215. 215

     Melinda S. Carmody, Joe R. Anderson. (2007) BiDil (Isosorbide Dinitrate and Hydralazine). Cardiology in Review 15:1, 46-53
     CrossRef

216. 216

     Paula T. Einhorn, Barry R. Davis, Barry M. Massie, William C. Cushman, Linda B. Piller, Lara M. Simpson, Daniel Levy, Chuke E. Nwachuku, Henry R. Black. (2007) The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) heart failure Validation Study: Diagnosis and prognosis. American Heart Journal 153:1, 42-53
     CrossRef

217. 217

     Masayuki Matsumoto. (2007) Clinical aspects of cardiac failure in the elderly people. Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics 44:5, 582-584
     CrossRef

218. 218

     Patrick B. Mark, Colin J. Petrie, Alan G. Jardine. (2007) Diagnostic, Prognostic, and Therapeutic Implications of Brain Natriuretic Peptide in Dialysis and Nondialysis-Dependent Chronic Renal Failure. Seminars in Dialysis 20:1, 40-49
     CrossRef

219. 219

     J. Malcolm O. Arnold, Jonathan G. Howlett, Paul Dorian, Anique Ducharme, Nadia Giannetti, Haissam Haddad, George A. Heckman, Andrew Ignaszewski, Debra Isaac, Philip Jong, Peter Liu, Elizabeth Mann, Robert S. McKelvie, Gordon W. Moe, John D. Parker, Anna M. Svendsen, Ross T. Tsuyuki, Kelly O’Halloran, Heather J. Ross, Vivek Rao, Errol J. Sequeira, Michel White. (2007) Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: Prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Canadian Journal of Cardiology 23:1, 21-45
     CrossRef

220. 220

     Michio Nakanishi, Masaki Harada, Ichiro Kishimoto, Koichiro Kuwahara, Rika Kawakami, Yasuaki Nakagawa, Shinji Yasuno, Satoru Usami, Hideyuki Kinoshita, Yuichiro Adachi, Akiyoshi Fukamizu, Yoshihiko Saito, Kazuwa Nakao. (2007) Genetic Disruption of Angiotensin II Type 1a Receptor Improves Long-Term Survival of Mice With Chronic Severe Aortic Regurgitation. Circulation Journal 71:8, 1310-1316
     CrossRef

221. 221

     Hani N. Sabbah, Makoto Imai, Doug Cowart, Antonino Amato, Paolo Carminati, Mihai Gheorghiade. (2007) Hemodynamic Properties of a New-Generation Positive Luso-Inotropic Agent for the Acute Treatment of Advanced Heart Failure. The American Journal of Cardiology 99:2, S41-S46
     CrossRef

222. 222

     S William Tam, Michael L Sabolinski, Manuel Worcel, Milton Packer, Jay N Cohn. (2007) Lack of Bioequivalence between Different Formulations of Isosorbide??Dinitrate and Hydralazine and??the??Fixed-Dose Combination of??Isosorbide Dinitrate/Hydralazine. Clinical Pharmacokinetics 46:10, 885-895
     CrossRef

223. 223

     Adnan Siddiqui, Peter R Kowey. (2006) Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies. Current Opinion in Internal Medicine 5:6, 544-552
     CrossRef

224. 224

     Jill M. Gelow, James C. Fang. (2006) Update in the Approach to and Management of Heart Failure. Southern Medical Journal 99:12, 1346-1355
     CrossRef

225. 225

     Masako Saka, Koji Obata, Sahoko Ichihara, Xian Wu Cheng, Hirotaka Kimata, Akiko Noda, Hideo Izawa, Kohzo Nagata, Mitsuhiro Yokota. (2006) ATTENUATION OF VENTRICULAR HYPERTROPHY AND FIBROSIS IN RATS BY PITAVASTATIN: POTENTIAL ROLE OF THE RhoA?EXTRACELLULAR SIGNAL-REGULATED KINASE?SERUM RESPONSE FACTOR SIGNALLING PATHWAY. Clinical and Experimental Pharmacology and Physiology 33:12, 1164-1171
     CrossRef

226. 226

     Philip B. Adamson, Edward M. Gilbert. (2006) Reducing the Risk of Sudden Death in Heart Failure With β-Blockers. Journal of Cardiac Failure 12:9, 734-746
     CrossRef

227. 227

     O. M. P. Jolobe. (2006) Usefulness of Left Ventricular Ejection Fraction in Patients With Overt Heart Failure. Mayo Clinic Proceedings 81:12, 1638-1639
     CrossRef

228. 228

     Ravi G. Assomull, Sanjay K. Prasad, Jonathan Lyne, Gillian Smith, Elizabeth D. Burman, Mohammed Khan, Mary N. Sheppard, Philip A. Poole-Wilson, Dudley J. Pennell. (2006) Cardiovascular Magnetic Resonance, Fibrosis, and Prognosis in Dilated Cardiomyopathy. Journal of the American College of Cardiology 48:10, 1977-1985
     CrossRef

229. 229

     Pascale Richard, Eric Villard, Philippe Charron, Richard Isnard. (2006) The Genetic Bases of Cardiomyopathies. Journal of the American College of Cardiology 48:9, A79-A89
     CrossRef

230. 230

     H. Knauf, M. A. Bailey, G. Hasenfuss, E. Mutschler. (2006) The influence of cardiovascular and antiinflammatory drugs on thiazide-induced hemodynamic and saluretic effects. European Journal of Clinical Pharmacology 62:11, 885-892
     CrossRef

231. 231

     2006. Chronic Heart Failure. .
     CrossRef

232. 232

     Nelson Kopyt. 2006. Chronic Kidney Disease. , 463-500.
     CrossRef

233. 233

     F Zannad, M Kessler, P Lehert, J P Grünfeld, C Thuilliez, A Leizorovicz, P Lechat. (2006) Prevention of cardiovascular events in end-stage renal disease: Results of a randomized trial of fosinopril and implications for future studies. Kidney International 70:7, 1318-1324
     CrossRef

234. 234

     Valentin Fuster, Lars E. Rydén, David S. Cannom, Harry J. Crijns, Anne B. Curtis, Kenneth A. Ellenbogen, Jonathan L. Halperin, Jean-Yves Le Heuzey, G. Neal Kay, James E. Lowe, S. Bertil Olsson, Eric N. Prystowsky, Juan Luis Tamargo, Samuel Wann. (2006) ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation. Journal of the American College of Cardiology 48:4, e149-e246
     CrossRef

235. 235

     J. Martijn Bos, Donald J. Hagler, Suchaya Silvilairat, Allison Cabalka, Patrick O’Leary, Otto Daniels, Fletcher A. Miller, Theodore P. Abraham. (2006) Right Ventricular Function in Asymptomatic Individuals with a Systemic Right Ventricle. Journal of the American Society of Echocardiography 19:8, 1033-1037
     CrossRef

236. 236

     W. Frank Peacock, Alex Harrison, Alan S. Maisel. (2006) The Utility of Heart Sounds and Systolic Intervals Across the Care Continuum. Congestive Heart Failure 12, 2-7
     CrossRef

237. 237

     Maria Tokmakova, Scott D Solomon. (2006) Inhibiting the renin–angiotensin system in myocardial infarction and heart failure: lessons from SAVE, VALIANT and CHARM, and other clinical trials. Current Opinion in Cardiology 21:4, 268-272
     CrossRef

238. 238

     María G. Crespo Leiro, María J. Paniagua Martín. (2006) Insuficiencia cardiaca. ¿Son diferentes las mujeres?. Revista Española de Cardiología 59:7, 725-735
     CrossRef

239. 239

     Douglas S. Lee, Ramachandran S. Vasan. (2006) Goals and guidelines for treating hypertension in a patient with heart failure. Current Treatment Options in Cardiovascular Medicine 8:4, 334-344
     CrossRef

240. 240

     W. Frank Peacock, Alex Harrison, Alan S. Maisel. (2006) The Utility of Heart Sounds and Systolic Intervals Across the Care Continuum. Congestive Heart Failure 12:s4, 2-7
     CrossRef

241. 241

     Steven E. Lipshultz. (2006) Exposure to Anthracyclines During Childhood Causes Cardiac Injury. Seminars in Oncology 33, 8-14
     CrossRef

242. 242

     Rachele Adorisio, Leonardo De Luca, Joseph Rossi, Mihai Gheorghiade. (2006) Pharmacological treatment of chronic heart failure. Heart Failure Reviews 11:2, 109-123
     CrossRef

243. 243

     Simon De Denus, Michel White, Jean-Claude Tardif, Martial G. Bourassa, Normand Racine, Sylvie Levesque, Anique Ducharme. (2006) Temporal Increases in Subclinical Levels of Inflammation Are Associated With Adverse Clinical Outcomes in Patients With Left Ventricular Dysfunction. Journal of Cardiac Failure 12:5, 353-359
     CrossRef

244. 244

     Lori B Daniels, Alan Maisel. (2006) B-type natriuretic peptide: time to incorporate natriuretic peptides in our practice. Journal of Cardiovascular Medicine 7:6, 414-415
     CrossRef

245. 245

     Verônica R.S. Fernandes, Joseph F. Polak, Thor Edvardsen, Benilton Carvalho, Antoinette Gomes, David A. Bluemke, Khurram Nasir, Daniel H. O’Leary, João A.C. Lima. (2006) Subclinical Atherosclerosis and Incipient Regional Myocardial Dysfunction in Asymptomatic Individuals. Journal of the American College of Cardiology 47:12, 2420-2428
     CrossRef

246. 246

     Lee A. Biblo, Johan Aasbo. (2006) To catch a moving target. Heart Rhythm 3:6, 638-639
     CrossRef

247. 247

     Monica Colvin Adams, Syed Sohail Ali. (2006) Who should pay for home monitoring of heart failure?. Current Cardiology Reports 8:3, 191-197
     CrossRef

248. 248

     Wilbert S. Aronow. (2006) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure. Cardiology in Review 14:3, 108-124
     CrossRef

249. 249

     Thomas S. Rector, Sumit N. Ringwala, Sudip N. Ringwala, Inder S. Anand. (2006) Validation of a Risk Score for Dying Within 1 Year of an Admission for Heart Failure. Journal of Cardiac Failure 12:4, 276-280
     CrossRef

250. 250

     Sylvie A. Ahn, Philip Jong, Salim Yusuf, Shrikant I. Bangdiwala, Hubert G. Pouleur, Michel F. Rousseau. (2006) Early Versus Delayed Enalapril in Patients With Left Ventricular Systolic Dysfunction: Impact on Morbidity and Mortality 15 Years After the SOLVD Trial. Journal of the American College of Cardiology 47:9, 1904-1905
     CrossRef

251. 251

     A. A. Mangoni, S. H. D. Jackson. (2006) The implications of a growing evidence base for drug use in elderly patients Part 2 - ACE inhibitors and angiotensin receptor blockers in heart failure and high cardiovascular risk patients. British Journal of Clinical Pharmacology 61:5, 502-512
     CrossRef

252. 252

     P B Mark, N Johnston, B A Groenning, J E Foster, K G Blyth, T N Martin, T Steedman, H J Dargie, A G Jardine. (2006) Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney International 69:10, 1839-1845
     CrossRef

253. 253

     E. M. L. Wong, E. B. Wu, W. W. M. Chan, C. M. Yu. (2006) A review of the management of patients after percutaneous coronary intervention. International Journal of Clinical Practice 60:5, 582-589
     CrossRef

254. 254

     M. Böhm, N. Werner, M. Kindermann. (2006) Stand der medikamentösen Therapie bei chronischer Herzinsuffizienz. Clinical Research in Cardiology 95:S4, 36-56
     CrossRef

255. 255

     Vincent E. Hagens, Dirk J. Van Veldhuisen, Harry J. G. M. Crijns, Isabelle C. Van Gelder. (2006) Implication from Randomized Trials of Rate and Rhythm Controls on Management of Patients with Persistent Atrial Fibrillation. Annals of Noninvasive Electrocardiology 11:2, 170-186
     CrossRef

256. 256

     Bodh I Jugdutt. (2006) Valsartan in the treatment of heart attack survivors. Vascular Health and Risk Management 2:2, 125-138
     CrossRef

257. 257

     Mouaz H. Al-Mallah, Imad M. Tleyjeh, Ahmed A. Abdel-Latif, W. Douglas Weaver. (2006) Angiotensin-Converting Enzyme Inhibitors in Coronary Artery Disease and Preserved Left Ventricular Systolic Function. Journal of the American College of Cardiology 47:8, 1576-1583
     CrossRef

258. 258

     Gastone Sabbadini, Marco Metra, Andrea Di Lenarda, Savina Nodari, Gianfranco Sinagra, Livio Dei Cas. (2006) Managing heart failure in the very old. Aging Health 2:2, 253-275
     CrossRef

259. 259

     David W. Markham, G. Michael Felker. 2006. Vasodilators in the Management of Heart Failure. , 99-112.
     CrossRef

260. 260

     R. Tkacova, S. Toth, D.D. Sin. (2006) Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy. Respiratory Medicine 100:3, 385-392
     CrossRef

261. 261

     G. William Dec. 2006. Epidemiology and Prognosis in Chronic Heart Failure. , 1-22.
     CrossRef

262. 262

     Stuart D. Russell. 2006. Acute Heart Failure. , 203-226.
     CrossRef

263. 263

     Gurbir S. Bhatia, Michael D. Sosin, Jeetesh V. Patel, Karl A. Grindulis, Fazal H. Khattak, Elizabeth A. Hughes, Gregory Y.H. Lip, Russell C. Davis. (2006) Left Ventricular Systolic Dysfunction in Rheumatoid Disease. Journal of the American College of Cardiology 47:6, 1169-1174
     CrossRef

264. 264

     Ulrich P. Jorde. (2006) Suppression of the Renin???Angiotensin???Aldosterone System in Chronic Heart Failure. Cardiology in Review 14:2, 81-87
     CrossRef

265. 265

     Raymond Ng, Nathan Better, Michael D. Green. (2006) Anticancer Agents and Cardiotoxicity. Seminars in Oncology 33:1, 2-14
     CrossRef

266. 266

     C. M. Schannwell, B. E. Strauer. (2006) CPAP-Therapie als additive/adjuvante Herzinsuffizienztherapie?. Der Internist 47:2, 183-191
     CrossRef

267. 267

     Robert D Winslow, Sean Pinney, Valentin Fuster. (2006) Impact of implantable-cardioverter-defibrillator trials on clinical management of patients with heart failure. Nature Clinical Practice Cardiovascular Medicine 3:2, 86-93
     CrossRef

268. 268

     Heart Failure Society of America. (2006) Section 7: Heart Failure in Patients With Left Ventricular Systolic Dysfunction. Journal of Cardiac Failure 12:1, e38-e57
     CrossRef

269. 269

     Erik B. Friedrich, Koon K. Teo, Michael Böhm. (2006) ACE Inhibition in secondary prevention: are the results controversial?. Clinical Research in Cardiology 95:2, 61-67
     CrossRef

270. 270

     M Mohsen Ibrahim. (2006) RAS inhibition in hypertension. Journal of Human Hypertension 20:2, 101-108
     CrossRef

271. 271

     Heart Failure Society of America. (2006) Section 13: Evaluation and Therapy for Heart Failure in the Setting of Ischemic Heart Disease. Journal of Cardiac Failure 12:1, e104-e111
     CrossRef

272. 272

     Rajaa F Faris, Marcus Flather, H Purcell, PA Poole-Wilson, Andrew JS Coats, Rajaa F Faris. 2006. Diuretics for heart failure. .
     CrossRef

273. 273

     J. Malcolm O. Arnold, Peter Liu, Catherine Demers, Paul Dorian, Nadia Giannetti, Haissam Haddad, George A. Heckman, Jonathan G. Howlett, Andrew Ignaszewski, David E. Johnstone, Philip Jong, Robert S. McKelvie, Gordon W. Moe, John D. Parker, Vivek Rao, Heather J. Ross, Errol J. Sequeira, Anna M. Svendsen, Koon Teo, Ross T. Tsuyuki, Michel White. (2006) Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: Diagnosis and management. Canadian Journal of Cardiology 22:1, 23-45
     CrossRef

274. 274

     Mark J. Eisenberg, Laura C. Gioia. (2006) Angiotensin II Receptor Blockers in Congestive Heart Failure. Cardiology in Review 14:1, 26-34
     CrossRef

275. 275

     Robert W. Schrier. (2006) Role of Diminished Renal Function in Cardiovascular Mortality. Journal of the American College of Cardiology 47:1, 1-8
     CrossRef

276. 276

     Yoshihisa Matsumura, Jun Takata, Hiroaki Kitaoka, Toru Kubo, Yuichi Baba, Eri Hoshikawa, Tomoyuki Hamada, Makoto Okawa, Nobuhiko Hitomi, Kyoko Sato, Naohito Yamasaki, Toshikazu Yabe, Takashi Furuno, Masanori Nishinaga, Yoshinori Doi. (2006) Long-Term Prognosis of Dilated Cardiomyopathy Revisited. Circulation Journal 70:4, 376-383
     CrossRef

277. 277

     Harlan M. Krumholz, Jeffrey L. Anderson, Neil H. Brooks, Francis M. Fesmire, Costas T. Lambrew, Mary Beth Landrum, W. Douglas Weaver, John Whyte, Robert O. Bonow, Susan J. Bennett, Gregory Burke, Kim A. Eagle, Harlan M. Krumholz, Costas T. Lambrew, Jane Linderbaum, Frederick A. Masoudi, Sharon-Lise T. Normand, Ileana L. PiÑa, Martha J. Radford, John S. Rumsfeld, James L. Ritchie, John A. Spertus. (2006) ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 47:1, 236-265
     CrossRef

278. 278

     Michael J Lipinski, George W Vetrovec. (2006) Medical Treatment of Patients with Heart Failure or Left Ventricular Dysfunction Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 6:5, 313-325
     CrossRef

279. 279

     Keith C. Ferdinand, Elijah Sounders. (2006) Hypertension-Related Morbidity and Mortality in African Americans?Why We Need to Do Better. The Journal of Clinical Hypertension 8:s1, 21-30
     CrossRef

280. 280

     George J. Philippides. (2006) Managing the Post-Myocardial Infarction Patient with Asymptomatic Left Ventricular Dysfunction. Cardiology 105:2, 95-107
     CrossRef

281. 281

     Alberto Zanchetti, Gianfranco Parati, Ettore Malacco. (2006) Zofenopril plus Hydrochlorothiazide. Drugs 66:8, 1107-1115
     CrossRef

282. 282

     W. S. Aronow. (2005) Drug Treatment of Systolic and of Diastolic Heart Failure in Elderly Persons. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 60:12, 1597-1605
     CrossRef

283. 283

     M. Saito, M. Takada, K. Hirooka, F. Isobe, Y. Yasumura. (2005) Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. Journal of Clinical Pharmacy and Therapeutics 30:6, 603-610
     CrossRef

284. 284

     Karlijn A. Wouters, Leontien C. M. Kremer, Tracie L. Miller, Eugene H. Herman, Steven E. Lipshultz. (2005) Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. British Journal of Haematology 131:5, 561-578
     CrossRef

285. 285

     Jens Mogensen, Tony Shaw. (2005) Current approaches to unravel the mystery of dilated cardiomyopathy, a common cause of hereditary heart failure. Expert Review of Proteomics 2:6, 827-830
     CrossRef

286. 286

     Hao-Min Cheng, Shao-Yuan Chuang, Pai-Feng Hsu, Pesus Chou, Chen-Huan Chen. (2005) Systolic time intervals revisited: correlations with N-terminal pro-brain natriuretic peptide in a community population. Heart and Vessels 20:6, 256-263
     CrossRef

287. 287

     Jaap J. Remmen, Wim R. M. Aengevaeren, Freek W. A. Verheugt, Rene W. M. M. Jansen. (2005) Normal values of pulmonary capillary wedge pressure and the blood pressure response to the Valsalva manoeuvre in healthy elderly subjects. Clinical Physiology and Functional Imaging 25:6, 318-326
     CrossRef

288. 288

     Jing Li, Ping Huang, Taixiang Wu, Xiaoyan Chen, Jing Li. 2005. Nitrates for chronic heart failure. .
     CrossRef

289. 289

     David S. Cannom, Morton Mower. (2005) Relationship of the Implantable Cardioverter Defibrillator and Chronic Resynchronization Therapy: The Perfect Marriage?. Annals of Noninvasive Electrocardiology 10:s4, 24-33
     CrossRef

290. 290

     Srinivas Murali, Marie R. Baldisseri. (2005) Peripartum cardiomyopathy. Critical Care Medicine 33:Supplement, S340-S346
     CrossRef

291. 291

     Sharon Ann Hunt, William T. Abraham, Marshall H. Chin, Arthur M. Feldman, Gary S. Francis, Theodore G. Ganiats, Mariell Jessup, Marvin A. Konstam, Donna M. Mancini, Keith Michl, John A. Oates, Peter S. Rahko, Marc A. Silver, Lynne Warner Stevenson, Clyde W. Yancy, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article. Journal of the American College of Cardiology 46:6, 1116-1143
     CrossRef

292. 292

     Lars Køber, Christian Torp-Pedersen. (2005) Valsartan: the past, present and future. Future Cardiology 1:5, 591-598
     CrossRef

293. 293

     J. Thomas Heywood, Mitchell T. Saltzberg. (2005) Strategies to reduce length of stay and costs associated with decompensated heart failure. Current Heart Failure Reports 2:3, 140-147
     CrossRef

294. 294

     Sharon Ann Hunt. (2005) ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult. Journal of the American College of Cardiology 46:6, e1-e82
     CrossRef

295. 295

     (2005) Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Revista Española de Cardiología 58:9, 1062-1092
     CrossRef

296. 296

     Daniel J. Garry, Sean C. Goetsch, Amanda J. McGrath, Pradeep P.A. Mammen. (2005) Alternative Therapies for Orthotopic Heart Transplantation. The American Journal of the Medical Sciences 330:2, 88-101
     CrossRef

297. 297

     U. C. Hoppe, M. Böhm, R. Dietz, P. Hanrath, H. K. Kroemer, A. Osterspey, A. A. Schmaltz, E. Erdmann. (2005) Leitlinien zur Therapie der chronischen Herzinsuffizienz. Zeitschrift für Kardiologie 94:8, 488-509
     CrossRef

298. 298

     Hiromitsu Miyamoto, Hisashi Kai, Hiroyuki Nakaura, Katsunori Osada, Yoshihiko Mizuta, Akira Matsumoto, Tsutomu Imaizumi. (2005) Safety and Efficacy of Repeated Sauna Bathing in Patients With Chronic Systolic Heart Failure: A Preliminary Report. Journal of Cardiac Failure 11:6, 432-436
     CrossRef

299. 299

     Nancy L. Geller, Lawrence M. Friedman. 2005. Cooperative Heart Disease Trials. .
     CrossRef

300. 300

     Xiaobing Guo, Harjot K Saini, Jingwei Wang, Suresh K Gupta, Ramesh K Goyal, Naranjan S Dhalla. (2005) Prevention of remodeling in congestive heart failure due to myocardial infarction by blockade of the renin–angiotensin system. Expert Review of Cardiovascular Therapy 3:4, 717-732
     CrossRef

301. 301

     Roxy Senior, Gavin Galasko. (2005) Cost-Effective Strategies to Screen for Left Ventricular Systolic Dysfunction in the Community?A Concept. Congestive Heart Failure 11:4, 194-211
     CrossRef

302. 302

     Robert D Winslow, Davendra Mehta, Valentin Fuster. (2005) Sudden cardiac death: mechanisms, therapies and challenges. Nature Clinical Practice Cardiovascular Medicine 2:7, 352-360
     CrossRef

303. 303

     Jeffrey H. Silber. (2005) Role of afterload reduction in the prevention of late anthracycline cardiomyopathy. Pediatric Blood & Cancer 44:7, 607-613
     CrossRef

304. 304

     Roy S. Gardner, Kwok S. Chong, James J. Morton, Theresa A. Mcdonagh. (2005) N-Terminal Brain Natriuretic Peptide, But Not Anemia, Is a Powerful Predictor of Mortality in Advanced Heart Failure. Journal of Cardiac Failure 11:5, S47-S53
     CrossRef

305. 305

     Elvira C van Dalen, Heleen J. H van der Pal, Johannes B Reitsma, Robbert J de Winter, Wim A Helbing, Jaap Ottenkamp, Huib N Caron, Leontien C. M Kremer. (2005) Management of Asymptomatic Anthracycline-Induced Cardiac Damage After Treatment for Childhood Cancer. Journal of Pediatric Hematology/Oncology 27:6, 319-322
     CrossRef

306. 306

     Hani N. Sabbah. (2005) Global Left Ventricular Remodeling with the Acorn Cardiac Support Device: Hemodynamic and Angiographic Findings in Dogs with Heart Failure. Heart Failure Reviews 10:2, 109-115
     CrossRef

307. 307

     Iver A. Juster. (2005) Technology-Driven Interactive Care Management Identifies and Resolves More Clinical Issues than a Claims-Based Alerting System. Disease Management 8:3, 188-197
     CrossRef

308. 308

     Victor G. Sharov, Anastassia V. Todor, Hani N. Sabbah. (2005) Left Ventricular Histomorphometric Findings in Dogs with Heart Failure Treated with the Acorn Cardiac Support Device. Heart Failure Reviews 10:2, 141-147
     CrossRef

309. 309

     Sharad Rastogi, Sudhish Mishra, Ramesh C. Gupta, Hani N. Sabbah. (2005) Reversal of Maladaptive Gene Program in Left Ventricular Myocardium of Dogs with Heart Failure Following Long-Term Therapy with the Acorn Cardiac Support Device. Heart Failure Reviews 10:2, 157-163
     CrossRef

310. 310

     Patricia A. Howard, Theresa I. Shireman. (2005) Heart Failure Drug Utilization Patterns for Medicaid Patients Before and After a Heart Failure-Related Hospitalization. Congestive Heart Failure 11:3, 124-128
     CrossRef

311. 311

     Wendy M. Book. (2005) Heart Failure in the Adult Patient with Congenital Heart Disease. Journal of Cardiac Failure 11:4, 306-312
     CrossRef

312. 312

     Denise D. Barnard. (2005) Heart failure in women. Current Cardiology Reports 7:3, 159-165
     CrossRef

313. 313

     Bryan M. Curtis, Adeera Levin, Patrick S. Parfrey. (2005) Multiple Risk Factor Intervention in Chronic Kidney Disease: Management of Cardiac Disease in Chronic Kidney Disease Patients. Medical Clinics of North America 89:3, 511-523
     CrossRef

314. 314

     V. Barrios Alonso, J.P. Tomás Zarlenga, A. Calderón Montero, C. Escobar Cervantes. (2005) Papel de los ARA-II en el tratamiento de la hipertensión arterial. De la evidencia a la práctica clínica. Clínica e Investigación en Arteriosclerosis 17, 70-82
     CrossRef

315. 315

     Steven D. Crowley, Susan B. Gurley, Michael I. Oliverio, A. Kathy Pazmino, Robert Griffiths, Patrick J. Flannery, Robert F. Spurney, Hyung-Suk Kim, Oliver Smithies, Thu H. Le, Thomas M. Coffman. (2005) Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. Journal of Clinical Investigation 115:4, 1092-1099
     CrossRef

316. 316

     Ernesto R. Soltero, Nancy J. Petersen, Nan R. Earle, Donald H. Glaeser, Diana L. Urbauer, Anita Deswal. (2005) Long-Term Results of Coronary Artery Bypass Grafting in Patients With Ischemic Cardiomyopathy: The Impact of Renal Insufficiency and Noncardiac Vascular Disease. Journal of Cardiac Failure 11:3, 206-212
     CrossRef

317. 317

     Bruce J Kimura, Anthony N DeMaria. (2005) Technology Insight: hand-carried ultrasound cardiac assessment—evolution, not revolution. Nature Clinical Practice Cardiovascular Medicine 2:4, 217-223
     CrossRef

318. 318

     M. Domanski, J. Fleg, M. Bristow, S. Knox. (2005) The Effect of Gender on Outcome in Digitalis-Treated Heart Failure Patients. Journal of Cardiac Failure 11:2, 83-86
     CrossRef

319. 319

     Milan Gupta, Eva M Lonn, Subodh Verma. (2005) Should patients with stable coronary artery disease be treated with ACE inhibitor therapy?. Nature Clinical Practice Cardiovascular Medicine 2:3, 124-125
     CrossRef

320. 320

     Areef Ishani, Eric Weinhandl, Zihong Zhao, David T. Gilbertson, Allan J. Collins, Salim Yusuf, Charles A. Herzog. (2005) Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. Journal of the American College of Cardiology 45:3, 391-399
     CrossRef

321. 321

     Pamela N. Peterson, Frederick A. Masoudi. (2005) ACE Inhibitors for Older Patients with Heart Failure: A Review of Evidence, Practice Patterns and Challenges. Heart Drug 5:2, 89-99
     CrossRef

322. 322

     Jiro Aoki, Yuji Ikari, Hiroyoshi Nakajima, Masaya Mori, Tokuichiro Sugimoto, Mitsuharu Hatori, Shuzou Tanimoto, Eisuke Amiya, Kazuhiro Hara. (2005) Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney International 67:1, 333-340
     CrossRef

323. 323

     Hideo Kusuoka, Yukihiro Koretsune, Masao Chino, Keiji Nishiyama, Teruo Shiraki, Kazuhiko Nakamura, Michitoshi Inoue, for the CAMPAIGN investigators. (2005) Disparity in the Process and Outcome of the Treatment for Acute Myocardial Infarction in Japan. Circulation Journal 69:12, 1447-1453
     CrossRef

324. 324

     Gillian A Whalley, Cara A Wasywich, Helen Walsh, Robert N Doughty. (2005) Role of echocardiography in the contemporary management of chronic heart failure. Expert Review of Cardiovascular Therapy 3:1, 51-70
     CrossRef

325. 325

     Roberto Fogari, Annalisa Zoppi. (2005) Is the Effect of Antihypertensive Drugs on Platelet Aggregability and Fibrinolysis Clinically Relevant?. American Journal of Cardiovascular Drugs 5:4, 211-223
     CrossRef

326. 326

     J. J. Remmen, W. R. M. Aengevaeren, F. W. A. Verheugt, A. Bos, R. W. M. M. Jansen. (2005) Lower body positive pressure by anti-G garment inflation: a suitable method to increase pulmonary capillary wedge pressure in healthy elderly subjects. Clinical Physiology and Functional Imaging 25:1, 27-33
     CrossRef

327. 327

     Roberto Ferrari. (2005) Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Review of Cardiovascular Therapy 3:1, 15-29
     CrossRef

328. 328

     Bin Ren, Qiming Shao, Pallab K Ganguly, Paramjit S Tappia, Nobuakira Takeda, Naranjan S Dhalla. (2004) Influence of long-term treatment of imidapril on mortality, cardiac function, and gene expression in congestive heart failure due to myocardial infarction. Canadian Journal of Physiology and Pharmacology 82:12, 1118-1127
     CrossRef

329. 329

     Ross T. Tsuyuki, Miriam Fradette, Jeffrey A. Johnson, Tammy J. Bungard, Dean T. Eurich, Thomas Ashton, Wendy Gordon, Roland Ikuta, Jan Kornder, Elizabeth Mackay, Dante Manyari, Ken O’Reilly, William Semchuk, for the react investigators. (2004) A multicenter disease management program for hospitalized patients with heart failure. Journal of Cardiac Failure 10:6, 473-480
     CrossRef

330. 330

     David Rosenthal, Maryanne R.K. Chrisant, Erik Edens, Lynn Mahony, Charles Canter, Steven Colan, Anne Dubin, Jacque Lamour, Robert Ross, Robert Shaddy, Linda Addonizio, Lee Beerman, Stuart Berger, Daniel Bernstein, Elizabeth Blume, Mark Boucek, Paul Checchia, Anne Dipchand, Jonathan Drummond-Webb, Jay Fricker, Richard Friedman, Sara Hallowell, Robert Jaquiss, Seema Mital, Elfriede Pahl, Bennett Pearce, Larry Rhodes, Kathy Rotondo, Paolo Rusconi, Janet Scheel, Tajinder Pal Singh, Jeffrey Towbin. (2004) International Society for Heart and Lung Transplantation: Practice guidelines for management of heart failure in children. The Journal of Heart and Lung Transplantation 23:12, 1313-1333
     CrossRef

331. 331

     AJ Scheen. (2004) Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Diabetes & Metabolism 30:6, 487-496
     CrossRef

332. 332

     The PEACE Trial Investigators. (2004) Angiotensin-Converting–Enzyme Inhibition in Stable Coronary Artery Disease. New England Journal of Medicine 351:20, 2058-2068
     Full Text

333. 333

     Siu-Sun Yao, Ehtasham Qureshi, Kenneth Nichols, George A. Diamond, E. Gordon Depuey, Alan Rozanski. (2004) Prospective validation of a quantitative method for differentiating ischemic versus nonischemic cardiomyopathy by technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. Clinical Cardiology 27:11, 615-620
     CrossRef

334. 334

     Mary Clare Derfler, Mark Jacob, Robert E. Wolf, Frank Bleyer, Paul J. Hauptman. (2004) Mode of Death From Congestive Heart Failure: Implications for Clinical Management. The American Journal of Geriatric Cardiology 13:6, 299-304
     CrossRef

335. 335

     R. Pfister, C.A. Schneider. (2004) Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives?. Clinica Chimica Acta 349:1-2, 25-38
     CrossRef

336. 336

     Jens Mogensen, Ross T. Murphy, Tony Shaw, Ajay Bahl, Charles Redwood, Hugh Watkins, Margaret Burke, Perry M. Elliott, William J. McKenna. (2004) Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy. Journal of the American College of Cardiology 44:10, 2033-2040
     CrossRef

337. 337

     Carl V. Leier. (2004) Dismantling mandates in the treatment of heart failure* *Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 44:9, 1831-1833
     CrossRef

338. 338

     Bunyong Phakdeekitcharoen, Pornthep Leelasa-nguan. (2004) Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. American Journal of Kidney Diseases 44:4, 738-746
     CrossRef

339. 339

     Flávio Danni Fuchs. (2004) Blood pressure-lowering drugs: essential therapy for some patients with normal blood pressure. Expert Review of Cardiovascular Therapy 2:5, 771-775
     CrossRef

340. 340

     Satish Kenchaiah, Jagat Narula, Ramachandran S. Vasan. (2004) Risk factors for heart failure. Medical Clinics of North America 88:5, 1145-1172
     CrossRef

341. 341

     Lars H. Lund, Donna Mancini. (2004) Heart failure in women. Medical Clinics of North America 88:5, 1321-1345
     CrossRef

342. 342

     Liviu Klein, Mihai Gheorghiade. (2004) Coronary artery disease and prevention of heart failure. Medical Clinics of North America 88:5, 1209-1235
     CrossRef

343. 343

     Meenakshi A. Bhalla, Audrey Chiang, Victoria A. Epshteyn, Radmila Kazanegra, Vikas Bhalla, Paul Clopton, Padma Krishnaswamy, L.K. Morrison, Albert Chiu, Nancy Gardetto, Sunder Mudaliar, Steven V. Edelman, Robert R. Henry, Alan S. Maisel. (2004) Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. Journal of the American College of Cardiology 44:5, 1047-1052
     CrossRef

344. 344

     Daniel M. Spevack, Arthur Schwartzbard. (2004) B-type natriuretic peptide measurement in heart failure. Clinical Cardiology 27:9, 489-494
     CrossRef

345. 345

     Joseph L. Izzo, Alan H. Gradman. (2004) Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Medical Clinics of North America 88:5, 1257-1271
     CrossRef

346. 346

     Qi Jiang, Steven Snapinn, Boris Iglewicz. (2004) Calculation of Sample Size in Survival Trials: The Impact of Informative Noncompliance. Biometrics 60:3, 800-806
     CrossRef

347. 347

     Olaf Hedrich, Mark Jacob, Paul J. Hauptman. (2004) Progression of coronary artery disease in non-ischemic dilated cardiomyopathy. Coronary Artery Disease 15:5, 291-297
     CrossRef

348. 348

     Brian Tomlinson, Jean Woo, G. Neil Thomas, Yee-Man Chau, Julian A.J.H. Critchley. (2004) Randomized, controlled, parallel-group comparison of ambulatory and clinic blood pressure responses to amlodipine or enalapril during and after treatment in adult chinese patients with hypertension. Clinical Therapeutics 26:8, 1292-1304
     CrossRef

349. 349

     Niall McLaughlin, Todd W. B. Gehr, Domenic A. Sica. (2004) Aldosterone-receptor antagonism and end-stage renal disease. Current Hypertension Reports 6:4, 327-330
     CrossRef

350. 350

     Pablo Navarro, Robert Moskowitz, Thierry H. Le Jemtel. (2004) Inhibition of RAAS—When is it too much?. Current Heart Failure Reports 1:2, 57-64
     CrossRef

351. 351

     (2004) References. American Journal of Kidney Diseases 43, 268-290
     CrossRef

352. 352

     James N Kirkpatrick, Andrew Davis, Jeanne M DeCara, Anne E Hong, Patricia L Kurtz, Beth Balasia, Kirk T Spencer. (2004) Hand-carried cardiac ultrasound as a tool to screen for important cardiovascular disease in an underserved minority health care clinic. Journal of the American Society of Echocardiography 17:5, 399-403
     CrossRef

353. 353

     Kirkwood F. Adams. (2004) Are angiotensin-converting enzyme inhibitors and β-blockers making an impact on the epidemiology of heart failure?. Current Cardiology Reports 6:3, 162-168
     CrossRef

354. 354

     Kathleen H. Berecek, Amal Farag, Gul Bahtiyar, Jeffery Rothman, Samy I. McFarlane. (2004) Clinical trials report. Current Hypertension Reports 6:3, 211-214
     CrossRef

355. 355

     Benjamin J. Epstein, Kurt A. Wargo, Kenneth Chong, Evelyn C. Y. Chan. (2004) Elevations in Serum Creatinine Concentration: Concerning or Reassuring?. Pharmacotherapy 24:5, 697-703
     CrossRef

356. 356

     Mariell Jessup, Ileana L Piña. (2004) Is it important to examine gender differences in the epidemiology and outcome of severe heart failure?. The Journal of Thoracic and Cardiovascular Surgery 127:5, 1247-1252
     CrossRef

357. 357

     Jacob Abarca, Daniel C. Malone, Edward P. Armstrong, Woodie M. Zachry. (2004) Angiotensin-Converting Enzyme Inhibitor Therapy in Patients with Heart Failure Enrolled in a Managed Care Organization: Effect on Costs and Probability of Hospitalization. Pharmacotherapy 24:3, 351-357
     CrossRef

358. 358

     Emma J. Birks, Magdi H. Yacoub, Nicholas R. Banner, Asghar Khaghani. (2004) The role of bridge to transplantation: should LVAD patients be transplanted?. Current Opinion in Cardiology 19:2, 148-153
     CrossRef

359. 359

     MAKOTO KODAMA, KIMINORI KATO, SATORU HIRONO, YUJI OKURA, HARUO HANAWA, TSUYOSHI YOSHIDA, MANABU HAYASHI, HITOSHI TACHIKAWA, TAKESHI KASHIMURA, KENICHI WATANABE, YOSHIFUSA AIZAWA. (2004) Linkage Between Mechanical and Electrical Alternans in Patients with Chronic Heart Failure. Journal of Cardiovascular Electrophysiology 15:3, 295-299
     CrossRef

360. 360

     Paul A Heidenreich, Matthew A Gubens, Gregg C Fonarow, Marvin A Konstam, Lynne W Stevenson, Paul G Shekelle. (2004) Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. Journal of the American College of Cardiology 43:6, 1019-1026
     CrossRef

361. 361

     Barnaby Reeves, Massimo Caputo, Gianni D Angelini. (2004) Reply to the Editor. The Journal of Thoracic and Cardiovascular Surgery 127:3, 894-895
     CrossRef

362. 362

     Yoshihiko Seino. (2004) Back to the Future: Pathophysiology and Therapeutic Strategies in Heart Failure. Journal of Nippon Medical School 71:6, 421-425
     CrossRef

363. 363

     Makoto KODAMA, Hitoshi TACHIKAWA, Takeshi KASHIMURA, Manabu HAYASHI, Tsuyoshi YOSHIDA, Haruo HANAWA, Yoshifusa AIZAWA, Mikio NAKAZAWA, Kenichi WATANABE. (2004) Effects of humoral factors on left ventricular remodeling under chronic heart failure.. Folia Pharmacologica Japonica 123:2, 63-70
     CrossRef

364. 364

     Satoru Komura, Masaomi Chinushi, Michiko Kudo, Takashi Saikawa, Yasutaka Tanabe, Hiroshi Furushima, Takashi Washizuka, Makoto Kodama, Hirotaka Oda, Seiichi Miyajima, Fumiaki Masani, Yutaka Igarashi, Minoru Murata, Yoshifusa Aizawa. (2004) Potential Candidates for Cardiac Resynchronization Therapy in Japanese Patients With Idiopathic Dilated Cardiomyopathy. Circulation Journal 68:12, 1104-1109
     CrossRef

365. 365

     Guy De Backer, Ettore Ambrosioni, Knut Broch-Johnsen, Carlos Brotons, Renata Cifkova, Jean Dallongeville, Shah Ebrahim, Ole Faergeman, Ian Graham, Guiseppe Mancia, Volkert Manger Cats, Kristina Orth-Gom??r, Joep Perk, Kalevi Py??r??l??, Jos?? L. Rodicio, Susana Sans, Vedat Sansoy, Udo Sechtem, Sigmund Silber, Troels Thomsen, David Wood. (2003) European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). European Journal of Cardiovascular Prevention and Rehabilitation 10:Supplement 1, S1-S78
     CrossRef

366. 366

     Miho Mizukami, Hiroshi Hasegawa, Takahide Kohro, Haruhiro Toko, Sumiyo Kudoh, Yunzeng Zou, Hiroyuki Aburatani, Issei Komuro. (2003) Gene Expression Profile Revealed Different Effects of Angiotensin II Receptor Blockade and Angiotensin-Converting Enzyme Inhibitor on Heart Failure. Journal of Cardiovascular Pharmacology 42, S1-S6
     CrossRef

367. 367

     William M. Tierney, J. Marc Overhage, Michael D. Murray, Lisa E. Harris, Xiao-Hua Zhou, George J. Eckert, Faye E. Smith, Nancy Nienaber, Clement J. McDonald, Fredric D. Wolinsky. (2003) Effects of Computerized Guidelines for Managing Heart Disease in Primary Care. A Randomized, Controlled Trial. Journal of General Internal Medicine 18:12, 967-976
     CrossRef

368. 368

     Carl J. Pepine, Jean-Lucien Rouleau, Karen Annis, Anique Ducharme, Patrick Ma, Jacques Lenis, Richard Davies, Udho Thadani, Bernard Chaitman, Harry E. Haber, S.Ben Freedman, Milton L. Pressler, Bertram Pitt. (2003) Effects of angiotensin-converting enzyme inhibition on transient ischemia. Journal of the American College of Cardiology 42:12, 2049-2059
     CrossRef

369. 369

     W. Frank Peacock. (2003) Emergency Department Observation Unit Management of Heart Failure. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2:4, 207-220
     CrossRef

370. 370

     Kim Fox. (2003) The EUROPA trial. The Lancet 362:9399, 1936-1937
     CrossRef

371. 371

     Ileana L Piña. (2003) A better survival for women with heart failure? it's not so simple…. Journal of the American College of Cardiology 42:12, 2135-2138
     CrossRef

372. 372

     Ole Dyg Pedersen, Bente Brendorp, Lars Køber, Christian Torp-Pedersen. (2003) Prevalence, Prognostic Significance, and Treatment of Atrial Fibrillation in Congestive Heart Failure With Particular Reference to the DIAMOND-CHF Study. Congestive Heart Failure 9:6, 333-340
     CrossRef

373. 373

     George L. Bakris, Nauman Tarif, Henry R. Black. 2003. Arterial Hypertension in Diabetes: Etiology and Treatment. .
     CrossRef

374. 374

     Michiel J. Janse. (2003) A brief history of sudden cardiac death and its therapy. Pharmacology & Therapeutics 100:1, 89-99
     CrossRef

375. 375

     William E. Chavey, Barry E. Bleske, John M. Nicklas. (2003) Controversies in the Use of Beta Blockers in Heart Failure. Congestive Heart Failure 9:5, 255-262
     CrossRef

376. 376

     (2003) Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet 362:9386, 782-788
     CrossRef

377. 377

     James P. Tsikouris, Craig D. Cox. (2003) Pharmacologic Blockade of the Renin-Angiotensin System: Vascular Benefits Beyond Commonly Understood Pharmacologic Actions. Pharmacotherapy 23:9, 1141-1152
     CrossRef

378. 378

     Savitri Fedson, Gregg Neithardt, Patrick Thomas, Alex Lickerman, Michael Radzienda, Jeanne M DeCara, Roberto M Lang, Kirk T Spencer. (2003) Unsuspected clinically important findings detected with a small portable ultrasound device in patients admitted to a general medicine service. Journal of the American Society of Echocardiography 16:9, 901-905
     CrossRef

379. 379

     H. Montgomery. (2003) Stressing the system. European Journal of Clinical Investigation 33:8, 635-641
     CrossRef

380. 380

     Paul A Heidenreich, Steven L Hancock, Byron K Lee, Carol S Mariscal, Ingela Schnittger. (2003) Asymptomatic cardiac disease following mediastinal irradiation. Journal of the American College of Cardiology 42:4, 743-749
     CrossRef

381. 381

     Adrian F Hernandez, Christopher M O'Connor. (2003) Sparing a little may save a lot. Journal of the American College of Cardiology 42:4, 709-711
     CrossRef

382. 382

     Nathalie Thilly, Serge Briancon, Yves Juilliere, Edith Dufay, Faiez Zannad. (2003) Improving ACE inhibitor use in patients hospitalized with systolic heart failure: a cluster randomized controlled trial of clinical practice guideline development and use. Journal of Evaluation in Clinical Practice 9:3, 373-382
     CrossRef

383. 383

     Antonio Pacifico, Philip D. Henry. (2003) Structural Pathways and Prevention of Heart Failure and Sudden Death. Journal of Cardiovascular Electrophysiology 14:7, 764-774
     CrossRef

384. 384

     Michael W. Rich. (2003) Drug Therapy Of Heart Failure in the Elderly. The American Journal of Geriatric Cardiology 12:4, 235-242
     CrossRef

385. 385

     Wilbert S. Aronow. (2003) Epidemiology, Pathophysiology, Prognosis, and Treatment of Systolic and Diastolic Heart Failure in Elderly Patients. Heart Disease 5:4, 279-294
     CrossRef

386. 386

     Jeanne M. DeCara, Roberto M. Lang, Kirk T. Spencer. (2003) The Hand-Carried Echocardiographic Device as an Aid to the Physical Examination. Echocardiography 20:5, 477-485
     CrossRef

387. 387

     Robert Lee Page, Wendolyn S. Gozansky, J. Mark Ruscin. (2003) Possible Heart Failure Exacerbation Associated with Rosiglitazone: Case Report and Literature Review. Pharmacotherapy 23:7, 945-954
     CrossRef

388. 388

     John Randolph Litaker, Jennie Yu Chou. (2003) Patterns of pharmacologic treatment of congestive heart failure in elderly nursing home residents and related issues: A review of the literature. Clinical Therapeutics 25:7, 1918-1935
     CrossRef

389. 389

     Helmy M. Siragy. (2003) Clinical Trials Report. Current Hypertension Reports 5:4, 293-294
     CrossRef

390. 390

     Pär Hedberg, Tommy Jonason, Egil Henriksen, Ingemar Lönnberg, Göran Nilsson, Kenneth Pehrsson, Ivar Ringqvist. (2003) Mitral annulus motion compared with wall motion scoring index in the assessment of left ventricular ejection fraction. Journal of the American Society of Echocardiography 16:6, 622-629
     CrossRef

391. 391

     Lisa G. Pont, Miriam C. J. M. Sturkenboom, Wiek H. van Gilst, Petra Denig, Flora M. Haaijer-Ruskamp. (2003) Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000. Pharmacoepidemiology and Drug Safety 12:4, 327-334
     CrossRef

392. 392

     N WISNIACKI, V GOWDA, O DAR, M LYE, S VINJAMURI. (2003) Does diastolic function evaluated with radionuclide ventriculography predict mortality, hospitalization and the development of new onset heart failure?. Nuclear Medicine Communications 24:6, 707-713
     CrossRef

393. 393

     John P. Higgins. (2003) Can Angiotensin-converting Enzyme Inhibitors Reverse Atherosclerosis?. Southern Medical Journal 96:6, 569-579
     CrossRef

394. 394

     Bobbi L. Hoppe, Denise D. Hermann. (2003) Sex differences in the causes and natural history of heart failure. Current Cardiology Reports 5:3, 193-199
     CrossRef

395. 395

     S. Raja Laskar, Daniel L. Dries. (2003) The prognostic significance of renal dysfunction in patients with chronic systolic heart failure. Current Cardiology Reports 5:3, 205-210
     CrossRef

396. 396

     Benjamin M. Schaefer, Vincent Caracciolo, William H. Frishman, Pamela Charney. (2003) Gender, Ethnicity, and Genes in Cardiovascular Disease.. Heart Disease 5:3, 202-214
     CrossRef

397. 397

     Richard J. Rodeheffer. (2003) The new epidemiology of heart failure. Current Cardiology Reports 5:3, 181-186
     CrossRef

398. 398

     Paul G. Shekelle, Michael W. Rich, Sally C. Morton, Col.Sid W. Atkinson, Wenli Tu, Margaret Maglione, Shannon Rhodes, Michael Barrett, Gregg C. Fonarow, Barry Greenberg, Paul A. Heidenreich, Tom Knabel, Marvin A. Konstam, Anthony Steimle, Lynne Warner Stevenson. (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. Journal of the American College of Cardiology 41:9, 1529-1538
     CrossRef

399. 399

     Philip Jong, Salim Yusuf, Michel F Rousseau, Sylvie A Ahn, Shrikant I Bangdiwala. (2003) Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. The Lancet 361:9372, 1843-1848
     CrossRef

400. 400

     S.Adam Strickberger, John D Hummel, Thomas G Bartlett, Howard I Frumin, Claudio D Schuger, Scott L Beau, Cynthia Bitar, Fred Morady. (2003) Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemicdilated cardiomyopathy and asymptomaticnonsustained ventricular tachycardia—AMIOVIRT. Journal of the American College of Cardiology 41:10, 1707-1712
     CrossRef

401. 401

     Frank Wagner, Ruhi Yeter, Susanne Bisson, Henryk Siniawski, Roland Hetzer. (2003) Beneficial hemodynamic and renal effects of intravenous enalaprilat following coronary artery bypass surgery complicated by left ventricular dysfunction*. Critical Care Medicine 31:5, 1421-1428
     CrossRef

402. 402

     Kathy A. Crispell. (2003) Familial cardiomyopathies: Significant causes of heart failure. Current Cardiology Reports 5:3, 187-192
     CrossRef

403. 403

     Steven E Lipshultz, Stacy D Fisher, Wyman W Lai, Tracie L Miller. (2003) Cardiovascular risk factors, monitoring, and therapy for HIV-infected patients. AIDS 17, S96-S122
     CrossRef

404. 404

     Marcin Gruchala, Dariusz Ciećwierz, Karolina Ochman, Bartosz Wasag, Andrzej Koprowski, Andrzej Wojtowicz, Witold Dubaniewicz, Radoslaw Targoński, Wojciech Sobiczewski, Adam Grzybowski, Piotr Romanowski, Janusz Limon, Andrzej Rynkiewicz. (2003) Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease. Clinical Chemistry and Laboratory Medicine 41:4, 522-528
     CrossRef

405. 405

     Domenic A. Sica. (2003) Aldosterone Receptor Blockade: A Therapy Resurrected. Heart Disease 5:2, 85-88
     CrossRef

406. 406

     Brian D. Le, Tayo Addo, James A. de Lemos. (2003) The Endocrine Heart: B-type Natriuretic Peptide as a Diagnostic and Therapeutic Agent in Cardiovascular Disease. The Endocrinologist 13:2, 97-105
     CrossRef

407. 407

     Robert N Foley. (2003) THE CLINICAL EPIDEMIOLOGY OF CARDIOVASCULAR DISEASES IN CHRONIC KIDNEY DISEASE: Clinical Epidemiology of Cardiac Disease in Dialysis Patients: Left Ventricular Hypertrophy, Ischemic Heart Disease, and Cardiac Failure. Seminars in Dialysis 16:2, 111-117
     CrossRef

408. 408

     Philip A Poole-Wilson. (2003) ACE inhibitors and ARBs in chronic heart failure: the established, the expected, and the pragmatic. Medical Clinics of North America 87:2, 373-389
     CrossRef

409. 409

     Frolkis, Joseph P., Pothier, Claire E., Blackstone, Eugene H., Lauer, Michael S., . (2003) Frequent Ventricular Ectopy after Exercise as a Predictor of Death. New England Journal of Medicine 348:9, 781-790
     Full Text

410. 410

     Wing, Lindon M.H., Reid, Christopher M., Ryan, Philip, Beilin, Lawrence J., Brown, Mark A., Jennings, Garry L.R., Johnston, Colin I., McNeil, John J., Macdonald, Graham J., Marley, John E., Morgan, Trefor O., West, Malcolm J., . (2003) A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the Elderly. New England Journal of Medicine 348:7, 583-592
     Full Text

411. 411

     Frohlich, Edward D., . (2003) Treating Hypertension — What Are We to Believe?. New England Journal of Medicine 348:7, 639-641
     Full Text

412. 412

     G. H. Goossens, E. E. Blaak, M. A. van Baak. (2003) Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obesity Reviews 4:1, 43-55
     CrossRef

413. 413

     Yoko Fujii, Yoshito Wakao. (2003) Spectral analysis of heart rate variability in dogs with mild mitral regurgitation. American Journal of Veterinary Research 64:2, 145-148
     CrossRef

414. 414

     Norman M Kaplan. (2003) The meaning of ALLHAT. Journal of Hypertension 21:2, 233-234
     CrossRef

415. 415

     J. Herbert Patterson. (2003) Angiotensin II Receptor Blockers in Heart Failure. Pharmacotherapy 23:2, 173-182
     CrossRef

416. 416

     Aasmund Reikvam, Elena Kvan, Knud Landmark, Ivar Aursnes. (2003) Angiotensin-converting enzyme (ACE) inhibitor therapy after myocardial infarction in relation to left ventricular function. Scandinavian Cardiovascular Journal 37:3, 130-134
     CrossRef

417. 417

     Rohit Arora, Luther Clark, Malcolm Taylor. (2003) Treatment of High-Risk African American Patients: Left Ventricular Dysfunction, Heart Failure, Renal Disease, and Postmyocardial Infarction. The Journal of Clinical Hypertension 5:1, 26-31
     CrossRef

418. 418

     Olav W Nielsen, Theresa A McDonagh, Stephen D Robb, Henry J Dargie. (2003) Retrospective analysis of thecost-effectiveness of using plasmabrain natriuretic peptide inscreening for left ventricularsystolic dysfunction in the general population. Journal of the American College of Cardiology 41:1, 113-120
     CrossRef

419. 419

     Yasuyuki Shimada, Hitoshi Yaku, Keisuke Shuntoh, Katsuhiko Oka, Takahisa Okano, Tsutomu Matsushita, Atsushi Fukumoto, Kyoko Hayashida, Yoshiaki Yamada, Taiji Watanabe, Nobuo Kitamura. (2003) Impact of Myocardial Angiotensin-Converting Enzyme Activity on Coronary Vascular Resistance and Serum Brain Natriuretic Peptide Concentration in Coronary Bypass Surgery. Circulation Journal 67:5, 379-383
     CrossRef

420. 420

     Elizabeth A. McGlynn, Christine K. Cassel, Sheila T. Leatherman, Alison DeCristofaro, Helen L. Smits. (2003) Establishing National Goals for Quality Improvement. Medical Care 41:Supplement, I-16-I-29
     CrossRef

421. 421

     A. M. Katz. (2003) Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. Journal of Cellular and Molecular Medicine 7:1, 1-10
     CrossRef

422. 422

     Ravi K. Garg, A. Nasser Khan, Allen S. Anderson. (2002) Contemporary use of beta receptor antagonists in chronic heart failure. Comprehensive Therapy 28:4, 207-213
     CrossRef

423. 423

     K.H. Tscheliessnigg. (2002) Surgical Treatment of Heart Failure - A Changing Paradigm?. European Surgery-Acta Chirurgica Austriaca 34:6, 347-353
     CrossRef

424. 424

     Anuradha Aggarwal, David M. Kaye. (2002) Neurohormonal assessment of cardiac function. Coronary Artery Disease 13:8, 415-419
     CrossRef

425. 425

     Dean A. Follmann. (2002) Regression analysis based on pairwise ordering of patients' clinical histories. Statistics in Medicine 21:22, 3353-3367
     CrossRef

426. 426

     Mark T Kearney, Keith A.A Fox, Amanda J Lee, Robin J Prescott, Ajay M Shah, Philip D Batin, Wazir Baig, Stephen Lindsay, Timothy S Callahan, William E Shell, Dwain L Eckberg, Azfar G Zaman, Simon Williams, James M.M Neilson, James Nolan. (2002) Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. Journal of the American College of Cardiology 40:10, 1801-1808
     CrossRef

427. 427

     Mark Greathouse. (2002) A Review of Olmesartan Medoxomil Monotherapy: Antihypertensive Efficacy Similar to That of Other Angiotensin II Receptor Blocker/Hydrochlorothiazide Combinations?. Congestive Heart Failure 8:6, 313-320
     CrossRef

428. 428

     Edward P. Havranek, Frederick A. Masoudi, Debra L. Ralston, Nancy J. Susman, Harlan M. Krumholz, Jane P. Taylor. (2002) Future Challenges in Quality Improvement in Heart Failure. Congestive Heart Failure 8:6, 342-345
     CrossRef

429. 429

     Clive Rosendorff. (2002) Managing the hypertensive patient with ischemic heart disease. Current Hypertension Reports 4:5, 350-357
     CrossRef

430. 430

     O. Gabrielli, A. M. Puyo, A. Rosa, I. Armando, M. Barontini, G. Levin. (2002) Atenolol improves ventricular function without changing plasma noradrenaline but decreasing plasma atrial natriuretic factor in chronic heart failure. Autonomic and Autacoid Pharmacology 22:5-6, 261-268
     CrossRef

431. 431

     Michael F. O'Rourke. (2002) From theory into practice: arterial haemodynamics in clinical hypertension. Journal of Hypertension 20:10, 1901-1915
     CrossRef

432. 432

     Matthew R. Weir. (2002) Progressive renal and cardiovascular disease: Optimal treatment strategies. Kidney International 62:4, 1482-1492
     CrossRef

433. 433

     Clarke E. Atkins, William A. Brown, Julie R. Coats, Mary Ann Crawford, Teresa C. DeFrancesco, Joel Edwards, Philip R. Fox, Bruce W. Keene, Linda Lehmkuhl, Michael Luethy, Kate Meurs, Jean-Paul Petrie, Frank Pipers, Steven Rosenthal, Jennifer A. Sidley, Justin Straus. (2002) Effects of long-term administration of enalapril on clinical indicators of renal function in dogs with compensated mitral regurgitation. Journal of the American Veterinary Medical Association 221:5, 654-658
     CrossRef

434. 434

     Eugene S. Smith, Suzanne Trussell, Laura J. Mencer. (2002) Prevention of heart failure. Current Opinion in Cardiology 17:5, 512-517
     CrossRef

435. 435

     Ross C. Peterson, Mark E. Dunlap. (2002) Angiotensin II Receptor Blockers in the Treatment of Heart Failure. Congestive Heart Failure 8:5, 246-256
     CrossRef

436. 436

     Patricia A. Howard, Theresa I. Shireman, Ashish Dhingra, Edward F. Ellerbeck, Jack E. Fincham. (2002) Patterns of ACE Inhibitor Use in Elderly Medicaid Patients With Heart Failure. The American Journal of Geriatric Cardiology 11:5, 287-294
     CrossRef

437. 437

     Stefan Krüger, J.ürgen Graf, Dagmar Kunz, Tina Stickel, Peter Hanrath, Uwe Janssens. (2002) brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. Journal of the American College of Cardiology 40:4, 718-722
     CrossRef

438. 438

     Daniel L Dries, Mark H Strong, Richard S Cooper, Mark H Drazner. (2002) Efficacy of angiotensin-converting enzyme inhibition in reducing progression from asymptomatic left ventricular dysfunction to symptomatic heart failure in black and white patients. Journal of the American College of Cardiology 40:2, 311-317
     CrossRef

439. 439

     Jean Geber, David Parra, Nick P. Beckey, Lisa Korman. (2002) Optimizing Drug Therapy in Patients with Cardiovascular Disease: The Impact of Pharmacist-Managed Pharmacotherapy Clinics in a Primary Care Setting. Pharmacotherapy 22:6, 738-747
     CrossRef

440. 440

     Howard D. Weinberger, Jennifer J. Weinberger. (2002) Use of Angiotensin-Converting Enzyme Inhibitors to Prevent Cardiovascular Disease. Primary Care Case Reviews 5:2, 61-67
     CrossRef

441. 441

     Fadi M.F. Alameddine, A. Maziar Zafari. (2002) Genetic Polymorphisms and Oxidative Stress in Heart Failure. Congestive Heart Failure 8:3, 157-172
     CrossRef

442. 442

     A.Mark Richards, John G Lainchbury, M.Gary Nicholls, Richard W Troughton, Timothy G Yandle. (2002) BNP in hormone-guided treatment of heart failure. Trends in Endocrinology & Metabolism 13:4, 151-155
     CrossRef

443. 443

     Tamara B. Horwich, Gregg C. Fonarow. (2002) Prevention of heart failure. Current Cardiology Reports 4:3, 194-199
     CrossRef

444. 444

     Kevin A. Lisman, Sonny J. Stetson, Michael M. Koerner, John A. Farmer, Guillermo Torre-Amione. (2002) The role of inflammation in the pathogenesis of heart failure. Current Cardiology Reports 4:3, 200-205
     CrossRef

445. 445

     Martin St. John Sutton, Victor A. Ferrari. (2002) Prevention of left ventricular remodeling after myocardial infarction. Current Treatment Options in Cardiovascular Medicine 4:2, 97-108
     CrossRef

446. 446

     Gilbert J. Perry, Chih-Chang Wei, Gerald H. Hankes, S.Ray Dillon, Patricia Rynders, Rupak Mukherjee, Francis G. Spinale, Louis J. Dell’Italia. (2002) Angiotensin II receptor blockade does not improve left ventricular function andremodeling in subacute mitral regurgitation in the dog. Journal of the American College of Cardiology 39:8, 1374-1379
     CrossRef

447. 447

     G. A. MacGowan, D. M. McNamara. (2002) New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies. Irish Journal of Medical Science 171:2, 99-104
     CrossRef

448. 448

     Rudolf A. de Boer, Peter P. van Geel, Yigal M. Pinto, Albert J. H. Suurmeijer, Harry J. G. M. Crijns, Wiek H. van Gilst, Dirk J. van Veldhuisen. (2002) Efficacy of Angiotensin II Type 1 Receptor Blockade on Reperfusion-Induced Arrhythmias and Mortality Early After Myocardial Infarction Is Increased in Transgenic Rats With Cardiac Angiotensin II Type 1 Overexpression. Journal of Cardiovascular Pharmacology 39:4, 610-619
     CrossRef

449. 449

     Hans R Brunner, Haralambos Gavras. (2002) Angiotensin blockade for hypertension: a promise fulfilled. The Lancet 359:9311, 990-992
     CrossRef

450. 450

     Alfredo J. Selim, Dan R. Berlowitz, Graeme Fincke, Amy K. Rosen, Xinhua S. Ren, Cindy L. Christiansen, Zhongxhiao Cong, Austin Lee, Lewis Kazis. (2002) Risk-Adjusted Mortality Rates as a Potential Outcome Indicator for Outpatient Quality Assessments. Medical Care 40:3, 237-245
     CrossRef

451. 451

     Yasuyuki Shimada, Suba Gunasegaram, Hiroyuki Yokoyama, Metin Avkiran. (2002) Inhibition of Angiotensin-Converting Enzyme Reduces Susceptibility of Hypertrophied Rat Myocardium to Ventricular Fibrillation. Circulation Journal 66:11, 1045-1053
     CrossRef

452. 452

     Ayan R. Patel, Marvin A. Konstam. (2002) Recent Advances in the Treatment of Heart Failure. Circulation Journal 66:2, 117-117
     CrossRef

453. 453

     Yasuyuki Shimada, Metin Avkiran. (2002) Left and Right Coronary Circulation in Left Ventricular Hypertrophy. Circulation Journal 66:12, 1168-1172
     CrossRef

454. 454

     Robert Kelly, Anthony Staines, Ron MacWalter, Peter Stonebridge, Hugh Tunstall-Pedoe, Allan D Struthers. (2002) The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes. Journal of the American College of Cardiology 39:2, 219-224
     CrossRef

455. 455

     S. Mitra, K. Findley, D. Frohnapple, J. L. Mehta. (2002) Trends in long-term management of survivors of acute myocardial infarction by cardiologists in a government university-affiliated teaching hospital. Clinical Cardiology 25:1, 16-18
     CrossRef

456. 456

     Weber, Karl T., . (2001) Aldosterone in Congestive Heart Failure. New England Journal of Medicine 345:23, 1689-1697
     Full Text

457. 457

     Carl V. Leier. (2001) Dilated cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 3:6, 451-462
     CrossRef

458. 458

     Susan Ammon. (2001) Managing Patients with Heart Failure. American Journal of Nursing 101:12, 34-40
     CrossRef

459. 459

     Kenneth L. Baughman. (2001) Peripartum cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 3:6, 469-480
     CrossRef

460. 460

     Nicolas W. Shammas, Melodee L. Harris, Dawn Mckinney, William J. Hauber. (2001) Digoxin withdrawal in patients with dilated cardiomyopathy following normalization of ejection fraction with beta blockers. Clinical Cardiology 24:12, 786-787
     CrossRef

461. 461

     William L. Lombardi, Edward M. Gilbert. (2001) Carvedilol in the failing heart. Clinical Cardiology 24:12, 757-766
     CrossRef

462. 462

     Philip A. Poole-Wilson. (2001) Implications of recent heart failure trials for patients with hypertension. Current Cardiology Reports 3:6, 504-510
     CrossRef

463. 463

     M Borgarelli, A Tarducci, A Tidholm, J Häggström. (2001) Canine Idiopathic Dilated Cardiomyopathy. Part II: Pathophysiology and therapy. The Veterinary Journal 162:3, 182-195
     CrossRef

464. 464

     R Faris, MD Flather, H Purcell, MY Heinan, P Poole-Wilson, AJS Coats, Rajaa Faris. 2001. Diuretics for heart failure. .
     CrossRef

465. 465

     G. J. Pearson, C. Cooke, W. K. T. Simmons, I. Sketris. (2001) Evaluation of the use of evidence-based angiotensin-converting enzyme inhibitor criteria for the treatment of congestive heart failure: opportunities for pharmacists to improve patient outcomes. Journal of Clinical Pharmacy and Therapeutics 26:5, 351-361
     CrossRef

466. 466

     Adalet Gurlek, Mustafa Kilickap, Irem Dincer, Rabih Dandachi, Huseyin Tutkak, Dervis Oral. (2001) Journal of Cardiovascular Risk 8:5, 279-282
     CrossRef

467. 467

     Brenner, Barry M., Cooper, Mark E., de Zeeuw, Dick, Keane, William F., Mitch, William E., Parving, Hans-Henrik, Remuzzi, Giuseppe, Snapinn, Steven M., Zhang, Zhonxin, Shahinfar, Shahnaz, . (2001) Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine 345:12, 861-869
     Full Text

468. 468

     John G.F. Cleland, Joseph John, Tim Houghton. (2001) Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors in hypertension or heart failure?. Current Opinion in Nephrology and Hypertension 10:5, 625-631
     CrossRef

469. 469

     Frank Enseleit, David Hürlimann, Thomas F Lüscher. (2001) Vascular Protective Effects of Angiotensin Converting Enzyme Inhibitors and their Relation to Clinical Events. Journal of Cardiovascular Pharmacology 37, S21-S30
     CrossRef

470. 470

     Domenic A. Sica. (2001) The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?. Current Opinion in Nephrology and Hypertension 10:5, 597-601
     CrossRef

471. 471

     Sameet A. Palkhiwala, William H. Frishman, Stephen Warshafsky. (2001) Bradykinin for the Treatment of Cardiovascular Disease. Heart Disease333-339
     CrossRef

472. 472

     Ettore Ambrosioni, Stefano Bacchelli, Daniela Degli Esposti, Claudio Borghi. (2001) Anti-Ischemic Effects of Angiotensin-Converting Enzyme Inhibitors: A Future Therapeutic Perspective. Journal of Cardiovascular Pharmacology 37, S3-S9
     CrossRef

473. 473

     Julie Dahl, Sue Penque. (2001) The effects of an advanced practice nurse-directed heart failure program. Dimensions of Critical Care Nursing 20:5, 20-28
     CrossRef

474. 474

     Ricardo Rocha, Charles T Stier. (2001) Pathophysiological effects of aldosterone in cardiovascular tissues. Trends in Endocrinology & Metabolism 12:7, 308-314
     CrossRef

475. 475

     Angelika Hammerer-Lercher, Elke Neubauer, Silvana Müller, Otmar Pachinger, Bernd Puschendorf, Johannes Mair. (2001) Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clinica Chimica Acta 310:2, 193-197
     CrossRef

476. 476

     Christian Delles, Roland E. Schmieder. (2001) The Kidney in Congestive Heart Failure: Renal Adverse Event Rate of Treatment. Journal of Cardiovascular Pharmacology 38:1, 99-107
     CrossRef

477. 477

     Anahit Anvari, Ernst Schuster, Michael Gottsauner-Wolf, Johann Wojta, Kurt Huber. (2001) PAI-I 4G/5G polymorphism and sudden cardiac death in patients with coronary artery disease. Thrombosis Research 103:2, 103-107
     CrossRef

478. 478

     Hiroyuki Tsutsui, Tomomi Ide, Shunji Hayashidani, Shintaro Kinugawa, Nobuhiro Suematsu, Hideo Utsumi, Akira Takeshita. (2001) Effects of ACE Inhibition on Left Ventricular Failure and Oxidative Stress in Dahl Salt-Sensitive Rats. Journal of Cardiovascular Pharmacology 37:6, 725-733
     CrossRef

479. 479

     Reinaldo B. Bestetti. (2001) Predictors of unfavourable prognosis in chronic Chagas' disease. Tropical Medicine and International Health 6:6, 476-483
     CrossRef

480. 480

     M.T Jaberansari, Gary F Baxter, Cecile A Muller, Sean E Latouf, E Röth, Lionel H Opie, Derek M Yellon. (2001) Angiotensin-converting enzyme inhibition enhances a subthreshold stimulus to elicit delayed preconditioning in pig myocardium. Journal of the American College of Cardiology 37:7, 1996-2001
     CrossRef

481. 481

     Mohammed E Khalil, Abul W Basher, Edward J Brown, Imad A Alhaddad. (2001) A remarkable medical story: benefits of angiotensin-converting enzyme inhibitors in cardiac patients. Journal of the American College of Cardiology 37:7, 1757-1764
     CrossRef

482. 482

     WB Hood, AL Dans, GH Guyatt, R Jaeschke, JJV McMurray. 2001. Digitalis for treatment of congestive heart failure in patients in sinus rhythm. .
     CrossRef

483. 483

     D. J. Campbell, V. Munir, O. F. Hennessy, A. W. Dent. (2001) Plasma amino-terminal pro-brain natriuretic peptide levels in subjects presenting to the Emergency Department with suspected acute coronary syndrome: possible role in selecting patients for follow up?. Internal Medicine Journal 31:4, 211-219
     CrossRef

484. 484

     Exner, Derek V., Dries, Daniel L., Domanski, Michael J., Cohn, Jay N., . (2001) Lesser Response to Angiotensin-Converting–Enzyme Inhibitor Therapy in Black as Compared with White Patients with Left Ventricular Dysfunction. New England Journal of Medicine 344:18, 1351-1357
     Full Text

485. 485

     Neville Suskin, Tej Sheth, Abdissa Negassa, Salim Yusuf. (2001) Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. Journal of the American College of Cardiology 37:6, 1677-1682
     CrossRef

486. 486

     Robert Moskowitz. (2001) The angiotensin-converting enzyme inhibitor and aspirin interaction in congestive heart failure:Fear or reality?. Current Cardiology Reports 3:3, 247-253
     CrossRef

487. 487

     Philip A Poole-Wilson, Rakesh Sharma, Aidan Bolger. 2001. Heart Failure. .
     CrossRef

488. 488

     Thomas Kahan, Per Wandell. (2001) Journal of Cardiovascular Risk 8:2, 73-79
     CrossRef

489. 489

     Nathalie Valli, Agnès Georges, Jean-Benoit Corcuff, Jean-Louis Barat, Laurence Bordenave. (2001) Assessment of brain natriuretic peptide in patients with suspected heart failure: comparison with radionuclide ventriculography data. Clinica Chimica Acta 306:1-2, 19-26
     CrossRef

490. 490

     John Stoves, Andrew J BACZKOWSKI2, John H TURNEY1. (2001) Factors influencing survival of diabetic patients after initiation of renal replacement therapy. Nephrology 6:2, 79-84
     CrossRef

491. 491

     Wayne L. Miller, Guy S. Reeder. (2001) Adjunctive Therapies in the Treatment of Acute Coronary Syndromes. Mayo Clinic Proceedings 76:4, 391-405
     CrossRef

492. 492

     W L Miller, G S Reeder. (2001) Adjunctive therapies in the treatment of acute coronary syndromes.. Mayo Clinic Proceedings 76:4, 391-405
     CrossRef

493. 493

     L. Wilhelmsen, A. Rosengren, H. Eriksson, G. Lappas. (2001) Heart failure in the general population of men - morbidity, risk factors and prognosis. Journal of Internal Medicine 249:3, 253-261
     CrossRef

494. 494

     L. Grain, M. Cortina-Borja, C. Forfar, D. Hilton-Jones, J. Hopkin, M. Burch. (2001) Cardiac abnormalities and skeletal muscle weakness in carriers of Duchenne and Becker muscular dystrophies and controls. Neuromuscular Disorders 11:2, 186-191
     CrossRef

495. 495

     Yoshiyu Takeda, Takashi Yoneda, Masashi Demura, Kenji Furukawa, Isamu Miyamori, Hiroshi Mabuchi. (2001) Effects of high sodium intake on cardiovascular aldosterone synthesis in stroke-prone spontaneously hypertensive rats. Journal of Hypertension 19:Supplement, 635-639
     CrossRef

496. 496

     Peter Carson, Thomas Giles, Michael Higginbotham, Norman Hollenberg, William Kannel, Helmy M. Siragy. (2001) Angiotensin receptor blockers: Evidence for preserving target organs. Clinical Cardiology 24:3, 183-190
     CrossRef

497. 497

     Stephen C. Textor, Christopher S. Wilcox. (2001) R ENAL A RTERY S TENOSIS : A Common, Treatable Cause of Renal Failure?. Annual Review of Medicine 52:1, 421-442
     CrossRef

498. 498

     Stephen MacMahon, Rory Collins. (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, II: observational studies. The Lancet 357:9254, 455-462
     CrossRef

499. 499

     R. Isnard. (2001) Le traitement médical de l'insuffisance cardiaque chronique. Annales de Cardiologie et d'Angéiologie 50:1, 30-37
     CrossRef

500. 500

     D Logeart. (2001) Perspectives médicamenteuses dans le traitement de l'insuffisance cardiaque. Annales de Cardiologie et d'Angéiologie 50:1, 38-49
     CrossRef

501. 501

     M. W. Rich. (2001) Heart Failure in the 21st Century: A Cardiogeriatric Syndrome. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:2, M88-M96
     CrossRef

502. 502

     Jun SUZUKI, Hisashi OHTA, Kayoko HANADA, Nobuko KAWAI, Takanori IKEDA, Mizuki NAKAO, Fumihiko IKEMOTO, Masaru NISHIKIBE. (2001) Acute Effects of E-3174, a Human Active Metabolite of Losartan, on the Cardiovascular System in Tachycardia-Induced Canine Heart Failure.. Hypertension Research 24:1, 65-74
     CrossRef

503. 503

     Lynne Warner Stevenson, Robert L Kormos. (2001) Mechanical cardiac support 2000: current applications and future trial design. Journal of the American College of Cardiology 37:1, 340-370
     CrossRef

504. 504

     J. C. Somberg. (2001) Clinical Therapeutic Conference: Congestive Heart Failure Therapy. American Journal of Therapeutics 8:1, 65-72
     CrossRef

505. 505

     M Gary Nicholls, John G Lainchbury, A Mark Richards, Richard W Troughton, Timothy G Yandle. (2001) Brain natriuretic peptide-guided therapy for heart failure. Annals of Medicine 33:6, 422-427
     CrossRef

506. 506

     M.T. Meinardi, J.A. Gietema, D.J. van Veldhuisen, W.T.A. van der Graaf, E.G.E. de Vries, D.T. Sleijfer. (2000) Long-term chemotherapy-related cardiovascular morbidity. Cancer Treatment Reviews 26:6, 429-447
     CrossRef

507. 507

     Tarik M. Ramahi, Marcella D. Longo, Kate Rohlfs, Natalie Sheynberg. (2000) Effect of Heart Failure Program on Cardiovascular Drug Utilization and Dosage in Patients with Chronic Heart Failure. Clinical Cardiology 23:12, 909-914
     CrossRef

508. 508

     Anis Rassi Jr, Anis Rassi, William C. Little. (2000) Chagas' Heart Disease. Clinical Cardiology 23:12, 883-889
     CrossRef

509. 509

     François Delahaye, Guy de Gevigney. (2000) Is the optimal dose of angiotensin-converting enzyme inhibitors in patients with congestive heart failure definitely established?. Journal of the American College of Cardiology 36:7, 2096-2097
     CrossRef

510. 510

     John N Nanas, George Alexopoulos, Maria I Anastasiou-Nana, Konstantinos Karidis, Argiris Tirologos, Spyridon Zobolos, Vlasios Pirgakis, Labros Anthopoulos, Dimitrios Sideris, Stamatis F Stamatelopoulos, Spyridon D Moulopoulos. (2000) Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. Journal of the American College of Cardiology 36:7, 2090-2095
     CrossRef

511. 511

     Israel M. Barbash, Uri Goldbourt, Shmuel Gottlieb, Solomon Behar, Jonathan Leor. (2000) Possible Interaction Between Aspirin and ACE Inhibitors: Update on Unresolved Controversy. Congestive Heart Failure 6:6, 313-318
     CrossRef

512. 512

     George A. Mensah. (2000) The Role of Echocardiography in Hypertensive Heart Disease in the Elderly. The American Journal of Geriatric Cardiology 9:6, 330-341
     CrossRef

513. 513

     Jo E. Rodgers, J. Herbert Patterson. (2000) The Role of the Renin-Angiotensin-Aldosterone System in the Management of Heart Failure. Pharmacotherapy 20:11 Part 2, 368S-378S
     CrossRef

514. 514

     Judith Haendeler, Bradford C Berk. (2000) Angiotensin II mediated signal transduction. Regulatory Peptides 95:1-3, 1-7
     CrossRef

515. 515

     Wendy A. Gattis. (2000) Practical Issues in the Treatment of Patients with Heart Failure. Pharmacotherapy 20:11 Part 2, 385S-391S
     CrossRef

516. 516

     Barry E. Bleske. (2000) Evolution and Pathophysiology of Chronic Systolic Heart Failure. Pharmacotherapy 20:11 Part 2, 349S-358S
     CrossRef

517. 517

     Henry Krum. (2000) New and emerging pharmacologic strategies in the management of chronic heart failure. Clinical Cardiology 23:10, 724-730
     CrossRef

518. 518

     Leslie W. Miller, Bradley Berry, Emil Missov. (2000) Idiopathic cardiomyopathy. Current Treatment Options in Cardiovascular Medicine 2:5, 421-430
     CrossRef

519. 519

     Theresa A. McDonagh. (2000) Asymptomatic left ventricular dysfunction in the community. Current Cardiology Reports 2:5, 470-474
     CrossRef

520. 520

     Maria-Teresa Olivari. (2000) Behavioral and environmental factors contributing to the development and progression of congestive heart failure11The author wishes to thank Tim Furlong for excellent secretarial assistance in the preparation of this manuscript.. The Journal of Heart and Lung Transplantation 19:8, S12-S20
     CrossRef

521. 521

     H. Krum. (2000) Recent advances in the management of chronic heart failure. Australian and New Zealand Journal of Medicine 30:4, 475-482
     CrossRef

522. 522

     Sean P. Clarke, Nancy Frasure-Smith, Franois Lesprance, Martial G. Bourassa. (2000) Psychosocial factors as predictors of functional status at 1 year in patients with left ventricular dysfunction. Research in Nursing & Health 23:4, 290-300
     CrossRef

523. 523

     Andreas Luchner, John C. Burnett, Michihisa Jougasaki, Hans-Werner Hense, Iris M. Heid, Frank Muders, Gänter A.J. Riegger, Heribert Schunkert. (2000) Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. Journal of Hypertension 18:8, 1121-1128
     CrossRef

524. 524

     James B Young. (2000) Sudden cardiac death syndrome and pump dysfunction: the link. The Journal of Heart and Lung Transplantation 19:8, S27-S31
     CrossRef

525. 525

     William J. Elliott. (2000) Therapeutic trials comparing angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers. Current Hypertension Reports 2:4, 402-411
     CrossRef

526. 526

     George S Chrysant. (2000) High salt intake and cardiovascular disease: is there a connection?. Nutrition 16:7-8, 662-664
     CrossRef

527. 527

     Curt D. Furberg. (2000) Class effects and evidence-based medicine. Clinical Cardiology 23:S4, IV-15-IV-19
     CrossRef

528. 528

     Willem J. Remme. (2000) Overview of the relationship between ischemia and congestive heart failure. Clinical Cardiology 23:S4, IV-4-IV-8
     CrossRef

529. 529

     Derek V. Exner. (2000) Blockers With ACE Inhibitors in Mild Heart Failure. Congestive Heart Failure 6:4, 215-219
     CrossRef

530. 530

     James Blake, Richard B. Devereux. (2000) Differential Effects of Direct Antagonism of AII Compared to ACE Inhibitors on Serum Potassium Levels and Azotemia in Patients With Severe Congestive Heart Failure. Congestive Heart Failure 6:4, 193-197
     CrossRef

531. 531

     Donald Hall. (2000) The aspirin–angiotensin-converting enzyme inhibitor tradeoff: to halve and halve not. Journal of the American College of Cardiology 35:7, 1808-1812
     CrossRef

532. 532

     Howard A Cooper, Derek V Exner, Michael J Domanski. (2000) Light-to-moderate alcohol consumption and prognosis in patients with left ventricular systolic dysfunction. Journal of the American College of Cardiology 35:7, 1753-1759
     CrossRef

533. 533

     Marcus D Flather, Salim Yusuf, Lars Køber, Marc Pfeffer, Alistair Hall, Gordon Murray, Christian Torp-Pedersen, Stephen Ball, Janice Pogue, Lemuel Moyé, Eugene Braunwald. (2000) Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet 355:9215, 1575-1581
     CrossRef

534. 534

     Teri Millane, Elizabeth J Bernard, Edgar Jaeggi, Robert B Howman-Giles, Roger F Uren, Timothy B Cartmill, Richard E Hawker, David S Celermajer. (2000) Role of ischemia and infarction in late right ventricular dysfunction after atrial repair of transposition of the great arteries. Journal of the American College of Cardiology 35:6, 1661-1668
     CrossRef

535. 535

     Pascale Mansuy, Nathalie Mougenot, Juan Fernando Ramirez-Gil, Dominique Bonnefont-Rousselot, Françoise Raillecove, Michel Komajda, Philippe Lechat. (2000) Effects of Prolonged Propranolol Treatment on Left Ventricular Remodeling and Oxidative Stress After Myocardial Infarction in Rats. Journal of Cardiovascular Pharmacology 35:5, 806-813
     CrossRef

536. 536

     T. Barry Levine, Arlene B. Levine, Janet Bolenbaug, Robert J. Stomel. (2000) Impact of left ventricular size on pharmacologic reverse remodeling in heart failure. Clinical Cardiology 23:5, 355-358
     CrossRef

537. 537

     Kerryn Simpson, Blair Jarvis. (2000) Lisinopril. Drugs 59:5, 1149-1167
     CrossRef

538. 538

     Kirkwood F. Adams, Kenneth L. Baughman, William G. Dec, Uri Elkayam, Alan D. Forker, Mihai Gheorghiade, Denise Hermann, Marvin A. Konstam, Peter Liu, Barry M. Massie, J. Herbert Patterson, Marc A. Silver, Lynne Warner Stevenson, Arthur M. Feldman, Jay N. Cohn, Gary S. Francis, Barry Greenberg, Marvin A. Konstam, Carl Leier, Beverly H. Lorell, Milton Packer, Bertram Pitt, Marc A. Silver, Edmund Sonnenblick, John Strobeck, Richard Walsh, Salim Yusuf. (2000) HFSA Guidelines for Management of Patients With Heart Failure Caused by Left Ventricular Systolic Dysfunction—Pharmacological Approaches. Pharmacotherapy 20:5, 495-522
     CrossRef

539. 539

     Pierre Vladimir Ennezat, Michael Berlowitz, Edmund H. Sonnenblick, Thierry H. Jemtel. (2000) Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Current Cardiology Reports 2:3, 258-262
     CrossRef

540. 540

     Thierry H. Jemtel. (2000) Management of heart failure. Current Cardiology Reports 2:3, 221-224
     CrossRef

541. 541

     Dave J. van Kraaij, Rene W. Jansen, Frank W. Gribnau, Willibrord H. Hoefnagels. (2000) Diuretic Therapy in Elderly Heart Failure Patients With and Without Left Ventricular Systolic Dysfunction. Drugs & Aging 16:4, 289-300
     CrossRef

542. 542

     Abhijit V. Kshirsagar, Melanie S. Joy, Susan L. Hogan, Ronald J. Falk, Romulo E. Colindres. (2000) Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials. American Journal of Kidney Diseases 35:4, 695-707
     CrossRef

543. 543

     Gary S. Francis. (2000) Heart failure. Journal of the American College of Cardiology 35:5, 6B-9B
     CrossRef

544. 544

     Stephen G Ball. (2000) Discontinuation of doxazosin arm of ALLHAT. The Lancet 355:9214, 1558
     CrossRef

545. 545

     Miguel A. Quiñones, Barry H. Greenberg, Helen A. Kopelen, Chris Koilpillai, Marian C. Limacher, Daniel M. Shindler, Brent J. Shelton, Debra H. Weiner. (2000) Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy. Journal of the American College of Cardiology 35:5, 1237-1244
     CrossRef

546. 546

     Alan J. Bank, Paul C. Lee, Spencer H. Kubo. (2000) Endothelial dysfunction in patients with heart failure: Relationship to disease severity. Journal of Cardiac Failure 6:1, 29-36
     CrossRef

547. 547

     W.B Kannel. (2000) Vital epidemiologic clues in heart failure. Journal of Clinical Epidemiology 53:3, 229-235
     CrossRef

548. 548

     Daniel L Dries, Derek V Exner, Michael J Domanski, Barry Greenberg, Lynne W Stevenson. (2000) The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. Journal of the American College of Cardiology 35:3, 681-689
     CrossRef

549. 549

     Lars Kjøller-Hansen, Rolf Steffensen, Peer Grande. (2000) The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). Journal of the American College of Cardiology 35:4, 881-888
     CrossRef

550. 550

     Ernesto L. Schiffrin. (2000) Hope gives reason for hope. Current Hypertension Reports 2:1, 59-61
     CrossRef

551. 551

     John A. Chiladakis, George Karapanos, George Agelopoulos, Dimitris Alexopoulos, Antonis S. Manolis. (2000) Effects of early captopril therapy after myocardial infarction on the incidence of late potentials. Clinical Cardiology 23:2, 96-102
     CrossRef

552. 552

     The Heart Outcomes Prevention Evaluation Study Investigators. (2000) Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. New England Journal of Medicine 342:3, 145-153
     Full Text

553. 553

     Ren?? R. Wenzel, Heike Bruck, Georg Noll, Rafael F. Sch??fers, Anton E. Daul, Thomas Philipp. (2000) Antihypertensive Drugs and the Sympathetic Nervous System. Journal of Cardiovascular Pharmacology 35, S43-S52
     CrossRef

554. 554

     Huang Chien-Ming, Young Mason-Shing, Wei Jeng. (2000) Predictors of Short-term Outcome in Chinese Patients with Ambulatory Heart Failure for Heart Transplantation with Ejection Fraction < 25 %.. Japanese Heart Journal 41:3, 349-369
     CrossRef

555. 555

     W W Parmley. (2000) Surviving heart failure: Robert L. Frye lecture.. Mayo Clinic Proceedings 75:1, 111-118
     CrossRef

556. 556

     James B Young. (1999) Angiotensin-converting enzyme inhibitors and cytokines in heart failure: dose and effect?. Journal of the American College of Cardiology 34:7, 2068-2071
     CrossRef

557. 557

     R.Preston Mason. (1999) Calcium channel blockers, apoptosis and cancer: is there a biologic relationship?. Journal of the American College of Cardiology 34:7, 1857-1866
     CrossRef

558. 558

     Heart Failure Society Of America. (1999) HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. Journal of Cardiac Failure 5:4, 357-382
     CrossRef

559. 559

     Jian-Dong Luo, Wei-Wen Zhang, Gui-Ping Zhang, Jin-Xia Guan, Xiu Chen. (1999) SIMVASTATIN INHIBITS CARDIAC HYPERTROPHY AND ANGIOTENSIN-CONVERTING ENZYME ACTIVITY IN RATS WITH AORTIC STENOSIS. Clinical and Experimental Pharmacology and Physiology 26:11, 903-908
     CrossRef

560. 560

     P. Stenvinkel, P. Andersson, T. Wang, B. Lindholm, J. Bergstrom, J. Palmblad, O. Heimburger, T. Cederholm. (1999) Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?. Journal of Internal Medicine 246:5, 503-507
     CrossRef

561. 561

     Pascal Colson, Frédérique Ryckwaert, Pierre Coriat. (1999) Renin Angiotensin System Antagonists and Anesthesia. Anesthesia & Analgesia 89:5, 1143-1155
     CrossRef

562. 562

     Aileen Bown Luzier, Lisanne DiTusa. (1999) Underutilization of ACE Inhibitors in Heart Failure. Pharmacotherapy 19:11, 1296-1307
     CrossRef

563. 563

     Hirofumi Soejima, Hisao Ogawa, Hirofumi Yasue, Koichi Kaikita, Keiji Takazoe, Koichi Nishiyama, Kenji Misumi, Shinzo Miyamoto, Michihiro Yoshimura, Kiyotaka Kugiyama, Shin Nakamura, Ichiro Tsuji. (1999) Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. Journal of the American College of Cardiology 34:4, 983-988
     CrossRef

564. 564

     LB Tan, R Murphy. (1999) Shifts in mortality curves: saving or extending lives?. The Lancet 354:9187, 1378-1381
     CrossRef

565. 565

     James W. Tam, Judy Nichol, Andrew L. MacDiarmid, Normand Lazarow, Kevin Wolfe. (1999) What Is the Real Clinical Utility of Echocardiography? A Prospective Observational Study. Journal of the American Society of Echocardiography 12:9, 689-697
     CrossRef

566. 566

     Kathy A. Crispell, Anita Wray, Hanyu Ni, Deirdre J. Nauman, Ray E. Hershberger. (1999) Clinical profiles of four large pedigrees with familial dilated cardiomyopathy. Journal of the American College of Cardiology 34:3, 837-847
     CrossRef

567. 567

     A Mark Richards, M Gary Nicholls. (1999) Aldosterone antagonism in heart failure. The Lancet 354:9181, 789-790
     CrossRef

568. 568

     Massoud A. Leesar, Marcus F. Stoddard, Srinivas Manchikalapudi, Roberto Bolli. (1999) Bradykinin-induced preconditioning in patients undergoing coronary angioplasty. Journal of the American College of Cardiology 34:3, 639-650
     CrossRef

569. 569

     Bosch, Lennertz, Kordes, Samtleben. (1999) Low Density Lipoprotein Hemoperfusion by Direct Adsorption of Lipoproteins from Whole Blood (DALI Apheresis): Clinical Experience from a Single Center. Therapeutic Apheresis and Dialysis 3:3, 209-213
     CrossRef

570. 570

     Leslie R. Harrold, Terry S. Field, Jerry H. Gurwitz. (1999) Knowledge, Patterns of Care, and Outcomes of Care for Generalists and Specialists. Journal of General Internal Medicine 14:8, 499-511
     CrossRef

571. 571

     Joachim Schmidt, Holger Kraul. (1999) Clinical Experience with Spirapril in Human Hypertension. Journal of Cardiovascular Pharmacology 34, S25-S30
     CrossRef

572. 572

     M.T. Meinardi, W.T.A.van der Graaf, D.J.van Veldhuisen, J.A. Gietema, E.G.E.de Vries, D.Th. Sleijfer. (1999) Detection of anthracycline-induced cardiotoxicity. Cancer Treatment Reviews 25:4, 237-247
     CrossRef

573. 573

     Christian Torp-Pedersen, Lars Køber. (1999) Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction. The Lancet 354:9172, 9-12
     CrossRef

574. 574

     Adeera Levin, Christopher R. Thompson, Jean Ethier, Euan J.F. Carlisle, Sheldon Tobe, David Mendelssohn, Ellen Burgess, Kailash Jindal, Brendan Barrett, Joel Singer, Ognjenka Djurdjev. (1999) Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. American Journal of Kidney Diseases 34:1, 125-134
     CrossRef

575. 575

     Helmy M. Siragy, Martin Bedigian. (1999) Mechanism of action of angiotensin-receptor blocking agents. Current Hypertension Reports 1:4, 289-295
     CrossRef

576. 576

     Carla A. Luque, Mariola Vazquez Ortiz. (1999) Treatment of ACE Inhibitor-Induced Cough. Pharmacotherapy 19:7, 804-810
     CrossRef

577. 577

     Avijit Lahiri, Roxy Senior, Raj Khattar. (1999) The Role of Neurohormonal Antagonists in Hibernating Myocardium. Journal of Cardiovascular Pharmacology 33, S9-S16
     CrossRef

578. 578

     John G.F. Cleland, James McGowan. (1999) Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. Journal of Cardiovascular Pharmacology 33, S17-S29
     CrossRef

579. 579

     John G.F. Cleland, James McGowan. (1999) Heart Failure due to Ischaemic Heart Disease: Epidemiology, Pathophysiology and Progression. Journal of Cardiovascular Pharmacology 33:Supplement 3, S17-S29
     CrossRef

580. 580

     Thierry H. LeJemtel. (1999) Review of the cardiac insufficiency bisoprolol study II (CIBIS-II). Current Cardiology Reports 1:1, 29-30
     CrossRef

581. 581

     Guillermo Torre-Amione. (1999) The syndrome of heart failure: emerging concepts in the understanding of its pathogenesis and treatment. Current Opinion in Cardiology 14:3, 193
     CrossRef

582. 582

     Aileen Bown Luzier, Anjana Navsarikar, Michael F. Wilson, Khalid Ashai, Alan Forrest. (1999) Patterns of Prescribing ACE Inhibitors after Myocardial Infarction. Pharmacotherapy 19:5, 655-660
     CrossRef

583. 583

     Axel Schmermund, Lilach O. Lerman, Erik L. Ritman, John A. Rumberger. (1999) Cardiac Production of Angiotensin II and Its Pharmacologic Inhibition: Effects on the Coronary Circulation. Mayo Clinic Proceedings 74:5, 503-513
     CrossRef

584. 584

     Axel Schmermund, Lilach O. Lerman, Erik L. Ritman, John A. Rumberger. (1999) Cardiac Production of Angiotensin II and Its Pharmacologic Inhibition: Effects on the Coronary Circulation. Mayo Clinic Proceedings 74:5, 503-513
     CrossRef

585. 585

     Audrey H. Wu, Sunil K. Das. (1999) Sudden death in dilated cardiomyopathy. Clinical Cardiology 22:4, 267-272
     CrossRef

586. 586

     Christopher E. Cannon, Sidney C. Smith. (1999) Current therapies for secondary prevention after myocardial infarction. Current Opinion in Cardiology 14:2, 155
     CrossRef

587. 587

     Derek V Exner, Daniel L Dries, Myron A Waclawiw, Brent Shelton, Michael J Domanski. (1999) Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction. Journal of the American College of Cardiology 33:4, 916-923
     CrossRef

588. 588

     SUZANNE OPARIL, ALBERT OBERMAN. (1999) Nontraditional Cardiovascular Risk Factors. The American Journal of the Medical Sciences 317:3, 193-207
     CrossRef

589. 589

     John E. Deanfield. (1999) Editorial: Intra-atrial repair of transposition—late results and management problems. The Journal of Thoracic and Cardiovascular Surgery 117:3, 486-487
     CrossRef

590. 590

     Michael J Domanski, Gary F Mitchell, James E Norman, Derek V Exner, Bertram Pitt, Marc A Pfeffer. (1999) Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. Journal of the American College of Cardiology 33:4, 951-958
     CrossRef

591. 591

     Mikko Kirjavainen, Juha-Matti Happonen, Ilmo Louhimo. (1999) Late results of senning operation. The Journal of Thoracic and Cardiovascular Surgery 117:3, 488-495
     CrossRef

592. 592

     Michael W. Rich. (1999) Heart failure disease management: a critical review. Journal of Cardiac Failure 5:1, 64-75
     CrossRef

593. 593

     Dries, Daniel L., Exner, Derek V., Gersh, Bernard J., Cooper, Howard A., Carson, Peter E., Domanski, Michael J., . (1999) Racial Differences in the Outcome of Left Ventricular Dysfunction. New England Journal of Medicine 340:8, 609-616
     Full Text

594. 594

     Gary S Francis. (1999) Heart failure. Journal of the American College of Cardiology 33:2, 291-294
     CrossRef

595. 595

     Gary E Sander, James J McKinnie, Stanley S Greenberg, Thomas D Giles. (1999) Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of heart failure caused by left ventricular systolic dysfunction. Progress in Cardiovascular Diseases 41:4, 265-300
     CrossRef

596. 596

     Darrell L. Ellsworth, Teri A. Manolio. (1999) The Emerging Importance of Genetics in Epidemiologic Research II. Issues in Study Design and Gene Mapping. Annals of Epidemiology 9:2, 75-90
     CrossRef

597. 597

     MICHAEL C. KONTOS. (1999) Role of Echocardiography in the Emergency Department for Identifying Patients with Myocardial Infarction and Ischemia. Echocardiography 16:2, 193-205
     CrossRef

598. 598

     J. A. Diamond, A. Gharavi, D. Roychoudhury, J. Machac, M. J. Henzlova, A. Travis, R. A. Phillips. (1999) Effect of Long-term Eprosartan Versus Enalapril Antihypertensive Therapy on Left Ventricular Mass and Coronary Flow Reserve in Stage I-II Hypertension. Current Medical Research and Opinion 15:1, 1-8
     CrossRef

599. 599

     Gilles W. Keulenaer, Dirk L. Brutsaert. (1999) Dilated Cardiomyopathy: Changing PathophysiologicaI Concepts and Mechanisms of Dysfunction. Journal of Cardiac Surgery 14:1, 64-74
     CrossRef

600. 600

     (1999) 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Clinical and Experimental Hypertension 21:5-6, 1009-1060
     CrossRef

601. 601

     Salim Yusuf, Eva Lonn, Jackie Bosch, Hertzel Gerstein. (1999) Summary of Randomized Trials of Angiotensin Converting Enzyme Inhibitors. Clinical and Experimental Hypertension 21:5-6, 835-845
     CrossRef

602. 602

     Michele Senni, Richard J Rodeheffer, Christophe M Tribouilloy, Jonathan M Evans, Steven J Jacobsen, Kent R Bailey, Margaret M Redfield. (1999) Use of echocardiography in the management of congestive heart failure in the community. Journal of the American College of Cardiology 33:1, 164-170
     CrossRef

603. 603

     Laurence O'Toole, Michael Stewart, Paul Padfield, Kevin Channer. (1998) Effect of the Insertion/Deletion Polymorphism of the Angiotensin-Converting Enzyme Gene on Response to Angiotensin-Converting Enzyme Inhibitors in Patients with Heart Failure. Journal of Cardiovascular Pharmacology 32:6, 988-994
     CrossRef

604. 604

     Karen P Alexander, Eric D Peterson, Christopher B Granger, A.Cecilia Casas, Frans Van de Werf, Paul W Armstrong, Alan Guerci, Eric J Topol, Robert M Califf. (1998) Potential impact of evidence-based medicine in acute coronary syndromes: insights from GUSTO-IIb. Journal of the American College of Cardiology 32:7, 2023-2030
     CrossRef

605. 605

     T. Barry Levine, Arlene B. Levine, Steven J. Keteyian, Barbara Narins. (1998) The impact of beta-receptor blocker addition to high-dose angiotensin-converting enzyme inhibitor-nitrate therapy in heart failure. Clinical Cardiology 21:12, 899-904
     CrossRef

606. 606

     Eji Ino-Oka, Showko Umeda, Yoshiharu Kutsuwa, Takashi Takahashi, Kouichi Sagawa, Takayuki Takahashi, Hikaru Inooka. (1998) The effects of an angiotensin-converting inhibitor (enalapril) on patients with mild cardiac failure-evaluating cardiac function based on the relationship between daily walking pace and heart rate. Clinical Cardiology 21:12, 893-898
     CrossRef

607. 607

     Carl J. Pepine, Eileen Handberg-Thurmond, Ronald G. Marks, Michael Conlon, Rhonda Cooper-Dehoff, Peter Volkers, Peter Zellig. (1998) Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. Journal of the American College of Cardiology 32:5, 1228-1237
     CrossRef

608. 608

     Ole Kongstad-Rasmussen, Peter Blomstrand, Mats Broqvist, Ulf Dahlström, Bengt Wranne. (1998) Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction. Clinical Cardiology 21:11, 807-811
     CrossRef

609. 609

     David Wood, Guy De Backer, Ole Faergeman, Ian Graham, Giuseppe Mancia, Kalevi Pyörälä. (1998) Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention1European Society of Cardiology, European Atherosclerosis Society, European Society of Hypertension, International Society of Behavioural Medicine, European Society of General Practice/Family Medicine, European Heart Network.1,2Published simultaneously in the European Heart Journal 1998;19:1434–1503 and the Journal of Hypertension (Summary only) 1998;16(10).2. Atherosclerosis 140:2, 199-270
     CrossRef

610. 610

     Julie A A Borland, Adrian H Chester, Karen A Morrison, Magdi H Yacoub. (1998) Alternative pathways of angiotensin II production in the human saphenous vein. British Journal of Pharmacology 125:3, 423-428
     CrossRef

611. 611

     O.M.P. Jolobe. (1998) Survival experience of the population needing hospital treatment for asthma or COPD at the age of 50–54 years. Respiratory Medicine 92:10, 1256
     CrossRef

612. 612

     James B Young, Mihai Gheorghiade, Barry F Uretsky, J.Herbert Patterson, Kirkwood F Adams. (1998) Superiority of “triple” drug therapy in heart failure: insights from the PROVED and RADIANCE trials. Journal of the American College of Cardiology 32:3, 686-692
     CrossRef

613. 613

     Eckhard Horstmann, Hans-Joachim Trappe. (1998) Herzinsuffizienz: Diagnostik und Therapie. Medizinische Klinik 93:9, 555-556
     CrossRef

614. 614

     DanielL Dries, DerekV Exner, BernardJ Gersh, MichaelJ Domanski, MyronA Waclawiw, LynneW Stevenson. (1998) Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Journal of the American College of Cardiology 32:3, 695-703
     CrossRef

615. 615

     John GF Cleland, Karl Swedberg, Philip A Poole-Wilson. (1998) Successes and failures of current treatment of heart failure. The Lancet 352, SI19-SI28
     CrossRef

616. 616

     Barry M Massie. (1998) 15 years of heart-failure trials: what have we learned?. The Lancet 352, SI29-SI33
     CrossRef

617. 617

     Andrew JS Coats. (1998) Is preventive medicine responsible for the increasing prevalence of heart failure?. The Lancet 352, SI39-SI41
     CrossRef

618. 618

     GERALD V. NACCARELLLI, DEBORAH L. WOLBRETTE, JOSEPH T. DELL'ORFANO, HEMANTKUMAR M. PATEL, JERRY C. LUCK. (1998) A Decade of Clinical Trial Developments in Postmyocardial Infarction, Congestive Heart Failure, and Sustained Ventricular Tachyarrhythmia Patients: From CAST to AVID and Beyond. Journal of Cardiovascular Electrophysiology 9:8, 864-891
     CrossRef

619. 619

     W Parmley. (1998) Evolution of angiotensin-converting enzyme inhibition in hypertension, heart failure, and vascular protection. The American Journal of Medicine 105:1, 27S-31S
     CrossRef

620. 620

     Mark C. Kowala, Maria Valentine, Ron Recce, Sophie Beyer, Nancy Goller, Stephen Durham, Gunnar Aberg. (1998) Enhanced Reduction of Atherosclerosis in Hamsters Treated with Pravastatin and Captopril: ACE in Atheromas Provides Cellular Targets for Captopril. Journal of Cardiovascular Pharmacology 32:1, 29-38
     CrossRef

621. 621

     CORNELIA K. TILNEY, STEPHEN B. WHITING, JAMES L. HORRAR, BRUCE D. PERKINS, RICHARD P. VANCE, JERRY D. REEVES. (1998) Improved Clinical and Financial Outcomes Associated with a Comprehensive Congestive Heart Failure Program. Disease Management 1:4, 175-183
     CrossRef

622. 622

     Christina Unterberg, Heinrich Kreuzer, Arnd B. Buchwald. (1998) Das Renin-Angiotensin-System bei kardiovaskulären Erkrankungen. Medizinische Klinik 93:7, 416-425
     CrossRef

623. 623

     Lilian Murray, Iain B. Squire, John L. Reid, Kennedy R. Lees. (1998) Determinants of the blood pressure response to the first dose of ACE inhibitor in mild to moderate congestive heart failure. British Journal of Clinical Pharmacology 45:6, 559-566
     CrossRef

624. 624

     D.K. Nagi, C.A. Foy, V. Mohamed-Ali, J.S. Yudkin, P.J. Grant, W.C. Knowler. (1998) Angiotensin-1—converting enzyme (ACE) gene polymorphism, plasma ACE levels, and their association with the metabolic syndrome and electrocardiographic coronary artery disease in Pima Indians. Metabolism 47:5, 622-626
     CrossRef

625. 625

     Kazunori Yoshida, Rose Perich, David J. Casley, Colin I. Johnston. (1998) Hypotensive effect of ZD7155, an angiotensin II receptor antagonist, parallels receptor occupancy in two-kidney, one-clip Goldblatt hypertensive rats. Journal of Hypertension 16:5, 645-655
     CrossRef

626. 626

     M. Konermann, C. Altmann, F. Laschewski, W. Josephs, H. J. Odenthal, E. Horstmann, B. Sanner. (1998) Influence of tissue affinity of angiotensin-converting enzyme inhibitors on left ventricular remodeling after myocardial infarction. Clinical Cardiology 21:4, 277-285
     CrossRef

627. 627

     Mary Mcgrae Mcdermott, Peter Lee, Shruti Mehta, Mihai Gheorghiade. (1998) Patterns of angiotensin-converting enzyme inhibitor prescriptions, educational interventions, and outcomes among hospitalized patients with heart failure. Clinical Cardiology 21:4, 261-268
     CrossRef

628. 628

     Estacio, Raymond O., Jeffers, Barrett W., Hiatt, William R., Biggerstaff, Stacy L., Gifford, Nancy, Schrier, Robert W., . (1998) The Effect of Nisoldipine as Compared with Enalapril on Cardiovascular Outcomes in Patients with Non-Insulin-Dependent Diabetes and Hypertension. New England Journal of Medicine 338:10, 645-652
     Full Text

629. 629

     Ayman S Al-Khadra, Deeb N Salem, William M Rand, James E Udelson, John J Smith, Marvin A Konstam. (1998) Warfarin Anticoagulation and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology 31:4, 749-753
     CrossRef

630. 630

     Lauren S Koniaris, Samuel Z Goldhaber. (1998) Anticoagulation in Dilated Cardiomyopathy. Journal of the American College of Cardiology 31:4, 745-748
     CrossRef

631. 631

     Kai Hu, Peter Gaudron, Georg Ertl. (1998) Long-Term Effects of Beta-Adrenergic Blocking Agent Treatment on Hemodynamic Function and Left Ventricular Remodeling in Rats With Experimental Myocardial Infarction. Journal of the American College of Cardiology 31:3, 692-700
     CrossRef

632. 632

     Ayman S Al-Khadra, Deeb N Salem, William M Rand, James E Udelson, John J Smith, Marvin A Konstam. (1998) Antiplatelet Agents and Survival: A Cohort Analysis From the Studies of Left Ventricular Dysfunction (SOLVD) Trial. Journal of the American College of Cardiology 31:2, 419-425
     CrossRef

633. 633

     Yasuma Nakamura, Tsutomu Ryoke, Nobuaki Tanaka, Tomoko Ohkusa, Masunori Matsuzaki. (1998) Celiprolol, a β-Adrenoceptor Antagonist with Vasodilator Effect, Improves Hemodynamic Response to Catecholamine, Spontaneous Locomotor Activity, and Survival in Cardiomyopathic Hamsters with Advanced Heart Failure. Journal of Cardiovascular Pharmacology 31:2, 171-178
     CrossRef

634. 634

     Bernard Waeber. (1998) Introduction. Journal of Cardiovascular Pharmacology 32, v-vi
     CrossRef

635. 635

     Maurizio D. Guazzi, Jeness Campodonico, Fabrizio Celeste, Marco Guazzi, Gloria Santambrogio, Marco Rossi, Daniela Trabattoni, Marina Alimento. (1998) Antihypertensive efficacy of angiotensin converting enzyme inhibition and aspirin counteraction. Clinical Pharmacology & Therapeutics 63:1, 79-86
     CrossRef

636. 636

     Claudio Borghi, Ettore Ambrosioni. (1998) Evidence-Based Medicine and ACE Inhibition. Journal of Cardiovascular Pharmacology 32, S24-S35
     CrossRef

637. 637

     Paul Ren?? de Cotret. (1998) Relationships Among Diabetes, Microalbuminuria, and ACE Inhibition. Journal of Cardiovascular Pharmacology 32:Supplement 2, S9-S17
     CrossRef

638. 638

     Paul René de Cotret. (1998) Relationships Among Diabetes, Microalbuminuria, and ACE Inhibition. Journal of Cardiovascular Pharmacology 32, S9-S17
     CrossRef

639. 639

     TA McDonagh, SD Robb, DR Murdoch, JJ Morton, I Ford, CE Morrison, H Tunstall-Pedoe, JJV McMurray, HJ Dargie. (1998) Biochemical detection of left-ventricular systolic dysfunction. The Lancet 351:9095, 9-13
     CrossRef

640. 640

     Janice Pogue, Salim Yusuf. (1998) Overcoming the limitations of current meta-analysis of randomised controlled trials. The Lancet 351:9095, 47-52
     CrossRef

641. 641

     Lennart Hansson, Anders Himmelmann. (1998) Carvedilol in the Treatment of Hypertension - A Review of the Clinical Data Base. Scandinavian Cardiovascular Journal 32:47, 67-80
     CrossRef

642. 642

     Claudio Borghi, Ettore Ambrosioni. (1998) Evidence-Based Medicine and ACE Inhibition. Journal of Cardiovascular Pharmacology 32:Supplement 2, S24-S35
     CrossRef

643. 643

     Lars Kjøller-Hansen, Rolf Steffense. (1998) The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES): Effects of Ramipril in Patients with Reduced Left Ventricular Function. Rationale, Design, Methods, Baseline Characteristics and First-Year Experience. Scandinavian Cardiovascular Journal 32:4, 225-232
     CrossRef

644. 644

     Bernard Waeber. (1998) Introduction. Journal of Cardiovascular Pharmacology 32:Supplement 2, v-vi
     CrossRef

645. 645

     Henk J. G. Bilo, Rijk O. B. Gans. (1998) Hypertensive Patients and Diabetes: A High-Risk Population. Journal of Cardiovascular Pharmacology 32, S1-S8
     CrossRef

646. 646

     Henk J. G. Bilo, Rijk O. B. Gans. (1998) Hypertensive Patients and Diabetes. Journal of Cardiovascular Pharmacology 32:Supplement 2, S1-S8
     CrossRef

647. 647

     Fuminari Yamaguchi, Atsushi Sanbe, Satoshi Takeo. (1998) Effects of long-term treatment with trandolapril on sarcoplasmic reticulum function of cardiac muscle in rats with chronic heart failure following myocardial infarction. British Journal of Pharmacology 123:2, 326-334
     CrossRef

648. 648

     Lennart Hansson. (1998) Hypertension-induced Congestive Heart Failure. Scandinavian Cardiovascular Journal 32:47, 5-7
     CrossRef

649. 649

     C. Morisco, G. Lembo, D. Sarno, L. Argenziano, L. Fratta, F. Rozza, B. Trimarco. (1998) Benefits of Combination Therapy in Hypertensive Patients with Associated Coronary Artery Disease: A Subgroup with Specific Demands. Journal of Cardiovascular Pharmacology 31, S27-S33
     CrossRef

650. 650

     Barry F Uretsky, Richard G Sheahan. (1997) Primary Prevention of Sudden Cardiac Death in Heart Failure: Will the Solution Be Shocking?. Journal of the American College of Cardiology 30:7, 1589-1597
     CrossRef

651. 651

     Pavel Hamet. (1997) Cancer and hypertension. Journal of Hypertension 15:12, 1573-1577
     CrossRef

652. 652

     R Temple. (1997) When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?. Controlled Clinical Trials 18:6, 613-620
     CrossRef

653. 653

     Judy W.M. Cheng, Leon Behar. (1997) Calcium channel blockers: association with myocardial infarction, mortality, and cancer. Clinical Therapeutics 19:6, 1255-1268
     CrossRef

654. 654

     Atsuyuki Wada, Takayoshi Tsutamoto, Daisuke Fukai, Masato Ohnishi, Keiko Maeda, Tomoko Hisanaga, Yukiharu Maeda, Yuzuru Matsuda, Masahiko Kinoshita. (1997) Comparison of the Effects of Selective Endothelin ETa and ETb Receptor Antagonists in Congestive Heart Failure. Journal of the American College of Cardiology 30:5, 1385-1392
     CrossRef

655. 655

     Lynda Stevens, Lynda Stevens. 1997. Antihypertensive therapy for preventing cardiovascular complications in people with diabetes mellitus. .
     CrossRef

656. 656

     Atsuyoshi Maeda, Masaaki Honda, Takehiko Kuramochi, Koichi Tanaka, Toshikazu Takabatake. (1997) AN ANGIOTENSIN-CONVERTING ENZYME INHIBITOR PROTECTS AGAINST DOXORUBICIN-INDUCED IMPAIRMENT OF CALCIUM HANDLING IN NEONATAL RAT CARDIAC MYOCYTES. Clinical and Experimental Pharmacology and Physiology 24:9-10, 720-726
     CrossRef

657. 657

     T. J. Campbell. (1997) The place of amiodarone: an overview of the four recent large controlled trials. Australian and New Zealand Journal of Medicine 27:5, 582-590
     CrossRef

658. 658

     Roberto M. Lang, Uri Elkayam, Laurence G. Yellen, Daniel Krauss, Robert S. McKelvie, Douglas E. Vaughan, Dawn E. Ney, Lukas Makris, Paul I. Chang. (1997) Comparative Effects of Losartan and Enalapril on Exercise Capacity and Clinical Status in Patients With Heart Failure. Journal of the American College of Cardiology 30:4, 983-991
     CrossRef

659. 659

     CHRISTIAN TORP-PEDERSEN, LARS KOBER, HANNE ELMING, HANS BURCHART. (1997) Classification of Sudden and Arrhythmic Death. Pacing and Clinical Electrophysiology 20:10, 2545-2552
     CrossRef

660. 660

     ROBERT P. FRANTZ, LYNE J. OLSON. (1997) Recipient Selection and Management Before Cardiac Transplantation. The American Journal of the Medical Sciences 314:3, 139-152
     CrossRef

661. 661

     Theresa A McDonagh, Caroline E Morrison, Audrey Lawrence, Ian Ford, Hugh Tunstall-Pedoe, John JV McMurray, Henry J Dargie. (1997) Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. The Lancet 350:9081, 829-833
     CrossRef

662. 662

     Peter H Pak, H.Bradley Nuss, Richard S Tunin, Stefan Kääb, Gordon F Tomaselli, Eduardo Marban, David A Kass. (1997) Repolarization Abnormalities, Arrhythmia and Sudden Death in Canine Tachycardia-Induced Cardiomyopathy. Journal of the American College of Cardiology 30:2, 576-584
     CrossRef

663. 663

     Martin E Edep, Nihir B Shah, Ida M Tateo, Barry M Massie. (1997) Differences Between Primary Care Physicians and Cardiologists in Management of Congestive Heart Failure: Relation to Practice Guidelines. Journal of the American College of Cardiology 30:2, 518-526
     CrossRef

664. 664

     (1997) Digoxin in Patients with Heart Failure. New England Journal of Medicine 337:2, 129-131
     Full Text

665. 665

     Stephen Scheidt. (1997) Changing Mortality from Coronary Heart Disease among Smokers and Nonsmokers over a 20-Year Interval. Preventive Medicine 26:4, 441-446
     CrossRef

666. 666

     J. Guindo, A. Bays Genis, J. M. Dominguez de Rozas, M. Fiol, X. Vinolas, A. Bays de Luna. (1997) Sudden death in heart failure. Heart Failure Reviews 1:4, 249-260
     CrossRef

667. 667

     Susie D Morris, Derek M Yellon. (1997) Angiotensin-Converting Enzyme Inhibitors Potentiate Preconditioning Through Bradykinin B2 Receptor Activation in Human Heart. Journal of the American College of Cardiology 29:7, 1599-1606
     CrossRef

668. 668

     Poole-Wilson, Philip A., . (1997) Prediction of Heart Failure — An Art Aided by Technology. New England Journal of Medicine 336:19, 1381-1382
     Full Text

669. 669

     L Køber, C Torp-Pedersen, D Cole, JR Hampton, AJ Camm. (1997) Bayesian interim statistical analysis of randomised trials: the case against. The Lancet 349:9059, 1168-1169
     CrossRef

670. 670

     T. Barry Levine, . (1997) The design of the mortality assessment in congestive heart failure trial (MACH-1, Mibefradil). Clinical Cardiology 20:4, 320-326
     CrossRef

671. 671

     Bertram Pitt, Robert Segal, Felipe A Martinez, Georg Meurers, Alan J Cowley, Ignatius Thomas, Prakash C Deedwania, Dawn E Ney, Duane B Snavely, Paul I Chang. (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). The Lancet 349:9054, 747-752
     CrossRef

672. 672

     Koh-ichiro Kinugawa, Osami Kohmoto, Takashi Serizawa, Toshiyuki Takahashi. (1997) CV-11974: A Nonpeptide Angiotensin II Type 1 Receptor Antagonist. Cardiovascular Drug Reviews 15:1, 59-74
     CrossRef

673. 673

     Martin Konermann, Bernd M. Sanner, Eckard Horstmann, Jürgen Grötz, Frank Laschewski, Wolfgang Josephs, Hans J. Odenthal, Alexander Sturm. (1997) Changes of the left ventricle after myocardial infarction-estimation with cine magnetic resonance imaging during the first six months. Clinical Cardiology 20:3, 201-212
     CrossRef

674. 674

     GIANNI TOGNONI, CLAUDIO FRESCO, ALDO P. MAGGIONI, FABIO M. TURAZZA. (1997) The GISSI Story (1983?1996): A Comprehensive Review. Journal of Interventional Cardiology 10:1, 3-28
     CrossRef

675. 675

     C. M. Reid. (1997) AUSTRALIAN COMPARATIVE OUTCOME TRIAL OF ANGIOTENSIN-CONVERTING ENZYME INHIBITOR- AND DIURETIC-BASED TREATMENT OF HYPERTENSION IN THE ELDERLY (ANBP2): OBJECTIVES PROTOCOL. Clinical and Experimental Pharmacology and Physiology 24:2, 188-192
     CrossRef

676. 676

     Hidetoshi Yonemochi, Tetsunori Saikawa, Seikou Yasunaga, Tetsu Iwao, Takeshi Takakura, Mikiko Nakagawa, Toshiie Sakata, Morio Ito. (1997) Angiotensin-Converting Enzyme Inhibitor Up-Regulates Cardiac β-Receptors in Cultured Neonatal Rat Myocytes. Japanese Circulation Journal 61:2, 170-179
     CrossRef

677. 677

     Peter W. de Leeuw, Thomas Notter, Peter Zilles. (1997) Comparison of different fixed antihypertensive combination drugs. Journal of Hypertension 15:1, 87-91
     CrossRef

678. 678

     Ronnie B. Willenheimer, Bo A. Israelsson, Charles M. J. Cline, Leif R. Erhardt. (1997) Simplified Echocardiography in the Diagnosis of Heart Failure. Scandinavian Cardiovascular Journal 31:1, 9-16
     CrossRef

679. 679

     Peter E. Pool. (1997) The clinical significance of neurohormonal activation. Clinical Therapeutics 19, 53-73
     CrossRef

680. 680

     Thomas Hedner, Lennart Hansson, Sverker Jern. (1997) Is Hypertension a Risk Factor for Cancer?. Blood Pressure 6:3, 132-133
     CrossRef

681. 681

     S. Pintus, P. Pintus, P. Maxia, S. Anedda. (1997) Use of Losartan in FH patients during treatment with DSC-LDL apheresis. Journal of Clinical Apheresis 12:3, 156-156
     CrossRef

682. 682

     C. Semeraro, F. Marchini, P. Ferlenga, C. Masotto, G. Morazzoni, L. Pradella, F. Pocchiari. (1997) The Role of Dopaminergic Agonists in Congestive Heart Failure. Clinical and Experimental Hypertension 19:1-2, 201-215
     CrossRef

683. 683

     Karl Swedberg, Axel Sigurdsson. (1996) The use of ACE inhibitors aftermyocardial infarction. Journal of Cardiac Failure 2, S231-S237
     CrossRef

684. 684

     Milton Packer. (1996) Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice?. Journal of the American College of Cardiology 28:5, 1323-1327
     CrossRef

685. 685

     R. Ferrari, C. Ceconi, S. Curello, F. Ferrari, R. Confortini, P. Pepi, O. Visioli. (1996) Activation of the neuroendocrine response in heart failure: Adaptive or maladaptive process?. Cardiovascular Drugs and Therapy 10:S2, 623-629
     CrossRef

686. 686

     Committee Members, Thomas J. Ryan, Jeffrey L. Anderson, Elliott M. Antman, Blaine A. Braniff, Neil H. Brooks, Robert M. Califf, L. David Hillis, Loren F. Hiratzka, Elliott Rapaport, Barbara J. Riegel, Richard O. Russell, Earl E. Smith, W. Douglas Weaver, James L. Ritchie, Melvin D. Cheitlin, Kim A. Eagle, Timothy J. Gardner, Arthur Garson, Raymond J. Gibbons, Richard P. Lewis, Robert A. O'Rourke, Thomas J. Ryan. (1996) ACC/AHA guidelines for the management of patients with acute myocardial infarction. Journal of the American College of Cardiology 28:5, 1328-1419
     CrossRef

687. 687

     DIRK J. van VELDHUISEN, PIETER A. de GRAEFF, WILLEM J. REMME, K.I. LIE. (1996) Value of Digoxin in Heart Failure and Sinus Rhythm: New Features of an Old Drug?. Journal of the American College of Cardiology 28:4, 813-819
     CrossRef

688. 688

     Emma Riva, Cristina Traquandi. (1996) Dose-response studies with idrapril in the rat heart during acute myocardial ischaemia and reperfusion. European Journal of Pharmacology 312:3, 293-300
     CrossRef

689. 689

     HL Elliott, PA Meredith. (1996) Calcium-channel blockers and cancer. The Lancet 348:9035, 1165-1166
     CrossRef

690. 690

     Yukihiro Seta, Kesavan Shan, Biykem Bozkurt, Hakan Oral, Douglas L. Mann. (1996) Basic mechanisms in heart failure: The cytokine hypothesis. Journal of Cardiac Failure 2:3, 243-249
     CrossRef

691. 691

     Linda L. Bachinski, Robert Roberts. (1996) Familial hypertrophic cardiomyopathy: diagnostic and therapeutic implications of recent genetic studies. Molecular Medicine Today 2:9, 387-393
     CrossRef

692. 692

     Kevin A. Schulman, Martin Buxton, Henry Glick, Mark Sculpher, Gladys Guzman, Janet Kong, Martin Backhouse, Jo Mauskopf, Larry Bell, John M. Eisenberg. (1996) Results of the Economic Evaluation of the FIRST Study: A Multinational Prospective Economic Evaluation. International Journal of Technology Assessment in Health Care 12:04, 698
     CrossRef

693. 693

     Bodh I. Jugdutt. (1996) Prevention of ventricular remodeling after myocardial infarction and in congestive heart failure. Heart Failure Reviews 1:2, 115-129
     CrossRef

694. 694

     Wood, Alastair J.J., , Cohn, Jay N., . (1996) The Management of Chronic Heart Failure. New England Journal of Medicine 335:7, 490-498
     Full Text

695. 695

     Pantaleo Giannuzzi, Pier L. Temporelli, Enzo Bosimini, Pedro Silva, Alessandro Imparato, Ugo Corrà, Michele Galli, Amerigo Giordano. (1996) Independent and incremental prognostic value of doppler-derived mitral deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. Journal of the American College of Cardiology 28:2, 383-390
     CrossRef

696. 696

     Manfred Zehetgruber, Renate Beckmann, Harald Gabriel, Günter Christ, Bernd R Binder, Kurt Huber. (1996) THE ACE-INHIBITOR LISINOPRIL AFFECTS PLASMA INSULIN LEVELS BUT NOT FIBRINOLYTIC PARAMETERS. Thrombosis Research 83:2, 143-152
     CrossRef

697. 697

     Rakesh V. Patel, Nabih M. Ramadan, Steven R. Levine, K. M. A. Welch, Susan C. Fagan. (1996) Effects of Ramipril and Enalapril on Cerebral Blood Flow in Elderly Patients with Asymptomatic Carotid Artery Occlusive Disease. Journal of Cardiovascular Pharmacology 28:1, 48-52
     CrossRef

698. 698

     Albert L Waldo, A John Camm, Hans deRuyter, Peter L Friedman, Daniel J MacNeil, John F Pauls, Bertram Pitt, Craig M Pratt, Peter J Schwartz, Enrico P Veltri. (1996) Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The Lancet 348:9019, 7-12
     CrossRef

699. 699

     Maria-Teresa Olivari. (1996) Cardiac transplantation: Current indications,short- and long-term results, economic implications, and future developments. Journal of Cardiac Failure 2:2, 141-152
     CrossRef

700. 700

     Veselin Mitrovic, Harald Mudra, Tassilo Bonzel, Wilhelm Schmidt, James C. Strand, Renata Bakovic-Alt, Edward L. Posvar. (1996) Hemodynamic and hormonal effects of quinaprilat in patients with congestive heart failure*. Clinical Pharmacology & Therapeutics 59:6, 686-698
     CrossRef

701. 701

     I. B. Squire, R. J. MacFadyen, J. L. Reid, A. Devlin, K. R. Lees. (1996) Differing Early Blood Pressure and Renin-Angiotensin System Responses to the First Dose of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure. Journal of Cardiovascular Pharmacology 27:5, 657-666
     CrossRef

702. 702

     Lindpaintner, Klaus, Lee, MinAe, Larson, Martin G., Rao, V. Srinivas, Pfeffer, Marc A., Ordovas, Jose M., Schaefer, Ernst J., Wilson, Alexander F., Wilson, Peter W.F., Vasan, Ramachandran S., Myers, Richard H., Levy, Daniel, . (1996) Absence of Association or Genetic Linkage between the Angiotensin-Converting–Enzyme Gene and Left Ventricular Mass. New England Journal of Medicine 334:16, 1023-1028
     Full Text

703. 703

     A. Postma, M.T.E. Bink-Boelkens, G.C.M. Beaufort-Krol, R.A.M. Kengen, N.J. Elzenga, M.J.M. Schasfoort-van Leeuwen, H. Schraffordt Koops, W.A. Kamps. (1996) Late cardiotoxicity after treatment for a malignant bone tumor. Medical and Pediatric Oncology 26:4, 230-237
     CrossRef

704. 704

     Guillermo Torre-Amione, Samir Kapadia, Claude Benedict, Hakan Oral, James B. Young, Douglas L. Mann. (1996) Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology 27:5, 1201-1206
     CrossRef

705. 705

     Philip A. Poole-Wilson. (1996) Spirals, paradigms, and the progression of heart failure. Journal of Cardiac Failure 2:1, 1-4
     CrossRef

706. 706

     William W. Parmley. (1996) Cost-effective management of heart failure. Clinical Cardiology 19:3, 240-242
     CrossRef

707. 707

     Allan D. Struthers. (1996) Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. Journal of Cardiac Failure 2:1, 47-54
     CrossRef

708. 708

     MARK E. COWEN, MARY BANNISTER, RICHARD SHELLENBERGER, ROBERT TILDEN. (1996) A Guide for Planning Community-Oriented Health Care. Medical Care 34:3, 264-279
     CrossRef

709. 709

     J. R. G. Butler, P. J. Fletcher. (1996) A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Australian and New Zealand Journal of Medicine 26:1, 89-95
     CrossRef

710. 710

     (1996) Heart Failure: Management of Patients With Left-Ventricular Systolic Dysfunction. Journal of the American Academy of Nurse Practitioners 8:2, 85-95
     CrossRef

711. 711

     Michael Horn, Stefan Neubauer, Stefan Frantz, Stephanie Hügel, Kai Hu, Peter Gaudron, Klaus Schnackerz, Georg Ertl. (1996) Preservation of Left Ventricular Mechanical Function and Energy Metabolism in Rats After Myocardial Infarction by the Angiotensin-Converting Enzyme Inhibitor Quinapril. Journal of Cardiovascular Pharmacology 27:2, 201-210
     CrossRef

712. 712

     C Théry, P Asseman, JJ Bauchart, C Loubeyre. (1996) Actualités sur le traitement de l'insuffisance cardiaque chronique. La Revue de Médecine Interne 17:2, 135-143
     CrossRef

713. 713

     Karl Josef Osterziel, Rainer Dietz. (1996) Improvement of Vagal Tone by ACE Inhibition: A Mechanism of Cardioprotection in Patients with Mild-to-Moderate Heart Failure. Journal of Cardiovascular Pharmacology 27, 25-30
     CrossRef

714. 714

     John R. Teerlink. (1996) Neurohumoral Mechanisms in Heart Failure: A Central Role for the Renin-Angiotensin System. Journal of Cardiovascular Pharmacology 27, 1-8
     CrossRef

715. 715

     SP Hart, JD Walker. (1996) Is metformin contra-indicated in diabetic patients with chronic stable heart failure?. Practical Diabetes International 13:1, 18-20
     CrossRef

716. 716

     Wolfgang Kiowski, Gabor Sütsch, Lucette Dössegger. (1996) Clinical Benefit of Angiotensin-Converting Enzyme Inhibitors in Chronic Heart Failure. Journal of Cardiovascular Pharmacology 27, 19-24
     CrossRef

717. 717

     Takahito Yonezawa, Seiji Umemoto, Akihisa Fujii, Kazuhiro Katayama, Masunori Matsuzaki. (1996) Comparative Effects of Type 1 Angiotensin II-Receptor Blockade with Angiotensin-Converting-Enzyme Inhibitor on Left Ventricular Distensibility and Collagen Metabolism in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology 27:1, 119-124
     CrossRef

718. 718

     Jay N. Cohn. (1996) Left Ventricular Dysfunction and Heart Failure Mechanistic and Therapeutic Distinctions. Clinical and Experimental Hypertension 18:3-4, 559-568
     CrossRef

719. 719

     Massimo Volpe, Maria A.E. Rao, Cristina Tritto, Angela Pisani, Alessandro F. Mele, Iolanda Enea, Mario Condorelli. (1995) Transition from asymptomatic left ventricular dysfunction to congestive heart failure. Journal of Cardiac Failure 1:5, 409-419
     CrossRef

720. 720

     Toru Kinugawa, Mark E. Dibner-Dunlap, Domenic A. Sica, Marc D. Thames. (1995) Treatment with enalapril fails to prevent impaired cardiopulmonary baroreflex control in dogs with left ventricular dysfunction. Journal of Cardiac Failure 1:5, 381-389
     CrossRef

721. 721

     P.J. Keeling, J.H. Goldman, A.K.B. Slade, P.M. Elliott, A.L.P. Caforio, J. Poloniecki, W.J. McKenna. (1995) Prognosis of idiopathic dilated cardiomyopathy. Journal of Cardiac Failure 1:5, 337-345
     CrossRef

722. 722

     M Jeserich. (1995) Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure. The American Journal of Cardiology 76:14, 1079-1082
     CrossRef

723. 723

     J. Widimský, O. Uhlíř, H. J. Kremer, P. Jerie. (1995) Czech and Slovak spirapril intervention study (CASSIS). European Journal of Clinical Pharmacology 49:1-2, 95-102
     CrossRef

724. 724

     ILYA E. OVSYSHCHER. (1995) Matching Optimal Pacemaker to Patient: Do We Need a Large Scale Clinical Trial of Pacemaker Mode Selection?. Pacing and Clinical Electrophysiology 18:10, 1845-1852
     CrossRef

725. 725

     Arnold M. Katz. (1995) Cell death in the failing heart: Role of an unnatural growth response to overload-Cell death in the failing heart. Clinical Cardiology 18:S4, IV36-IV44
     CrossRef

726. 726

     Jay N. Cohn, Gary S. Francis. (1995) Cardiac failure: A revised paradigm. Journal of Cardiac Failure 1:4, 261-266
     CrossRef

727. 727

     Henrik D. Pedersen, Jørgen Koch, Knud Poulsen, Asger L. Jensen, Annette Flagstad. (1995) Activation of the Renin-Angiotensin System in Dogs With Asymptomatic and Mildly Symptomatic Mitral Valvular Insufficiency. Journal of Veterinary Internal Medicine 9:5, 328-331
     CrossRef

728. 728

     I Todd, S Donald, B Pentland. (1995) Cardiac rehabilitation for older people. Reviews in Clinical Gerontology 5:03, 321
     CrossRef

729. 729

     Harold L. Kennedy, Robert S. Rosenson. (1995) Physician use of beta-adrenergic blocking therapy: a changing perspective. Journal of the American College of Cardiology 26:2, 547-552
     CrossRef

730. 730

     William W. Parmley. (1995) Neuroendocrine changes in heart failure and their clinical relevance. Clinical Cardiology 18:8, 440-445
     CrossRef

731. 731

     Lee Goldman. (1995) Internal medicine update. Journal of General Internal Medicine 10:6, 331-341
     CrossRef

732. 732

     Thierry H. LeJemtel, Judith S. Hochman, Edmund H. Sonnenblick. (1995) Indications for immediate angiotensin-converting enzyme inhibition in patients with acute myocardial infarction. Journal of the American College of Cardiology 25:7, S47-S51
     CrossRef

733. 733

     Bodh I. Jugdutt. (1995) Effect of captopril and enalapril on left ventricular geometry, function and collagen during healing after anterior and inferior myocardial infarction in a dog model. Journal of the American College of Cardiology 25:7, 1718-1725
     CrossRef

734. 734

     Stephen G. Ball, Alistair S. Hall, Gordon D. Murray. (1995) Angiotensin-converting enzyme inhibitors after myocardial infarction: Indications and timing. Journal of the American College of Cardiology 25:7, S42-S46
     CrossRef

735. 735

     Pantaleo Giannuzzi, Claudio Marcassa, Pier L. Temporelli, Michele Galli, Ugo Corra, Alessandro Imparato, Pedro Silva, Marinella Gattone, Riccardo Campini, Amerigo Giordano, Luigi Tavazzi. (1995) Residual exertional ischemia and unfavorable left ventricular remodeling in patients with systolic dysfunction after anterior myocardial infarction. Journal of the American College of Cardiology 25:7, 1539-1546
     CrossRef

736. 736

     Carl J. Pepine. (1995) The effects of ACE inhibition on ischemic cardiac events: Pump failure, reinfarction, hospitalization for angina, and ventricular tachyarrhythmias. Clinical Cardiology 18:S2, I-26-I-33
     CrossRef

737. 737

     Wolfgang Kübler. (1995) Cardioprotection and cardiovascular reparation by ACE inhibition?. Clinical Cardiology 18:S2, I-1-I-2
     CrossRef

738. 738

     Patricia E. Assmann, Wim R. Aengevaeren, Jan G.P. Tijssen, Cornelis J. Slager, Wim Vletter, Jos R. Roelandt. (1995) Early identification of patients at risk for significant left ventricular dilation one year after myocardial infarction. Journal of the American Society of Echocardiography 8:2, 175-184
     CrossRef

739. 739

     Karl T, Weber. (1995) Heart failure: Lessons learned over the past 25 years. Clinical Cardiology 18:3, 123-130
     CrossRef

740. 740

     Panithaya Chareonthaitawee, Timothy F. Christian, Ken Hirose, Raymond J. Gibbons, John A. Rumberger. (1995) Relation of initial infarct size to extent of left ventricular remodeling in the year after acute myocardial infarction. Journal of the American College of Cardiology 25:3, 567-573
     CrossRef

741. 741

     Jay N. Cohn. (1995) Who should treat cardiac failure?. Journal of Cardiac Failure 1:2, 97-99
     CrossRef

742. 742

     H. ERIKSSON. (1995) Heart failure: a growing public health problem. Journal of Internal Medicine 237:2, 135-141
     CrossRef

743. 743

     James L. Ritchie, Timothy M. Bateman, Robert O. Bonow, Michael H. Crawford, Raymond J. Gibbons, Robert J. Hall, Robert A. O'Rourke, Alfred F. Parisi, Mario S. Verani, Melvin D. Cheitlin, Arthur Garson, Richard P. Lewis, Thomas J. Ryan, Robert C. Schlant, William L. Winters. (1995) Guidelines for clinical use of cardiac radionuclide imaging report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. Journal of the American College of Cardiology 25:2, 521-547
     CrossRef

744. 744

     Ambrosioni, Ettore, Borghi, Claudio, Magnani, Bruno, . (1995) The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction. New England Journal of Medicine 332:2, 80-85
     Full Text

745. 745

     Glenn Davison, Christopher S. Hall, James G. Miller, Michael Scott, Samuel A. Wickline. (1995) Ultrasonic tissue characterization of end-stage dilated cardiomyopathy. Ultrasound in Medicine & Biology 21:7, 853-860
     CrossRef

746. 746

     Irene Guggenmoos-Holzmann. (1995) “Exploratory or analytic meta-analysis: Should we distinguish between them”: Discussion. Journal of Clinical Epidemiology 48:1, 117-118
     CrossRef

747. 747

     Dec, G. WilliamFuster, Valentin. (1994) Idiopathic Dilated Cardiomyopathy. New England Journal of Medicine 331:23, 1564-1575
     Full Text

748. 748

     P. A. Zwieten. (1994) Pharmacotherapy of congestive heart failure. Pharmacy World & Science 16:6, 334-342
     CrossRef

749. 749

     Shahid H. Sial, Michael Malone, Jean L Freeman, Richard Battiola, John Nachodsky, James S. Goodwin. (1994) Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. Journal of General Internal Medicine 9:11, 599-605
     CrossRef

750. 750

     David S. Celermajer, Keld E. Sorensen, Jacqueline Barley, Steve Jeffrey, Nicholas Carter, John Deanfield. (1994) Angiotensin-converting enzyme genotype is not associated with endothelial dysfunction in subjects without other coronary risk factors. Atherosclerosis 111:1, 121-126
     CrossRef

751. 751

     C. R. Conti. (1994) Acronyms for heart failure trials. Clinical Cardiology 17:11, 576-578
     CrossRef

752. 752

     JENS JUNG, ARMIN HEISEL, CEM OZBEK, WOLFGANG BAY, HANS P. STOLL, SEMI SEN, CHRISTOPH ALEXANDER, HERMANN SGHIEFFER. (1994) High Resolution ECG and Left Ventricular Volume After Acute Myocardial Infarction. Pacing and Clinical Electrophysiology 17:11, 2183-2186
     CrossRef

753. 753

     Motoyuki Nakamura, Tsutomu Funakoshi, Naoshi Arakawa, Hiroaki Yoshida, Shinji Makita, Katsuhiko Hiramori. (1994) Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. Journal of the American College of Cardiology 24:5, 1321-1327
     CrossRef

754. 754

     Masatsugu Hori, Hideyuki Sato, Michiko Karita, Kazuhisa Kodama, Noritake Hoki, Tohru Hayashi, Masashi Naka, Shinsuke Nanto, Yoshio Yamada, Takenobu Kamada. (1994) Long-term clinical effect of nilvadipine in patients with chronic heart failure: A double-blind placebo-controlled study. Heart and Vessels 9:5, 249-253
     CrossRef

755. 755

     Robert R. Lazzara, Dennis R. Trumble, James A. Magovern. (1994) Dynamic descending thoracic aortomyoplasty: Comparison with intraaortic balloon pump in a model of heart failure. The Annals of Thoracic Surgery 58:2, 366-371
     CrossRef

756. 756

     Marc J. Semigran, Cynthia M. Thaik, Michael A. Fifer, Charles A. Boucher, Igor F. Palacios, G.William Dec. (1994) Exercise capacity and systolic and diastolic ventricular function after recovery from acute dilated cardiomyopathy. Journal of the American College of Cardiology 24:2, 462-470
     CrossRef

757. 757

     Robert A. Wright, Andrew D. Flapan, K.George M.M. Alberti, Christopher A. Ludlam, Keith A.A. Fox. (1994) Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. Journal of the American College of Cardiology 24:1, 67-73
     CrossRef

758. 758

     Lionel H. Opie. (1994) The ever expanding spectrum of ischemic left ventricular dysfunction. Cardiovascular Drugs and Therapy 8:S2, 297-304
     CrossRef

759. 759

     M. Bobbio, B. Demichelis, G. Giustetto. (1994) Completeness of reporting trial results: effect on physicians' willingness to prescribe. The Lancet 343:8907, 1209-1211
     CrossRef

760. 760

     Claude R. Benedict, David E. Johnstone, Debra H. Weiner, Martial G. Bourassa, Vera Bittner, Richard Kay, Philip Kirlin, Barry Greenberg, Robert M. Kohn, John M. Nicklas, Kevin McIntyre, Miguel A. Quinones, Salim Yusuf. (1994) Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: A report from the registry of studies of left ventricular dysfunction. Journal of the American College of Cardiology 23:6, 1410-1420
     CrossRef

761. 761

     Robert Neil Doughty, Stephen MacMahon, Norman Sharpe. (1994) Beta-blockers in heart failure: Promising or proved?. Journal of the American College of Cardiology 23:3, 814-821
     CrossRef

762. 762

     Andrew L. Clark, Andrew J. S. Coats. (1994) New evidence for improved survival in chronic heart failure. Clinical Cardiology 17:2, 55-58
     CrossRef

763. 763

     Thomas S. Rector, Ph.D, Jay N. Cohn, M.D. (1994) PROGNOSIS IN CONGESTIVE HEART FAILURE. Annual Review of Medicine 45:1, 341-350
     CrossRef

764. 764

     Laura Demopoulos, Thierry H. LeJemtel. (1994) Peripheral factors in the management of congestive heart failure. Cardiovascular Drugs and Therapy 8:1, 75-82
     CrossRef

765. 765

     William J. Rogers, David E. Johnstone, Salim Yusuf, Debra H. Weiner, Philip Gallagher, Vera A. Bittner, Sylvie Ahn, Eleanor Schron, Sally A. Shumaker, L.Thomas Sheffield. (1994) Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The studies of left ventricular dysfunction. Journal of the American College of Cardiology 23:2, 393-400
     CrossRef

766. 766

     Bodh I. Jugdutt. (1994) Use of nitroglycerin for the treatment of acute myocardial infarction. Heart and Vessels 9:1, 3-13
     CrossRef

767. 767

     Margaret M. Redfield, Bernard J. Gersh, Kent R. Bailey, David J. Ballard, Richard J. Rodeheffer. (1993) Natural history of idiopathic dilated cardiomyopathy: effect of referral bias and secular trend. Journal of the American College of Cardiology 22:7, 1921-1926
     CrossRef

768. 768

     Dirk J. van Veldhuisen, Arie J. Man in't Veld, Peter H.J.M. Dunselman, Dirk J.A. Lok, Henk J.M. Dohmen, J.Cees Poortermans, Adrie J.A.M. Withagen, W.Hans Pasteuning, Jan Brouwer, K.I. Lie. (1993) Double-Blind Placebo-Controlled Study of Ibopamine and Diagoxin in Patients With Mild to Moderate Heart Failure: Results of the Dutch of the Ibopamine Multicenter Trial (DIMT). Journal of the American College of Cardiology 22:6, 1564-1573
     CrossRef

769. 769

     Wataru Hayashida, Christian Van Eyll, Michel F. Rousseau, Hubert Pouleur, The SOLVD Investigators. (1993) Regional remodeling and nonuniform changes in diastolic function in patients with left ventricular dysfunction: Modification by long-term enalapril treatment. Journal of the American College of Cardiology 22:5, 1403-1410
     CrossRef

770. 770

     Claude R. Benedict, Debra H. Weiner, David E. Johnstone, Martial G. Bourassa, Jalal K. Ghali, John Nicklas, Philip Kirlin, Barry Greenberg, Miguel A. Quinones, Salim Yusuf. (1993) Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the studies of left ventricular dysfunctions (SOLVD) registry. Journal of the American College of Cardiology 22:4, A146-A153
     CrossRef

771. 771

     Rekha Garg, Salim Yusuf. (1993) Current and ongoing randomized trials in heart failure and left ventricular dysfunction. Journal of the American College of Cardiology 22:4, A194-A197
     CrossRef

772. 772

     Rekha Garg, Milton Packer, Bertram Pitt, Salim Yusuf. (1993) Heart failure in the 1990s: Evolutions of a major public health problem in cardiovascular medicine. Journal of the American College of Cardiology 22:4, A3-A5
     CrossRef

773. 773

     John S. Floras. (1993) Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. Journal of the American College of Cardiology 22:4, A72-A84
     CrossRef

774. 774

     Bertram Pitt. (1993) Use of converting enzyme inhibitors in patients with asymptomatic left ventricular dysfunction. Journal of the American College of Cardiology 22:4, A158-A161
     CrossRef

775. 775

     Hubert G. Pouleur, Marvin A. Konstam, James E. Udelson, Michel F. Rousseau. (1993) Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. Journal of the American College of Cardiology 22:4, A43-A48
     CrossRef

776. 776

     Philip A. Poole-Wilson. (1993) Relation of pathophysiologic mechanisms to outcome in heart failure. Journal of the American College of Cardiology 22:4, A22-A29
     CrossRef

777. 777

     Kalon K.L. Ho, Joan L. Pinsky, William B. Kannel, Daniel Levy. (1993) The epidemiology of heart failure: The Framingham Study. Journal of the American College of Cardiology 22:4, A6-A13
     CrossRef

778. 778

     Andrew I. MacIsaac, J.A.mes D. Thomas, Eric J. Topol. (1993) Toward the quiescent coronary plaque. Journal of the American College of Cardiology 22:4, 1228-1241
     CrossRef

779. 779

     James A. Magovern, George J. Magovern, Thomas D. Maher, Daniel H. Benckart, Sang B. Park, Ignacio Y. Christlieb, George J. Magovern. (1993) Operation for congestive heart failure: Transplantation, coronary artery bypass, and cardiomyoplasty. The Annals of Thoracic Surgery 56:3, 418-425
     CrossRef

780. 780

     Mitchell I. Steinberg, Sally A. Wiest, Alan D. Palkowitz. (1993) Nonpeptide Angiotensin II Receptor Antagonists. Cardiovascular Drug Reviews 11:3, 312-358
     CrossRef

781. 781

     Edward G. Lakatta, Jerome D. Cohen, Jerome L. Fleg, Edward D. Frohlich, Alan H. Gradman. (1993) Hypertension in the elderly: Age- and disease-related complications and therapeutic implications. Cardiovascular Drugs and Therapy 7:4, 643-653
     CrossRef

782. 782

     Jean L. Rouleau, Jacques de Champlain, Marc Klein, Daniel Bichet, Lemuel Moyé, Milton Packer, Gilles R. Dagenais, Bruce Sussex, J.Malcolm Arnold, François Sestier, John O. Parker, Patricia McEwan, Victoria Bernstein, T.Edward Cuddy, Gervasio Lamas, Stephen S. Gottlieb, John McCans, Claude Nadeau, François Delage, Peggy Hamm, Marc A. Pfeffer. (1993) Activation of neurohumoral systems in postinfarction left ventricular dysfunction. Journal of the American College of Cardiology 22:2, 390-398
     CrossRef

783. 783

     L.B. Tan, A. Hall, D.B. Barnett. (1993) Diagnosis of symptomless left ventricular dysfunction. The Lancet 342:8863, 116-117
     CrossRef

784. 784

     Athanase Pipilis, Marcus Flather, Rory Collins, Andrew Coats, Michael Conway, Paul Appleby, Peter Sleight. (1993) Hemodynamic effects of captopril and isosorbide mononitrate started early in acute myocardial infarction: A randomized placebo-controlled study. Journal of the American College of Cardiology 22:1, 73-79
     CrossRef

785. 785

     Nigel Benjamin, Krystyna Czapla, Ejaz Ahmed, MargaretA. McMillan, Michel Azizi, Thomas Lavergne, Martin Day, Charles Pauly-Laubry, Pierre François Plouin. (1993) Renal artery stenosis and congestive heart failure. The Lancet 342:8866, 301-302
     CrossRef

786. 786

     C. Richard Conti. (1993) Heart failure: Drug therapy in the nineties and beyond. Clinical Cardiology 16:6, 459-460
     CrossRef

787. 787

     DavidB. Barnett. (1993) HEART FAILURE. The Lancet 341:8853, 1124-1125
     CrossRef

788. 788

     A. Lerman, R.J. Gibbons, R.J. Rodeheffer, K.R. Bailey, L.J. McKinley, D.M. Heublein, J.C. Burnett. (1993) Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction. The Lancet 341:8853, 1105-1109
     CrossRef

789. 789

     J.G. Motwani, A.D. Struthers, H. McAlpine, N. Kennedy. (1993) Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. The Lancet 341:8853, 1109-1113
     CrossRef

790. 790

     LANCE LARSEN, JAY MARKHAM, CHARLES L HAFFAJEE. (1993) Sudden Death in Idiopathic Dilated Cardiomyopathy: Role of Ventricular Arrhythmias. Pacing and Clinical Electrophysiology 16:5, 1051-1059
     CrossRef

791. 791

     Neal L. Weintraub, Bernard R. Chaitman. (1993) Newer concepts in the medical management of patients with congestive heart failure. Clinical Cardiology 16:5, 380-390
     CrossRef

792. 792

     (1993) ACE Inhibitors after Myocardial Infarction. New England Journal of Medicine 328:13, 966-969
     Full Text

793. 793

     J. David Talley. (1993) Progress in Interventional Cardiology. Journal of Interventional Cardiology 6:1, 89-94
     CrossRef

794. 794

     Salim Yusuf, JohnB. Kostis, Bertram Pitt. (1993) ACE inhibitors for myocardial infarction and unstable angina. The Lancet 341:8848, 829
     CrossRef

795. 795

     Patrick S. Parfrey, Robert N. Foley. (1993) How Can the Mortality Rate of Chronic Dialysis Patients Be Reduced?. Seminars in Dialysis 6:2, 97-100
     CrossRef

796. 796

     Lawrence Friedman. (1993) The NHLBI model: A 25 year history. Statistics in Medicine 12:5-6, 425-431
     CrossRef

797. 797

     Haralambos Gavras, J. Mcmurray, H.J. Dargie. (1993) ACE inhibitors and myocardial infarction. The Lancet 341:8843, 493-494
     CrossRef

798. 798

     (1993) Memorandum from a Who/Ish Meeting. Clinical and Experimental Hypertension 15:6, 1363-1395
     CrossRef

799. 799

     P Besse, P Coste, P Bernadet. (1993) Thérapeutiques de l'insuffisance myocardique congestive: leur évaluation immédiate et à distance. La Revue de Médecine Interne 14:10, 928-930
     CrossRef

800. 800

     Karl T. Weber, Christian G. Brilla, John G. F. Cleland, Jay N. Cohn, Lennart Hansson, Anthony M. Heagerty, John H. Laragh, Stéphane Laurent, Jean-Pierre Ollivier, Paolo Pauletto, Hubert Pouleur, Jos F. M. Smits, Lip-Bun Tan. (1993) Cardioreparation and the Concept of Modulating Cardiovascular Structure and Function. Blood Pressure 2:1, 6-21
     CrossRef

801. 801

     A. Zanchetti, J. P. Chalmers, K. Arakawa, I. Gyarfas, P. Hamet, L. Hansson, S. Julius, S. Macmahon, G. Mancia, J. Ménard, T. Omae, J. Reid, M. Safar. (1993) The 1993 Guidelines for the Management of Mild Hypertension: Memorandum from a WHO/ISH Meeting. Blood Pressure 2:2, 86-100
     CrossRef

802. 802

     J.Malcolm O. Arnold. (1993) The role of phosphodiesterase inhibitors in heart failure. Pharmacology & Therapeutics 57:2-3, 161-170
     CrossRef

803. 803

     (1992) The Cardiac Arrhythmia Suppression Trial. New England Journal of Medicine 327:25, 1818-1818
     Full Text

804. 804

     John Mcmurray, HenryJ. Dargie, AlistairS. Hall, LipB. Tan, David Gray, StephenG. Ball, J.M. Cruickshank, Prabir Roy-Chaudhury, IzharH. Khan, GraemeR.D. Catto. (1992) ACE inhibitors for myocardial infarction and unstable angina. The Lancet 340:8834-8835, 1547-1549
     CrossRef

805. 805

     Leszek Ceremuzynski, Elzbieta Kleczar, Maria Krzeminska-Pakula, Jerzy Kuch, Edmund Nartowicz, Jadwiga Smielak-Korombel, Andrzej Dyduszynski, Jerzy Maciejewicz, Teresa Zaleska, Elzbieta Lazarczyk-Kedzia, Janina Motyka, Barbara Paczkowska, Olga Sczaniecka, Salim Yusuf. (1992) Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study. Journal of the American College of Cardiology 20:5, 1056-1062
     CrossRef

806. 806

     S. Yusuf, C.J. Pepine, C. Garces, H. Pouleur, M. Rousseau, D. Salem, J. Kostis, C. Benedict, M. Bourassa, B. Pitt. (1992) Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. The Lancet 340:8829, 1173-1178
     CrossRef

807. 807

     (1992) From cardiac to vascular protection: the next chapter. The Lancet 340:8829, 1197-1198
     CrossRef

808. 808

     Cohn, Jay N., . (1992) The Prevention of Heart Failure — A New Agenda. New England Journal of Medicine 327:10, 725-727
     Full Text

809. 809

     Swedberg, Karl, Held, Peter, Kjekshus, John, Rasmussen, Knut, Rydén, Lars, Wedel, Hans, . (1992) Effects of the Early Administration of Enalapril on Mortality in Patients with Acute Myocardial Infarction. New England Journal of Medicine 327:10, 678-684
     Full Text

810. 810

     Gilles W. De Keulenaer, Dirk L. Brutsaert. (1985) Dilated Cardiomyopathy: Changing PathophysiologicaI Concepts and Mechanisms of Dysfunction. Echocardiography 2:1, 64-72
     CrossRef